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The gag gene of HIV-1 encodes for one of the major structural proteins, which
contains several conserved cytotoxic T cell (CTL) epitopes. Gag specific CTL
responses are important in controlling viral load during acute infection and
asymptomatic stages of the infection. Currently, only one complete South African
HIV-1 subtype C gag sequence has been published. The first aim of this study
was to characterise the complete gag gene of 15 HIV-1 subtype C isolates, to be
used as a set of reference sequences in the design of a South African HIV-1
subtype C vaccine.
Fifteen HIV-1 subtype C isolates selected for this study, were isolated during 1998
and 1999 from the HIV-1 positive patients attending the Infectious Disease Clinic at
Tygerberg Hospital. The gag gene of these isolates was amplified by PCR, cloned
into mammalian expression vectors and sequenced. Restriction digest analyses as
well as phylogenetic analyses were performed on the sequencing data. Previously
published mutational analyses and CTL epitopes were compared to the predicted
amino acid sequences of the gag clones.
Sequences of 23 complete gag genes representing the 15 HIV-1 subtype C
isolates as well as one complete sequence of an HIV-1 subtype B isolate were
compiled. Subtyping by restriction fragment length polymorphism (RFLP) would
have correctly identified 14 of the 15 subtype C isolates as subtype C and one as
unidentifiable. The subtype B isolate would have also been correctly identified.
Phylogenetic analyses showed that our subtype C isolates clustered with reference
subtype C strains from various countries, including Botswana, India, Israel,
Tanzania and Zambia. Strains from Ethiopia and Brazil formed a separate subtype
C cluster. The diversity between our isolates was comparable to the diversity seen
between all the HIV-1 subtype C strains. Comparisons of previously published
mutational analyses and CTL epitopes to the predicted amino acid sequences of
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the gag clones, showed conservation in most of the clones throughout the
sequence.
A second aim was to establish transfection and Western Blot techniques in our
laboratory for use in future studies. An in vitro transcription! translation assay was
performed on the gag clones and the protein producing clones were used to
transfect mammalian cells using electroporation. A Western blot was then used to
screen for Gag protein expression in the transfected cell Iysates.
The in vitro transcription! translation assay showed that seven of the 23 clones
could produce a protein of -55 kDa in size. Four out of the seven of these clones
gave a weak expression of a-55 kDa protein after transfection in a mammalian
cell line. Since the completion of the experimental work of this study, other cloned
HIV-1 genes have successfully been transfected into mammalian cells using the
electroporation technique and the proteins produced were screened for by Western
blot.
To conclude with; the native form of the gag gene does not elicit strong expression
of the protein, but studies have shown that expression can be improved by
sequence-modification of the gag nucleotide sequence. Due to the conservation of





Die HIV-1 gag geen kodeer vir een van die hoof strukturele proterene en bevat
verskeie sitotoksiese T-limfosiet epitope. Gag spesifieke sellulere immuun respons
is belangrik vir die beheer van virale lading tydens akute infeksies en tydens
asimptomatiese fases van die infeksie. Tans is slegs een volledige Suid
Afrikaanse HIV-1 subtipe C nuklerensuur volgorde gepubliseer. Die eerste doel
van hierdie studie was om die volledige gag geen van 15 HIV-1 subtipe C isolate te
karakteriseer, om gebruik te word as In stel verwysings nukleiensuur volgordes, vir
die ontwerp van In Suid Afrikaanse HIV-1 subtipe C entstof.
Die 15 HIV-1 subtipe C isolate wat vir hierdie studie geselekteer is, is tydens 1998
en 1999 ge·lsoleer vanaf HIV-1 positiewe pasiente wat die Infeksiesiekte Kliniek,
Tygerberg Hospitaal bygewoon het. Die gag geen van hierdie isolate is
geamplifiseer deur PKR, gekloneer in soogdier ekspressie vektore en die
nukleiensuur volgorde is bepaal. Die nuklerensuur volgorde is gebruik in restriksie
ensiem analises asook filogenetiese analises. Reeds gepubliseerde mutasie
analises en limfosiet epitope is met die voorspelde aminosuur volgorde van die gag
klone vergelyk.
Die nukleiensuur volgordes van die 23 volledige gag gene wat die 15 HIV-1
subtipe C isolate verteenwoordig, asook een volledige nukleiensuur volgorde van
een HIV-1 subtipe B isolaat, is saamgestel. Subtipering deur middel van restriksie
fragment lengte polimorfisme (RFLP) sou 14 uit die 15 subtipe C isolate korrek
qerdentifiseer het, maar sou een nie kon identifiseer nie. RFLP sou ook die
subtipe B isolaat korrek qerdentifiseer het. Filogenetiese analises het gewys dat
ons subtipe C isolate met die verwysings subtipe C stamme van verskeie lande,
insluitend Botswana, lndie, Israel, Tanzania en Zambie groepeer. Stamme van
Ethiopie en Brasilie het In aparte subtipe C groep gevorm. Die diversiteit tussen
ons isolate was vergelykbaar met die diversiteit tussen al die subtipe C stamme.
Vergelykings van gepubliseerde mutasie analises en limfosiet epitope met die
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voorspelde aminosuur volgorde van die gag klone, het konservasie in meeste van
die klone, deur die hele nukleiensuur volgorde, getoon.
Die tweede doel was om die metodes van transfeksie en Westerse klad in ons
laboratorium tot stand te bring. In vitro transkripsie/ translasie toetse is gedoen op
die gag klone en die proteten produserende klone is gebruik om soogdierselle te
transfekteer deur gebruik te maak van elektroporasie. In Westerse klad is toe
gebruik om vir Gag proterenuitdrukkinq in die sellisate te toets.
Die in vitro transkripsie/ translasie toets het getoon dat sewe uit 23 klone, In
proteren van -55 kDa kon produseer. Vier uit die sewe van hierdie klone het In
-55 kDa proteren swak uitgedruk na transfektering van soogdier selle. Sedert die
voltooiing van die eksperimentele werk van hierdie stud ie, is ander gekloneerde
HIV-1 gene suksesvol in soogdierselle getransfekteer met die gebruik van
elektroporasie en die proterene is met In Westerse klad aangetoon.
Ten slotte: die natuurlike vorm van die gag geen ontlok nie In sterk ekspressie van
die proteren nie, maar ander studies het wei aangetoon dat die ekspressie verbeter
kan word met modifikasie van die gag nukleiensuur volgorde. As gevolg van die
konservasie van gag, kan die nuklerensuur volgorde van enige subtipe C stam
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According to the latest United Nations global AIDS report, there are currently 36.1
million people world-wide living with HIV/AIDS and a total of 16.3 million people
have died of AIDS related diseases since the beginning of the epidemic
(UNAIDSIWHO, 2000). It is therefore of global importance to develop an effective
vaccine to combat further spread of the disease. HIV-1 subtype C constitutes
more than 55 % of the circulating viruses world-wide (Esparza & Bhamarapravati,
2000) and is the most prevalent subtype in South Africa (Bredell et ai, 1998;
Engelbrecht et ai, 1999; Van Harmelen et ai, 1999a). It is therefore of national
importance to concentrate on developing an HIV-1 subtype C vaccine. A safe and
effective HIV vaccine should be able to elicit a broad-based humoral and cellular
immune response without potentially causing disease.
The gag gene is of the more conserved genes in the virus genome and is
translated into a polyprotein precursor, which is proteolytically cleaved into p17
matrix, p24 capsid, p7 nucleocapsid and p6 proteins. Gag specific cytotoxic T-cell
responses playa meaningful role in the control of disease progression. It is
therefore important to look at the Gag polyprotein as a promising candidate in the
development of an HIV vaccine.
The first Chapter will give an overview of the history, diversity and morphology of
the HIV-1 virus, and then progress to describe Gag, as a protein, as well as to look
at the techniques used in this study to characterise the gene. A short overview will
then be given of HIV-1 vaccines. The second Chapter will describe the materials
and methods used in this study. In Chapter three the results will be presented, and
discussed in Chapter four. Large Figures and Figures stretching over several
pages were listed in the Appendices. The Figures of materials and methods are
2
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given in Appendix A, while the tables are given at the end of Chapter two. Tables
and Figures (photos of gels and blots, phylogenetic trees, examples of similarity
plots, graphs, and a helix cartoon) of results are listed at the back of Chapter three,
while additional result figures (sequence raw data, restriction analysis and maps,
similarity plots, distance matrixes, and alignments) are listed in Appendix B.
1.2 Aim of this Study
Currently, only one complete South African HIV-1 subtype C gag sequence has
been described (Rodenburg et ai, 2001). The first aim of this study was to
characterise the gag gene of 15 HIV-1 subtype C isolates, to be used as a set of
reference sequences in the design of a South African HIV-1 subtype C vaccine.
The characterisation of gag was achieved by the amplification, cloning and
sequencing of the gene. The sequencing data was then used in restriction digest-
and phylogenetic analyses, as well as to compile predicted amino acid sequences
for the protein. Phylogenetic analyses, and amino acid comparisons to previous
mutational analyses and CTL epitopes were done on the predicted amino acid
sequence. Conserved CTL epitopes are important for vaccine induced immunity.
A second aim was to establish transfection and Western Blot techniques in our
laboratory for use in future studies. Although it was known that gag did not elicit
good protein expression, the expression of proteins from the cloned gag genes
was however studied to establish the techniques, by transfecting the clones into
mammalian cells and screening for protein production by Western blot. This was
done by evaluating three different transfection methods on the production of
chloramphenicol acetyltransferase type 1 protein (CAT) in cells transfected with a
CAT expression plasmid. The technique, which delivered the highest concentration
of the CAT protein, was then chosen to transfect cells with selected gag clones,





1.3.1 History of the Human Immunodeficiency virus
Twenty years ago, in 1981, several cases of acquired immune deficiency were
reported in The New England Journal of Medicine (Gottlieb et ai, 1981a; Masur et
ai, 1981; Siegal et ai, 1981). All patients reported on, mostly of whom were
homosexual men, were previously healthy, but presented with Pneumocystis carinii
pneumonia, a disease caused by an organism, which rarely if ever causes disease
in immunologically competent persons (Hughes, 1977). Some of the patients also
developed Kaposi's sarcoma. The combination of Kaposi's sarcoma and
Pneumocystis pneumonia in homosexual men were also previously reported on in
the Morbidity and Mortality Weekly Report of June, July and August 1981, already
suggesting the start of an outbreak (Gottlieb et ai, 1981 b; Friedman-Kien et ai,
1981; Friedman et ai, 1981). The cases were from both the west and east coasts
of the United States of America in mostly homosexual men, but also in drug
abusers. The disease was named: the acquired immune deficiency syndrome
(AIDS). Two years later, in 1983, the group of Luc Montagnier isolated the first T-
Iymphotropic retrovirus in a patient at risk for AIDS (Barre-Sinoussi et ai, 1983).
Although the exact role that this retrovirus played in AIDS was not known at that
time, it was later established to be the etiologic agent of AIDS (Broder & Gallo,
1984; Ratner et ai, 1985) and was named the Human Immunodeficiency virus
(HIV) (Coffin et ai, 1986a, 1986b).
1.3.2 Diversity of the Human Immunodeficiency virus
Since the realisation of HIV/AIDS in 1981, the epidemic has spread through out the
world with an estimated 36.1 million people currently infected with HIV, of whom
5.3 million were infected in the year 2000. The global distribution of HIV infected
people is given in Figure 1.1. Since the beginning of the epidemic a total of 21.8
4
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million people have died of AIDS related illnesses. Of the 36.1 million HIV infected
people, 25.3 million live in sub-Saharan Africa - a staggering 70% (UNAIDSIWHO,
2000).
Adults and children estimated to be living
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Figure 1.1 The global view of the total number of people living with
mv/AIDS. (http://www. unaids. org/epidemic _ update/ report/index. html)
There are two distinct human immunodeficiency viruses: type one (HIV-1) and type
two (HIV-2) (Clavel et ai, 1986). The worldwide pandemic is caused predominantly
by HIV-1, with HIV-2 primarily found in West Africa (Van der Loeff et ai, 1999).
HIV-1 is divided into major groups, M (main), N (non-M, non-O) and ° (outlier)
(Louwagie et ai, 1995; De Leys et ai, 1990; Gurtler et ai, 1994; Simon et ai, 1998),
while group M is further divided into nine genetically distinct subtypes (A-D, F-H, J,
K) (Kuiken et ai, 2000). Most strains found worldwide and which is responsible for
5
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the pandemic, belong to the HIV-1 group M. Genetic diversity of group M is further
broadened by the occurrence of quasispecies within the same host (Hahn et ai,
1986; Sakai et ai, 1988), giving rise to recombinant forms (Hu & Temin, 1990;
Robertson et al 1995), which are spread and result in circulating recombinant
forms (CRFs). The former subtypes E and I are now classified as CRFs (Kuiken et
ai, 2000). The most commonly transmitted HIV virus, is the HIV-1 subtype C virus,
which constitute more than 55% of all circulating viruses worldwide and is the
dominant subtype in southern Africa and India (Esparza & Bhamarapravati, 2000).
The high genetic diversity of HIV is the result of multiple introductions of simian
viruses into humans (Hahn et ai, 2000). Both HIV-1 and HIV-2 are results of
zoonotic transmissions from chimpanzees (Pan troglodytes) (SIVcpz) (Gao et ai,
1999) and sooty mangabeys (Cercocebus atys) (SIVsm) (Hirsch et ai, 1989; Gao
et ai, 1992) respectively. Similarly, the three groups of HIV-1 represent multiple
introductions of SIVcpz into humans (Hahn et ai, 2000). The HIV-1 group M
viruses, however appear to have risen from a single cross-species transmission
(Gao et ai, 1999). The genetic divergence within this group, might have been
caused by the high error rate of reverse transcriptase and the high replication rate
of the virus in infected individuals (Peeters & Sharp, 2000).
1.3.3 HIV-1 in South Africa
South Africa has one of the fastest growing HIV-1 epidemics (UNAIDSIWHO,
2000) with 4.7 million people out of a population of 40.6 million infected with the
virus. There is a geographical variation in severity of the epidemic with KwaZulu-
Natal having the highest prevalence rate (36.2%) and the Western Cape the lowest
(8.7%) (Department of Health / Directorate Health Systems Research, 2001). The
initial HIV-1 epidemic in South Africa occurred mainly in the homosexual
population, but then shifted to a predominantly heterosexual epidemic (Williamson
et ai, 1995). In South Africa, homosexual transmission is associated with HIV-1
6
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subtype B viruses, while heterosexual transmission is associated with the subtype
C virus (Williamson et ai, 1995; Van Harmelen et ai, 1997). HIV-1 subtype C is the
domihant subtype in the present South African epidemic (Van Harmelen et ai,
1999a).
HIV-1 infected South Africans account for 13% of HIV-1 infections worldwide.
Several factors may contribute to the high prevalence in South Africa, which
include the migrant labour system, the low socio-economic status of women, high
rates of other sexually transmitted diseases, and the limited availability of anti-HIV
drug therapies in South Africa (Morris & Williamson, 2001). Studies have also
suggested that the period from HIV-1 infection to the progression of AIDS is
shortened by about two years in developing countries, where access to health care
is limited (Grant et ai, 1997). The opportunistic infection, tuberculosis, which is
associated with poor communities, low socio-economic status, and malnutrition, is
the major cause of death in sub-Saharan African AIDS patients (Shafer et ai, 1996;
De Cock et ai, 1996, Morris & Williamson, 2001).
Although poverty and the lower socio-economic status of sub-Saharan African
countries surely playa role in the high prevalence rate of HIV-1 infected people, a
multitude of other factors also contribute to this African epidemic. One such a
factor might be the viral genotype. HIV-1 subtype C, the dominant subtype in
South Africa and the world, differ from other HIV-1 subtypes in several ways. The
preferred co-receptor for subtype C viruses isolated from patients at all stages of
disease is the CC chemokine type 5 receptor (CCR5) (Morris et ai, 2001; Peeters
et ai, 1999; Treurnicht et ai, in press), while other subtypes often switch to CXC
chemokine type 4 receptor (CXCR4) usage at later stages of the disease
(Tscherning et ai, 1998; Connor et ai, 1997). Majority of subtype C viruses,
including the South African subtype C strains, contains an additional NF-K~ binding
site in their LTR regions (Hunt & Tiemessen, 2000; Johansson et ai, 1995;
Montano et ai, 1997). A recent study also identified further additional NF-K~-like
sites in South African HIV-1 subtype C isolates (Scriba et ai, in press). Both the
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occurrence of additional NF-K~-binding sites and the dominant CCR5 co-receptor
usage might theoretically play a role in improving the replication kinetics and
transmission respectively, but must still be proven experimentally (Morris &
Williamson, 2001, Scriba et ai, in press).
Although the HIV-1 subtype C virus is the most common HIV-1 subtype worldwide,
it has been relatively poorly studied. Currently there are 47 full length HIV-1
subtype C gag sequences in the Los Alamos sequence database, of which only 1
comes from a South African strain (Rodenburg et ai, 2001). While there are 16
South African subtype C p17 sequences available in the Los Alamos database
(Becker et ai, 1995; Williamson et ai, 1995; Rodenburg et ai, 2001), there are no
South African sequences, except for the full length sequence, available for p24. A
study, which looked at the HIV-1 Gag-specific CTL responses in South African
adults and children, found the dominant Gag epitope in these subjects to be in the
p24 region (Goulder et ai, 2000).
1.3.4 The HIV-1 virion and life cycle
1.3.4.1 HIV-1 virion
The near 9 kb viral genome encodes several viral proteins, of which there are
structural, regulatory and accessory proteins. The structural proteins, namely,
capsid (CA), matrix (MA), nucleocapsid (NC), surface envelope glycoprotein (SU),
transmembrane envelope glycoprotein (TM), reverse transcriptase (RT), protease
(PR) and integrase (IN), form the virus particle. All mature structural proteins are
translated as polyprotein precursors, which are proteolytically cleaved by either
viral or host cellular protease. The regulatory proteins, Tat (trans-activator of viral
transcription) and Rev (regulator of viral expression) control viral replication by
regulating viral transcription, and viral RNA transport and splicing respectively.
The accessory proteins, Nef, Vpu, Vif and Vpr, playa variety of roles throughout
8
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the viral life cycle. Figure 1.2 illustrates the structural protein arrangement in an
HIVvirion.







Figure 1.2 A cartoon portraying the HIV virion (http://www.urmc.rochester.edulsmdl
mbilgrad2lhiv99B.html). The HIV -1 virion consists of several structural proteins.
The envelope glycoproteins, gp120 and gp 41 function as adhesion and fusion
proteins. The virus is covered by a lipid host derived membrane, which is
surrounded in the inside by the p17 matrix proteins. The p24 capsid forms a shell
surounding the nucleocore, consisting of viral genome, p7 nucleocapsid, p6, reverse
transcriptase, and integrase.
The HIV-1 virion contains a host derived lipid membrane, with the envelope
glycoproteins protruding from it. The matrix (MA) surrounds the inner portion of the
membrane. Inside the virion, the capsid proteins together with a cellular protein,
cyclophilin A (CypA) form an icosahedral cone encapsulating the viral genome and





single stranded RNA genome, which is surrounded by the nucleocapsid proteins,
two copies of the reverse transcriptase, and the integrase protein.
1.3.4.2 The HIV-1 lifecycle
HIV-1 infects CD4+ cells like T cells or macro phages (Maddon et ai, 1986). The
HIV-1 life cycle begins with viral attachment to the host cell by means of the
binding of the surface glycoprotein, gp120 to the cellular CD4 molecule. This
interaction causes conformational changes in both the envelope glycoproteins,
gp120 and gp41, resulting in the exposure of a variable loop in gp120, the V3 loop,
which then binds to a chemokine receptor serving as a viral entry co-receptor. The
predominant chemokine receptors used by HIV-1 are the CCR5 and the CXCR4.
CCR5 usage is predominantly found in early infections, while the CXCR4 usage is
mainly found in late-stage infections or after in vitro passage (Connor et ai, 1997).
As stated before, the subtype C viruses are mostly the exception to the co-receptor
rule. The interaction of gp120, the CD4 molecule and the co-receptor results in a
conformational change in the gp41, exposing a hydrophobic fusion domain,
allowing fusion between the viral and cell membranes, releasing the capsid (p24)
containing the viral genome into the cellular cytoplasm (Chan & Kim, 1998). CypA
facilitates the uncoating of the p24 capsid (Gamble et ai, 1996), releasing the
nucleocore into the cytoplasm, where the viral RNA is converted into double
stranded linear DNA by the reverse transcriptase. The viral DNA, together with the
nucleocapsid, matrix, integrase and vpr, form a preintegration complex, which due
to the nuclear localisation signals contained in the nucleocapsid and vpr, can be
imported into the cellular nucleus via an active uptake mechanism (Bukrinsky et ai,
1993; Gallay et ai, 1995, Jenkins et ai, 1998). Inside the nucleus, the viral
integrase causes the linear HIV-1 DNA to be integrated into the host cell
chromosome, which then becomes a provirus (Farnet & Bushman, 1996). The
provirus contains two copies, one on each side of the HIV-1 genome, of the viral
long terminal repeat (LTR), which contains various transcriptional control elements,
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including a TATAA box (Okamoto et ai, 1990). Viral RNA is synthesised from the
provirus and expression is regulated by both cellular and viral factors. The viral
protein Tat interacts with cellular kinases to enhance the processivity of RNA
polymerase" at the elongation process. In the nucleus, the viral mRNA exists in
three forms: doubly spliced mRNA, which codes for Rev, Tat and Nef, singly
spliced mRNA, which codes for Env, Vpr, Vpu and Vif, and unspliced mRNA, which
codes for Gag-pol. The unspliced and singly spliced mRNA are unstable RNAs,
which is not transported to the cytoplasm by cellular factors and would be retained
and degraded in the nucleus. Rev however, shuttles the unstable mRNAs through
an active process out of the nucleus into the cytoplasm, where cellular proteins
translate it into viral proteins and undergo post-translational processes like
phosphorylation and glycosylation (Coffin, 1996). The envelope proteins (Env) are
translated as a 160 kDa polyprotein, which is cleaved by a cellular protease into a
gp120 and gp41. The Env proteins are glycosylated and displayed on the outside
of the cellular membrane, with gp 120 on the outside and gp41 serving as an
anchor within the membrane. The two glycoproteins are non-covalently attached
to each other (Chan & Kim, 1998). The Gag protein is a 55 kDa precursor
polyprotein, which is cleaved by the viral protease into the p17 matrix, p24 capsid,
p7 nucleocapsid, p6 and two spacer peptides. Protease is a product of self-
cleavage of a polyprotein, Pol, which also produces reverse transcriptase and
integrase. The viral proteins, together with copies of the unspliced mRNA, which
will serve as the viral genome, assemble at the cellular membrane, containing the
envelope glycoproteins. New HIV-1 virions bud, which can infect new cells and the
process repeated. Cleavage of the Gag polyprotein occurs during or after budding
(Freed, 1998).
1.3.5 The Gag Protein
The gag gene is 1.5 kb in length and is translated into a 55 kDa polyprotein
precursor (Pr55Ga9), which can produce non-infectious, virus-like particles in the
11
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absence of other viral proteins or packageable viral RNA (Freed, 1998). PrSSGag
plays an important role in virus assembly and budding, while the mature Gag
proteins play important roles in disassembly following virus entry into cells.
Maturation is a result of proteolytic cleavage of the PrSSGag by the viral protease
into the p17 matrix, p24 capsid, p7 nucleocapsid, p6, p2 and p1 (Figure 1.3).
MAA
c
Figure 1.3 An illustration of the genomic (A) and virion layout of the immature and
mature Gag proteins. The cleavage sites are indicated in C. (Von Schwedler et al,
1998).
The HIV-1 protease recognises two types of cleavage sites as substrates, namely
the class one aromatic*proline cleavage site and the class two
hydrophobic*hydrophobic cleavage site (Pettit et ai, 1991; Griffiths et ai, 1992),
12
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where the cleavage sites are indicated by an asterisk (*). The matrix! capsid
cleavage site falls into the class one type, while the rest of the cleavage sites in the
Gag polyprotein fall into the class two type.
1.3.5.1 Matrix
The matrix forms the N-terminal domain of the Pr5SOag and plays a role in targeting
of Gag to the plasma membrane, Env glycoprotein incorporation into virions, and
early postentry events (Freed, 1998). The mature matrix protein folds into a
compact core domain consisting largely of a-helices and three ~-sheets and is
trimeric. The structure was determined by both nuclear magnetic resonance
(NMR) spectroscopy and X-ray crystallography (Massiah et ai, 1996). A major
function of the immature matrix protein is to direct binding and assembly at the
plasma membrane, which is made possible by a myristoylated N-terminal glycine
residue (Gottlinqer et ai, 1989; Bryant & Ratner, 1990) and several domains in the
N-terminus as well as in the vicinity of residues 55 and 85 (Freed et ai, 1994). The
highly basic domain between residue 17 and 31 have also been linked to
membrane targeting (Yuan et ai, 1993; Zhou et ai, 1994, Ono et ai, 2000). Upon
maturation, the matrix protein undergoes conformational changes, which favour
membrane dissociation after viral entry (Scarlata et ai, 1998). The matrix protein
contains two nuclear localisation signals (NLS), which regulates the nuclear import
of the pre-integration complex (PIC) (Haffar et ai, 2000). The membrane
associated matrix protein plays an important role in the incorporation of Env
glycoprotein complex. While single and multiple amino acid mutations can block
the incorporation of full-length HIV-1 Env proteins into virions, short cytoplasmic tail




The mature capsid protein forms the capsule around the viral genome and
associated proteins. The structure of the capsid has been studied by both NMR
spectrophotometry (Gitti et ai, 1996) and X-ray crystallography (Gamble et ai,
1996; Momany et ai, 1996) and have been divided into two domains, namely the
core N-terminal domain and the dimerisation C-terminal domain. The core domain
functions in the virion maturation and CypA incorporation, while the dimerisation
domain contributes to the Gag-Gag interactions and therefore formation of
dimeres. Both domains are highly helical, with the core domain composed of
seven a-helices, two p-sheets and an exposed loop, which serves as a binding site
for CypA (Gamble et ai, 1996). The core domain also contains eight highly
conserved proline residues, which is essential for the assembly of proper functional
virion cores (Fitzon et ai, 2000). Upon proteolytic cleavage, the core domain
refolds into a p-hairpinl helix structure, which is stabilised by a salt bridge formation
between the proline residue at position one (Pro-1) and a highly conserved
aspartine residue (Asp-51) (Von Schwedler et ai, 1998). A conserved proline rich
region within the capsid was also implicated in the binding of the capsid to CypA.
Cyclophilin A is a cytoplasmic protein and is a receptor for the immunosuppressant
cyclosporine A. It binds Gag in a ratio of one molecule CypA to 10 Gag molecules
(Gamble et ai, 1996) and may playa role in the destabilisation of the capsid cone
after infection (Endrich et ai, 1999). Incorporation of CypA requires a glycine-
proline motif and is present in the capsid protein in the core domain at position 90
(Luban, 1996) as well as in the dimerisation domain at positions 157 and 224
(Endrich et ai, 1999).
The phosphorylation of three serine residues (Ser-109, Ser-149, and Ser-178)
within the capsid protein, have also been implicated as being essential for viral
uncoating (Cartier et ai, 1999). The dimerisation domain contains a region that is
highly conserved among different genera of retroviruses called the major homology
region (MHR) (Wills & Craven, 1991). Mutations in the MHR showed defects in
14
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virus assembly, maturation and infectivity (Mammano et ai, 1994), which might be
due to structural hindrance. Looking at the crystal structure of the capsid, the MHR
forms a network of hydrogen bonds that stabilise the overall structure of the
dimerisation domain (Gamble et ai, 1997). The C-terminal region of the MHR form
an amphipathic a-helix, which might playa role in the interaction between adjacent
Gag monomeres, other viral components or cellular factors to facilitate virus
assembly and/ or infection (Clish et ai, 1996).
1.3.5.3 Nucleocapsid
The HIV-1 nucleocapsid protein contains two domains with a Cys-X2-Cys-~-His-
Xa-Cys (CCHC) motif, where X equals any variable amino acid (Freed, 1998).
These two domains are similar to zinc finger domains found in many cellular DNA
binding proteins (Berg, 1986) and plays an important role in virion morphogenesis,
genomic RNA packaging and viral infectivity, through binding with single-stranded
nucleic acid (Freed, 1998). The basic linker domain e9RAPRKKG35) between the
two zinc fingers is thought to be important in the spatial proximation of the two
domains (Morellet et ai, 1994). The nucleocapsid also assists in several steps of
reverse transcription, including the stimulation of the binding of the primer for HIV-1
reverse transcription, tRNALys to the primer binding site (Freed, 1998).
1.3.5.4 p6 and Spacer peptides
The C-terminal p6 domain of Gag is a proline-rich domain and is involved in late
stages of virus maturation, which include the packaging of cleaved Pol proteins in
viral particles (Dettenhofer & Yu, 1999). Mutational analyses of the hydrophobic tail
of p6 also revealed that mutations within the hydrophobic tail block the
incorporation of the Env proteins (Ott et ai, 1999). A highly conserved motif (L-X-
X-L-F) (Kondo & Gottlinger, 1996) or more specifically, (L-X-S-L-F-G), was found to
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play a direct role in the incorporation of Vpr. Point mutations within this motif
showed to completely abolish the interaction between Vpr and Pr55Gag, thus
preventing the incorporation of Vpr into the virion (Bachand et ai, 1999).
The capsid and nucleocapsid, as well as the nucleocapsid and p6 domain are
separated by short spacer peptides, p1 and p2 respectively. Although there exists
no consensus in the literature to the naming of the spacer peptides (Pettit et ai,
1994; Wiegers et ai, 1998), this study will refer to the spacer peptide between the
capsid and nucleocapsid as p2, while the spacer peptide between the
nucleocapsid and p6 domain will be referred to as p1. Assembly of virus particles
at the plasma membrane requires several stages of particle development, which
involves the multimerisation of the Gag proteins (Tritel & Resh, 2000; Morikawa et
ai, 2000). It was shown that the p2 domain is essential for ordered assembly as
well as for the higher order multimerisation of Gag proteins (Kraussllch et ai, 1995;
Morikawa et ai, 2000). The spacer peptides are also involved in the regulation of
the sequential steps of the maturation of the Gag polyprotein (Wiegers et ai, 1998;
Pettit et ai, 1994; Krausslich et ai, 1995).
1.3.5.5 Techniques used to characterise the gag gene and Gag protein
1.3.5.5a Cloning and Sequencing
In 1973 Stanley Cohen and his colleagues performed the first cloning experiment
(Cohen et ai, 1973) and together with Kary Mullis and his colleagues, who
discovered the polymerase chain reaction (PCR) (Mullis & Faloona, 1987),
empowered us with two of the most powerful techniques in molecular biology.
These days, one can isolate a particular gene by using PCR and clone it into
vectors, which can be inserted into various organisms to characterise the gene or
the protein it expresses.
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Cloning involves inserting a foreign gene into a vector that can replicate in the
organism to be transformed with the cloned gene. Usually the vector is a plasmid,
which is placed into a bacterial strain. Plasm ids are circular double-stranded DNA,
found in a variety of bacterial species and may carry accessory genes, which can
confer resistance to antibiotics, the use of unusual substances as nutrients and/ or
production of toxins. They are accessory chromosomes and can replicate
autonomously of the host bacteria. Commercially available plasm ids contain
multiple cloning sites, with various restriction enzyme recognition sites, in which the
foreign gene can be inserted. When cloning directional, both the insert and
plasmid are cut with a combination of two enzymes; each enzyme with a different
recognition site, resulting in only one orientation that the insert can be cloned into.
TA cloning is bi-directional and involves the ligation of an insert, usually a PCR
product, containing 3' deoxyadenosine (A) residues, into a vector containing 3'
deoxythymidine (T) residues resulting in an insert that is inserted in any orientation
(Zhou et ai, 1995). Once the foreign gene is inserted into the vector, the
recombinant vector can be inserted into a bacterial strain. It is important to choose
a bacterial strain with a genotype that is complimentary to the plasmid/ vector, as
certain enzymes produced by certain bacterial strains can inhibit or interfere with
the reproduction of foreign DNA (Hanahan, 1985; Kaiser & Murray, 1985).
Plasmids contain a number of characteristics, important for its existence in the host
cell. For replication in bacteria, the plasmid contains an origin of replication site
(Ori), which allows the plasmid to replicate independently from the host DNA. For
expression of the cloned gene in eukaryotic cells, the plasmid must contain a
promoter region and a polyadenylation signal for mRNA stability and effective
termination of transcription. It is important that the foreign gene be inserted in the
forward orientation in expression vectors, when looking at protein production
(Weaver & Philip, 1992).
PCR is the amplification of DNA by using cycles of heat denaturation, primer
annealing, incorporation of dNTPs and elongation of DNA strands by a DNA
17
Stellenbosch University http://scholar.sun.ac.za
polymerase (Mullis & Faloona, 1987) and can therefore be seen as an induced
form of DNA replication. Depending on the primers chosen, PCR can be very
specific and can be used to isolate very specific DNA fragments or even to confirm
the identity of DNA fragments.
Sequencing is the ultimate in genetic mapping, whereby the exact base sequence
of a DNA fragment can be obtained. The method used for sequencing is a PCR
based method, incorporating both dNTPs and dideoxy ribonucleotides (ddNTPs).
Where a ddNTP is incorporated, the elongation of the chain is terminated, resulting
in various lengths of DNA strands, which can be distinguished by electrophoresis,
where the strands are separated according to length (Sambrook et ai, 1989). The
four different ddNTPs are distinguished from one another by labelling each one
with a different dye or separately adding them in four different reactions. The
labelled ddNTPs can be done in one reaction and visualised on machines
recognising the dyes, such as the ASI Prism 310 Genetic Analyzer (Applied
Siosystems, USA), which uses a polymer in an electrophoresis capillary column in
which the DNA fragments are separated according to size; the smaller fragments
run through faster. A window in the capillary is positioned by a laser, which detects
the dye terminators as they pass through and generates an electropherogram,
converting the signals into peaks. The ddNTP connected to a particular length
strand, correlates to the dNTP at that particular position in the sequence (Swerdlow
& Gesteland, 1990). High quality DNA is necessary for sequencing as
contaminants, such as RNA, can interfere with the sequencing reactions by acting
as random primers, resulting in false peaks on the electropherogram.
Contaminating inhibitors of polymerase can also inhibit the sequencing reactions.





Molecular phylogenetics can be defined as the study of evolutionary relationships
among organisms by using molecular data, such as DNA and protein sequences
(Li & Graur, 1991). The comparison of two sequences is referred to as a sequence
alignment. Pairs of bases can align as either matched bases, mismatched bases,
or as insertions/ deletions. An alignment of two sequences can however not show
whether a deletion or insertion had occurred, and the outcome is referred to as a
gap or indel. A gap penalty can be assigned to an alignment of sequences, which
depends on the frequency of gap occurrence relative to point substitutions. A
greater gap penalty will therefore be assigned for sequences with a tendency for
insertions or deletions, while a lesser gap penalty will be given to sequences where
mismatches are more common.
The process in the evolution of DNA sequences is the change in nucleotides with
time. Nucleotide substitutions can be either a transition or a transversion.
Transitions are substitutions between the two purines, adenine and guanine, or
between the two pyrimidines, thymine and cytosine, while transversions are
substitutions between purines and pyrimidines (Weaver & Philip, 1992). There are
numerous mathematical models describing the dynamics of nucleotide
substitutions, but the two most frequently used, are the Jukes and Cantor's one-
parameter model and the Kimura's two-parameter model. The Jukes and Cantor's
model makes the assumption that substitutions occur randomly and with no bias
among the four nucleotides, which is not realistic in most DNA models (Li & Graur,
1991). Kimura's two-parameter model takes into account that transitions generally
occur more frequently than transversions do (Kimura, 1980). Due to the
degeneracy of the genetic code, most of the 20 amino acids are encoded by more
than one codon, and therefore not all nucleotide substitutions in a codon result in a
change in amino acid. A nucleotide substitution that does not change the amino
acid is a synonymous substitution, while a substitution resulting in a change in
amino acid is a nonsynonymous substitution. Generally, the third position in a
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codon is a nonsynonymous site. The rate of nucleotide substitution is defined as
the number of substitutions per site per year. For the majority of eukaryotic genes,
the synonymous substitution rate is greater than the nonsynonymous substitution
rate. The variation in substitution rates is determined by two factors: the rate of
mutation and the probability of fixation of a mutation. Both factors indicate a
selection process, which depends on whether the mutation is advantageous,
neutral, or deleterious. Substitution rates vary between different genes as well as
within different regions of genes, depending on the selection pressures the regions
are exposed to.
The evolutionary relationships among a group of organisms are illustrated as a
phylogenetic tree, which is composed of nodes and branches, in which the nodes
represent taxonomic units and the branches the relationship between the
taxonomic units in terms of their ancestry. External nodes represent the units to be
compared, called operational taxonomic units (OTUs) while the internal nodes
represent the ancestral units. Phylogenetic trees can be either rooted, with a
common ancestor as a root, or unrooted, which only describes the relationships
among the OTUs. There are numerous tree-making methods and most can be
divided into two types: the distance matrix methods and maximum parsimony
methods. Distance matrix methods first convert aligned sequences into a pairwise
distance matrix, then input that matrix into a tree building method, whereas the
maximum parsimony methods consider each nucleotide site directly (Page &
Holmes, 1998).
The simplest method for tree construction is the unweighted pair group method
with arithmetic mean (UPGMA). The UPGMA method assumes that the rates of
evolution among the different lineages are approximately constant (Tate no et ai,
1982). The number of nucleotide or amino acid substitutions are used to employ a
sequential clustering algorithm, whereby the local topological relationships among
OTUs depend on similarity and the tree is built in a stepwise manner of pairing and
clustering. If the rate of evolution among the lineages are not constant, UPGMA
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may give an erroneous topology, but can be corrected by using the transformed
distance method, which uses an outgroup as reference and then applies UPGMA
to infer the tree topology. An outgroup is an OTU that is known to have diverged
from the common ancestor prior to the other OTUs.
One of the most common used tree-making methods is the neighbour-joining
method. This method computes a distance matrix and selects neighbours by
calculating the distances between pairs of OTUs and selecting the smallest sum.
On an unrooted tree, neighbours are connected through a single internal node.
The neighbour-joining method sequentially identifies neighbour pairs that minimise
the total length of the tree and results in a single, unique tree (Saitou & Nei, 1987).
Another commonly used tree-making method is the maximum parsimony method,
which identifies the tree that requires the smallest number of evolutionary changes
to explain the differences in the observed OTUs, but often results in more than one
tree with the same minimum number of changes found (Fitch, 1971).
The majority of tree-constructing methods result in unrooted trees, which can be
rooted with an outgroup. A node is then placed between the outgroup and the rest
of the OTUs. Although the outgroup had to diverge prior to the rest of the OTUs
from the common ancestor, it should not be too distantly related to the rest of the
OTUs, as it might become difficult to obtain reliable estimates of the distances
between the outgroup and other OTUs. In the absence of an outgroup, the root
can be placed at the midpoint of the longest pathway between two OTUs, which
makes the that the rate of evolution has been uniform over all the branches. To
evaluate whether the inferred tree topology is reliable, the bootstrap technique is
employed. The bootstrap estimates the confidence level by repeatedly resample of
data from the original data set (Felsenstein, 1985). Bootstrap values are indicated
on internal branches defining clades.
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1.3.S.Sc In vitro transcription! translation
!n vitro transcription/ translation is the synthesis of mRNA and translation thereof
into proteins in cell-free extracts. For the synthesis of mRNAs, a bacteriophage
DNA-dependant RNA polymerase is used that specifically recognises the
promoter, such as the T7 promoter, of the plasmid wherein the gene to be
transcribed is cloned. Lysates of rabbit reticulocytes or extracts of wheat germ can
be prepared to contain the necessary ribosomes and amino acids needed for
translation (Sam brook et ai, 1989). Certain commercially available kits exclude
certain amino acids, which can be substituted for by labelled amino acids. The
labelled amino acids can then be screened for, which simplifies the screening
process for the produced protein.
1.3.S.Sd Transfection
Most eukaryotic proteins need to undergo post-translational modifications, such as
disulphide bond formation, glycosylation, phosphorylation, oligomerisation, or
specific proteolytic cleavage, which is not available in the prokaryotic model of
bacterial cells. Thus, the expression of proteins form eukaryotic genes is best
studied in eukaryotic cells, such as mammalian cells.
The introduction of foreign genes into mammalian cells is termed transfection.
Transfection can be stable or transient. Foreign genes are firstly cloned into
mammalian expression vectors and then used to transfect the cells. Stable
transfections result in clones stably producing the protein coded for by the inserted
gene. This is achieved when the vector becomes integrated into the host DNA
where it replicates with the host cell. Selection based on negative pressure, like
addition of lethal drugs, allows for the identification of cells containing the
expression vector conferring protection against the negative pressure. Cells that
survive the negative pressure, such as drug treatment, expand into clonal groups,
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which can be selected, propagated and analysed. Transient transfection, however
does not require the integration of the vector into the host DNA. The expression
vectors used contain all the transcription factors necessary for transcription of the
foreign gene. All the transient tranfected cells are harvested within 72 hours of
transfection and screened for protein expression. Expression vectors can also
contain genes encoding selectable markers like the chloramphenicol
acetyltransferase type 1 protein (CAT), which can be detected and quantified by
many commercially available ELISA assays. (Sambrook et ai, 1989, Aldovini &
Feinberg, 1990)
There are many transfection techniques available, including the calcium
phosphate-mediated (CaP04) method, electroporation and the use of liposomes.
The CaP04 method involves the formation of a DNA-calcium precipitate, which is
taken up by cells by phagocytosis or endocytosis and transferred to the nucleus
(Graham & Van der Eb, 1973). The DNA forms a tight complex with the CaP04
and this complex is then resistant to nuclease present in the cell or serum (Loyter
et ai, 1982). The CaP04 method is widely used, because the components used in
the method is easily available and the protocol easy to use. Electroporation
introduces nucleic acids into cells by using an electric pulse to greatly disturb the
cell membrane and form pores through which the nucleic acid can pass (Wong &
Neumann, 1982; Shigekawa & Dower, 1988). Cells that are poorly transfected by
other methods, or are sensitive to chemicals have been shown to be effectively
transfected by electroporation (Aldovini & Feinberg, 1990). The use of liposomes
(Iipofection) involves the encapsulation of the negatively charged nucleic acid by
the cationic lipid molecule (Fraley et ai, 1980). The lipid-DNA molecule has a
positive net charge, which allows it to come into close proximity of the negatively
charged cell membrane, followed by internalisation of the DNA complex.
Irrespective of the transfection method used, the efficiency is largely dependent on
the cell type used, as some cell lines are resistant to transfection by standard




To screen for protein production, the protein preferably has to be in a soluble form.
This involves the harvesting of the transfected cells and lysing the cells to release
the expressed proteins. It is important that the method of lysis be as gentle on the
protein as possible, leaving the protein in an immunoreactive, undegraded and
biologically active form. Most cytoplasmic proteins can be effectively solubilised in
a lysis buffer containing the nonionic detergent Nonidet P-40 (NP-40) and the
addition of protease inhibitors, such as phenylmethylsulfonyl fluoride (PM8F) and
ethylenediaminetetra-acetic acid (EOTA) will limit the amount of degradation
(8ambrook et ai, 1989).
Proteins can then be separated according to size on a polyacrylamide gel. Under
denaturing and reducing conditions the proteins are dissociated into their basic
polypeptide subunits, allowing more accurate prediction of the protein size. The
use of sodium dodecyl sulphate (808), ~-mercaptoethanol and heat are of the
most common substances used for denaturing and reducing conditions (Laemmli,
1970). Under native conditions, the protein exists in its correctly folded,
oligomerised structure and migration through a polyacrylamide gel is not entirely
dependent on size. The gels can be non-specifically stained to visualise all the
proteins in the cell lysate. The electrophoretically separated proteins can also be
transferred to a solid support, where specific proteins can be immunologically
detected for by using a Western blot assay. The transfer of proteins to a
nitrocellulose solid support requires the addition of a current (Towbin et ai, 1979).
Once the protein is on the membrane, the rest of the membrane is blocked for non-
specific binding and then probed with a primary antibody specific for the protein
detected for. A secondary antibody directed against the primary antibody, usually
species specific, and which is conjugated with an enzyme with an easily detectable
biological activity, is then incubated with the membrane. Lastly, a substrate for the
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conjugated enzyme is added, resulting in a reaction, which can be visualised as
bands (Sam brook et ai, 1989).
1.3.6 HIV-1 vaccines strategies
1.3.6.1 Immunology
The immune system responds against infectious agents as a humoral response
and a cell-mediated response. The humoral response involves the production of
secreted antibodies by the B lymphocytes, which recognises and destroys antigens
in the extracellular fluid. Cell-mediated responses induce helper T lymphocytes
(CD4+ cells) that stimulates antibody responses and cytotoxic T lymphocytes
(CTLs)/ (CD8+ cells). CTLs recognise intracellularly processed antigens displayed
on the major histocompatibilty complex (MHC) of an infected cell and lyse the
infected cell, before new antigens/ virus can be produced within that cell. Both of
the humoral and cell-mediated immune responses can be manipulated in the
development of vaccines.
1.3.6.1a Humorallmmunity
Shortly after HIV-1 infection, the body produces antibodies against different viral
proteins and can be detected by a variety of techniques, including ELISA. Most of
the antibodies produced are however not neutralising and do not protect the host
from further infection or disease. The neutralising epitopes of the HIV-1 virus are
located on the gp120 envelope protein and are protected by the variable loops V1
and V2 (Sanders et ai, 2000; Cao et ai, 1997), which shows a high percentage of
diversity in sequence. Neutralising antibodies directed against the native gp120
protein tend to protect against homologous challenge, but not against heterologous
challenge. Recent studies are looking at different constructs and modifications of
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the Env protein to direct antibody productions against the more conservative parts
of the protein (Stamatatos & Cheng-Mayer, 1998; Barnett et ai, 2001).
1.3.6.1.b Cell mediated Immunity
HIV-1 specific CTL responses have been shown to be important in controlling the
virus in HIV-1 infected individuals in the acute stage of infection (Borrow et ai,
1994, Koup et ai, 1994). It also appears that a strong CTL response correlates
inversely to the viral load in infected patients (Clerici et ai, 1996; Musey et ai,
1997). Indirect evidence of CTL control of the HIV-1 virus, comes from highly
exposed, HIV-seronegative persons who display CTL responses against HIV
(Langlade-Demoyen et ai, 1994; Rowland-Jones et ai, 1993, 1999), and the late
seroconversion of previously HIV-resistant prostitutes after the waning of their HIV-
specific CD8+ responses due to reduced antigenic exposure (Kaul et ai, 2001).
More specifically, there appears to be a relationship between HIV-1 Gag-specific
CTL and disease progression (Klein et ai, 1995). Gag is one of the more
conserved HIV-1 proteins and broad, cross-clade CTL responses have been
detected in HIV infected people (Durali et ai, 1998; McAdam et ai, 1998; Buseyne
et ai, 2001). According to the latest Los Alamos Immunology compendium, there
are currently 187 published Gag CTL epitopes. There are 56 p17 CTL epitopes
spanning three areas of the protein, while the 127 epitopes found in the p24
domain, cover the entire region, excluding a small area of 10 amino acids. The
nucleocapsid, p6 and spacer peptide domain contains four published CTL epitopes
spanning three areas (Korber et ai, 2000). It has been shown that HIV-specific
CTL responses can be induced in humans by immunisation with a DNA vaccine in
the form of a plasmid (Calarota et ai, 1998, 1999; MacGregor et ai, 1998).
1.3.6.2 Types of Vaccines
Two main types of vaccines have been developed in the past to stimulate
protective immune responses against viral pathogens. These two types of
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vaccines are firstly, the inactivated whole virus vaccines, which have been
successfully used to protect against poliomyelitis and influenza, and secondly, the
live attenuated viruses, which are infectious but do not cause disease and have
been used as the Sabin oral polio vaccine and the vaccine for mumps, rubella, and
yellow fever (Rovinski & Klein, 1994). It is however thought not to be wise to use
these classical types of vaccines for HIV-1, as there is the risk of integration of the
viral genome into the host genome, or the risk of back mutations resulting in active
viruses (Vermund et ai, 1994). Current approaches involve genetically engineered
HIV-1 vaccines, which include the recombinant envelope-based subunit vaccines,
non-infectious HIV-1 like particles, live recombinant vaccines and DNA vaccines.
Live recombinant vaccines use for example, the recombinant vaccinia viruses or
the Mycobacterium bovis bacillus Calmette-Guerin (BCG) as vectors, into which
HIV-1 genes are inserted (Rovinski & Klein, 1994). There are several types of
DNA vaccines, which mainly differs on the gene inserted and whether the whole
gene or epitopes are used.
Considering the dominance of the subtype C virus within South Africa, the potential
vaccine for South Africa should preferably be derived from the subtype C strains
(Morris et ai, 1997; Esparza & Bhamarapravati, 2000). The current vaccine trials
around the world are of subtype B or E origin (Esparza & Bhamarapravati, 2000).
Table 1.1 summarises the current vaccine trials in developing countries. Only one
vaccine candidate has so far progressed to a phase III trail, which tests for efficacy
of the vaccine. The outcome of the phase III trail will become known within the
year 2002. Although there are studies done on developing subtype C vaccines,




HIV-1 preventive vaccine trials in less-developed countries*
Starting Candidate vaccine Subtype Country Number of
date volunteers
Phase IIII
1993 Synthetic peptide MN-V3 B China 23
1994 Synthetic peptide MN-V3 B Thailand 24
Synthetic peptide MN-V3 B Brazil 30
1995 Envelope gp120 B Thailand 30
Envelope gp120 B Thailand 52
1996 Recombinant V3 protein B Cuba 30
1997 Envelope gp120 B, E, B/E Thailand 380
1998 Envelope bivalent gp120 B/E Thailand 90
1999 Canarypox vector B Uganda 40
2000 Prime-boost canarypox E+E Thailand 130
vector plus gp160 or gp120
Prime-boost canarypox E + B/E Thailand 125
vector plus gp160 or gp120
Phase III
1999 Envelope bivalent gp120 B/E Thailand 2500
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2. Materials and Methods
2.1 Materials
2.1.1 HIV-1 Isolates
HIV-1 was previously isolated from positive patients attending the Infectious
Disease Clinic at the Tygerberg hospital during the period from 1998 to 1999. The
subtype of the virus was determined by serotyping and 18 isolates (15 HIV-1
subtype C and three HIV-1 subtype B) were chosen to be expanded to high
concentrations virus stock (Claassen, 1999). Briefly, the peripheral blood
mononuclear cells (PBMCs) of the HIV-1 positive patients were isolated, co-
cultured with uninfected donor PBMCs and the HIV-1 virus allowed to grow to high
concentrations (Gartner & Popovic, 1990). The PBMCs were lysed and high
molecular weight DNA isolated (Sambrook et ai, 1989). The clinical data and
characteristics of the 18 patients are summarised in Table 2.1. The HIV-1 isolates
were named according to their respective patients from whom they were isolated.
There is no TV011. The isolates TV015 and TV016 were also genotyped as HIV-1
subtype B isolates by sequencing a -650 bp fragment in the gp120 protein,
including the V3 loop (Treurnicht et ai, in press).
2.1.2 Plasmids
2.1.2.1 pCR®3.1 (Invitrogen, USA)
The vector pCR@3.1 is a 5060 bp plasmid and is a mammalian expression vector.
The vector is supplied linearised for TA-cloning in the Eukaryotic TA cloning kit
(Invitrogen, USA). A map and summary of the features of pC~3.1 is given in
Appendix A 1. The vector contains a cytomegalovirus (CMV) promoter, ensuring
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high-level expression of the cloned gene and a bovine growth hormone (BGH)
polyadenylation signal that improves mRNA stability and effective termination.
pCR®3.1 confers resistance to the antibiotics kanamycin, neomycin as well as
ampicillin. For replication and maintenance in E. coli, the vector contains a pUC
origin. The insert can be sequenced by using the BGH reverse priming site and T7
primer binding site. The T7 promoter can also be used in in vitro transcription and
translation assays.
2.1.2.2 pcDNA3.1 (Invitrogen, USA)
For expression studies in mammalian cells, the gene to be studied must be in the
forward orientation in the expression vector. The isolates of which no positive
clones with inserts in the forward orientation in pCR®3.1 were obtained, were
directionally cloned into pcDNA3.1. The plasmid pcDNA3.1 is a mammalian
expression vector of 5428 bp. A map and summary of the features of pcDNA3.1 is
given in Appendix A2. pcDNA3.1 has the same basic features as described for the
pCR®3.1, only without the kanamycin resistance gene. There are two versions of
the pcDNA3.1 vector, which differs in the orientation of the multiple cloning site. In
this study we used the pcDNA3.1 (-) vector.
2.1.2.3 pCR®3.1/CAT (Invitrogen, USA)
To evaluate the different transfection techniques, cells were transfected with the
plasmid, pCR®3.1/CAT (Invitrogen, USA). A map and summary of the vector
pCR®3.1/CAT is given in Appendix A3. The pCR®3.1/CAT vector is a 5809 bp
plasmid containing the gene that encodes for chloramphenicol acetyltransferase
type 1 (CAT). Except for the CA T insert, the plasmid is identical to the vector
pCR®3.1 (Invitrogen, USA) described earlier.
32
Stellenbosch University http://scholar.sun.ac.za
2.1.3 Competent Bacterial strain (Top10F')
As recommended by the suppliers of the plasmids, the competent bacterial strain,
Top 10F' was used in the transformation reactions using pCR@3.1 and pcONA3.1.
A list of genotypes and their corresponding phenotypes is given in Appendix A4.
The genotype of the Top10F' competent cells is:
F' {/aclQTn10(TetR)} mcrM(mrr-hsdRMS-mcrBC) <jl801acUM 15 I'1/acX74
deoR recA1 ara01391'1(ara-/eu)7697 galU ga/K rpsL endA1 nupG
2.1.4 Cell lines
2.1.4.1 Vero cell line
The Vero cell line, an adherent epithelial cell line of the African green monkey
kidney was obtained from W. Hann and J.S. Rhim through the American Type
Culture Collection, USA (ATCC), ATCC number CCL-81. The Vero cell line was
cultured in Oulbecco's modified eagle's medium (OMEM) (Sigma-Aldrich, UK)
supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 units/ml
penicillin and 100 !lg/ml streptomycin (complete medium) and incubated at 3rC.
The media was changed every three to four days and the cells subcultured once a
week. Subculturing or trypsinisation was done by incubating the cells in a 0.25%
active trypsin versine (ATV) solution (135 mM NaCI, 5 mM KCI, 5.6 mM Glucose, 7
mM NaHC03, 0.5% Trypsin, 0.5 mM EOTA) for two minutes or until the cells
detached from the flask wall. The cells were then centrifuged at 1 000 g for five
minutes, the trypsin removed, and the cells seeded at 3 x 105 cells per 75 mm cell




The CV-1 cell line, an adherent fibroblast cell line of the African green monkey
kidney, was obtained by F.C. Jensen (Jensen, 1964) through ATCC, number CCl-




2.2.1.1 Amplification of gag
2.2.1.1a Templates for the amplification of gag
2.2.1.1a(i) Near full-length fragment of the HIV-1genome
A near full-length -9 kb fragment of the HIV-1 genome was previously amplified by
Dr. S Engelbrecht. The -9 kb fragment was amplified by PCR from high molecular
weight (HMW) DNA with the primer set UP1A and low2 (Gao et ai, 1998) and the
Expand long Template kit (Roche, Germany). The PCR products were separated
by agarose gel electrophoresis, the -9 kb fragment excised and purified using the
QIAEX II Gel Extraction kit (Qiagen, Germany).
2.2.1.1a(ii) RNA
RNA was purified from supernatant fluid (SNF) of the last passage of viral culture,
before HMW DNA isolation (2.1.1.1 a(i)), using the QIAamp@ Viral RNA mini kit
(Qiagen, Germany) according to the manufacturer's instructions. The RNA was
converted to cDNA by using the Access RT-PCR system (Promega, USA)
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according to the manufacturer's guidelines, using only the AMV reverse
transcriptase enzyme, without the Tfl DNA polymerase in a 50 III reaction. The
reaction was incubated at 48°C for a period of 45 minutes and the reverse
transcriptase was inactivated by an incubation period of three minutes at 94°C.
2.2.1.1 b Optimisation of peR conditions
A nested PCR was done, using the - 9kb fragment as a pre-nested template. The
primer pair used for the amplification of the gag gene, was GagF (5'GCTAGA
AGGTCTAGAATGGGTGCGAGAGCG3'), with a melting temperature (Tm) of
67.21°C, and GagR (5'AGTTGCCCCCGAATTCTTATTGTGACGAGG3'), with a
Tm of 66.65°C (Qiu et aI, 1999). Both primers have restriction enzyme cleavage
sites, shown by the underlined sections. GagF has a Xbal cleavage site and GagR
an EcoRI cleavage site.
The Expand High Fidelity PCR System (Roche, Germany) was used for the
amplification. The MgCI2 concentration was optimised for the primer pair, using a
titration of 1.5 mM, 2 mM and 3 mM MgC~ in the reactions. The enzyme, primer
and nucleotide concentrations were used according to the manufacturer's
instructions.
The PCR temperature cycle used was as follows: one cycle of denaturing at 94°C
for five minutes, primer annealing at 59°C for one minute and elongation at 72°C
for five minutes. This was followed by 30 cycles of denaturing at 94°C for one
minute, primer annealing at 59°C for one minute and elongation at 72°C for five
minutes. A final elongation was allowed at 72°C for 15 minutes after which the
reaction was cooled down to 4 "C for an indefinite period, until the reaction tubes
were removed from the PCR machine.
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A 3 ul aliquot of the PCR sample was added to 2 ul of sample loading buffer
(0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll) and diluted with
water to a final volume of 12 ul. The mixture was loaded into a slot of a 16 well 1%
agarose minigel in TAE buffer (0.04 M Tris acetate, 0.001 M EDTA), containing 0.5
j..lg/ml ethidium bromide. The DNA molecular weight marker, Lambda/Hind III
(Stratagene, California) was used as a size marker. The dimensions of the minigel
electrophoresis chamber were 10 cm by 10cm and was run at a constant voltage of
5 Volts/cm. The DNA bands were visualised under an ultra violet light at a
wavelength of 302 nm and photographed with the Syngene GeneGenius
(Synoptics Ltd, UK). Non-specific bands were identified as background bands
other than the - 1.5 kb band. The ratio of the concentration of smaller non-specific
bands compared to the concentration of the - 1.5 kb bands were determined by
using the GeneTools version 2.10.02 (Synoptics Ltd, UK) program.
To confirm that the amplified products were indeed of HIV-1 origin and more
specifically of gag, the products were hybridised with the 41 bp digoxigenin labeled
oligo probe, SK19 (5'-ATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCC
CTAC-3') specific for HIV-1 gag (Ou et ai, 1988). The probe was labeled using the
DIG oligonucleotide 3'-end labeling kit (Roche, Germany) according to the
manufacturer's instructions. The detection was in the form of spot blots. Briefly, 2
j..llof the PCR product was mixed with 8 ul denaturation buffer (4 N NaOH, 250 mM
EDTA) and spotted 2.5 ul at a time on a Hybond™-N gridded nylon membrane
(Amersham Life Science, UK). Eight ul of the denaturation buffer was used as a
negative control. The membrane was air-dried and the nucleic acid fixed with ultra
violet light using a Spectrolinker XL-1500 UV crosslinker (Spectronics Corporation,
USA) at 120 millijoules per unit area. The hybridisation and detection were
performed according to the manufacturer's instructions supplied in the DIG nucleic




2.2.1.1 c PCR Reactions
Two III of the purified -9 kb fragment and 5 III of the cDNA were used in
subsequent PCR reactions, using the optimised conditions (2.2.1.1 b). The PCR
products were loaded on a 1% agarose gel and electrophoresis and visualisation
performed as described earlier. The concentration ratios for smaller non-specific
bands to the - 1.5 kb bands were measured with the GeneTools version 2.10.02
(Synoptics Ud, UK) program. Spot blot hybridisations, with an HIV-1 specific probe
as described earlier, were performed on all the PCR products. The products were
then purified using the QIAquick PCR purification kit (Qiagen, Germany).
2.2.1.2 Cloning of gag
2.2.1.2a Cloning into pCR®3.1 (Invitrogen, USA)
The Eukaryotic TA cloning" kit (Invitrogen, USA) was used to clone the amplified
gag PCR products into the plasmid vector pCR®3.1. The ligation reactions were
done according to the manufacturer's guidelines. Briefly, 4 III of the purified PCR
product was ligated into 2 III of the pre-cut vector pCR®3.1. The ligation reaction
was incubated overnight at 14°C. Top 10F' competent cells (Invitrogen, USA) were
transformed with the ligation reactions according to the manufacturer's instructions.
Fifty III and 100 III of the transformed bacterial cells were plated on Luria-Bertani
medium (LB) plates (10 gil bacto-tryptone, 5 gil bacto-yeast extract, 10 gil NaCI, 15
gil bacto agar) containing 50 Ilglml of the antibiotic, kanamycin. The plates were




2.2.1.2b Cloning into pcDNA3.1 (-) (Invitrogen, USA)
2.2.1.2b(i) Restriction Digest
For directional cloning into the vector pcDNA3.1 (-) (Invitrogen, USA), both the
enzymes EcoRI and Xbal were used to digest the PCR products and the vector.
Twelve units of each enzyme were used to digest 1 III of purified PCR product, in
the presence of buffer H (0.9 M Tris-CI, pH 7.5, 0.5 M NaCI, 0.1 M MgC~) and 21lg
of acetylated bovine serum albumin (BSA) at 3rC for four hours. A 5111aliquot of
the digested samples was run on a 1% agarose gel to establish if the chosen
restriction enzymes only cut in the primer sequences and that the PCR product did
not contain a recognition site for EcoRI or Xbal. One)11 of the PCR products that
had recognition sites for Xbal or EcoRI were digested with 12 units of each enzyme
separately and run on a 1% agarose gel as described earlier, to determine which
enzyme cleaved the product.
Two )1g of pcDNA3.1 was digested with either 12 units each of EcoRI and Xbal or
12 units each of EcoRI and EcoRV, under the same conditions as earlier. To
remove unwanted smaller digested fragments of DNA, the samples were purified
through a Centri-sep sephadex spin column (Princeton Separations, USA).
2.2.1.2b(ii) Ligation and Transformation Reactions
PCR products digested with both Xbal and EcoRI were ligated into the vector,
pcDNA digested with both Xbal and EcoRI. The PCR product digested with only
EcoRI was ligated into the vector pcDNA3.1 digested with EcoRI and EcoRV.
Briefly, 2 III of the digested vector and 4 )11of the digested PCR product was ligated
using 4.0 Weiss units of T4 ligase (Invitrogen, USA) in the presence of 1 x ligation
buffer (6 mM Tris-CI, pH 7.5, 6 mM MgC~, 5 mM NaCI, 0.1 mg/ml BSA, 7 mM ~-
mercaptoethanol, 0.1 mM ATP, 2 mM dithiothreitel, 1 mM spermidine). The ligase
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reaction was incubated at 14°C overnight. Top 10F' competent cells (Invitrogen,
USA) were transformed with the ligation mixture according to the manufacturer's
instructions. Fifty III and 100 III of the transformed bacterial cells were plated on
LB plates (10 gil bacto-tryptone, 5 gil bacto-yeast extract, 10 gil NaCI, 15 gil bacto
agar) containing 50 Ilglml of the antibiotic, ampicillin. The plates were incubated at
27°C overnight. After the incubation period, the plates were screened for
recombinant colonies.
2.2.1.2c Screening for recombinants
The transformed bacterial colonies were screened for recombinants with HIV-1 gag
inserts. The protocol followed was the alkaline lysis method as described in small-
scale preparations of plasmid DNA (Sam brook et ai, 1989). The isolated plasmid
DNA (miniprep DNA) was loaded on a 1% agarose gel, and electrophoresis and
visualisation performed as described earlier (2.2.1.1 b). The clones were evaluated
by size, as a plasmid containing a 1.5 kb insert would be significantly larger than
the original plasmid. The recombinant plasm ids were named according to the
plasmid, the isolate number and the number of the miniprep culture, ego
pTV001G15 was cloned into the vector pCR@3.1, from the isolate TV001 and was
the fifteenth miniprep DNA isolated on the day after cloning, while pcTV004G18
was cloned into pcDNA3.1, from the isolate TV004 and the eighteenth miniprep
DNA isolated.
To confirm that the larger plasmids contained a copy of HIV-1 gag, denatured
plasmid DNA was spot blotted on a Hybond™-N Gridded nylon membrane
(Amersham Life Science, UK) and hybridised as described earlier. The spot blot
method requires an overnight incubation and is time consuming. The confirmation
was therefore also done by using PCR incorporating HIV-1 gag specific primers.
PCR confirmation was performed when a set of 20 or less recombinants were
screened, while the spot blot confirmation was performed for the screening of more
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than 20 recombinants at a time. The PCR amplified a 160 bp fragment, using Taq
DNA polymerase (Promega, USA) and the primers HIVgagA (5'-
AGAGAACCAAGGGGAAGTGA-3') with a Tm of 56.56°C and HIVgagB (5'-
TCTCTAAAGGGTTCCTTTGG-3') with a Tm of 52.59°C (Kemp et ai, 1989). The
PCR cycle performed was with two minutes of denaturation at 96°C, followed by 30
cycles of one minute at 94°C, one minute at 44°C and one minute at 72°C. A
further one minute elongation at 72°C was allowed before ending the cycle at 4°C.
The amplified products were loaded on a 2% agarose gel, and electrophoresis and
visualisation performed as described earlier (2.2.1.1 b).
The orientation of the insert in pCR@3.1 was determined by digesting 1 ).11of
miniprep DNA with 6 units of EcoRI in buffer H (0.9 M Tris-CI, pH 7.5, 0.5 M NaCI,
0.1 M MgCb) and in the presence of 2 ).1gof acetylated bovine serum albumin at
37°C for four hours. Ten).11 of the digestion reaction was loaded onto a 1%
agarose gel, and electrophoresis and visualisation performed as described earlier
(2.2.1.1 b).
2.2.1.3 Sequencing of gag
2.2.1.3a Preparation of high quality DNA for sequencing
High quality DNA was prepared by using the Qiagen plasmid midi kits (Qiagen,
Germany). The manufacturer's instructions, with a few modifications were used.
Briefly, 100 ml LB medium (10 gil bacto-tryptone, 5 gil bacto-yeast extract, 10 gil
NaCI, 15 gil) containing 50 ).1g/ml of either kanamycin or ampicillin (depending on
plasmid) was inoculated with 200 ).11of an overnight culture and incubated at 2rC
overnight. The bacterial cells were pelleted and resuspended in 12 ml Buffer P1
(50 mM Tris-CI, pH 8.0, 10 mM EDTA, 100 ).1g/ml Rnase A). The cells were lysed
by gentle mixing with 12 ml of Buffer P2 (200 mM NaOH, 1% SDS). The cell lysate
was then neutralized with 12 ml of chilled Buffer P3 (3.0 M potassium acetate, pH
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5.5) and the genomic DNA, proteins and cell debris precipitated by incubation on
ice for 30 minutes. The precipitate was removed by centrifugation at 20 000 x g for
30 minutes and the cleared cell lysate placed in a clean tube. Ten ml of the lysate
was applied to an equilibrated Oiagen-tip 100 and allowed to flow through the resin
by using vacuum suction. The column was washed twice with 10 ml of Buffer OC
(1.0 mM NaCI, 50 mM MOPS, pH 7.0,15% isopropanol) and the DNA eluted with 5
ml of Buffer OF (1.25 M NaCI, 50 mM Tris, pH 8.5, 15% isopropanol). The column
was equilibrated and the remaining cell lysate applied, washed and eluted in two
subsequent applications. The DNA was precipitated in 30 ml isopropanol,
centrifuged at 20 000 x g for 45 minutes, washed in one ml 70% ethanol and
placed in a microfuge tube. The DNA was pelleted at 13 000 g in a
microcentrifuge, dried and dissolved in 50 III to 150 III of deionised water.
The concentration of the DNA was determined by measuring the optical density of
a diluted sample of the plasmid DNA at 260 nm (00260). The concentration was
then calculated by using the formula, 00260 +- 20 x dilution factor. The optical
density was measured in a Spectronic® Genesys 5 spectrophotometer. To
determine the purity of the plasmid DNA, the optical density was measured at 260
nm (00260) and 280 nm (00280). The purity of the DNA was calculated as a ratio
of optical densities at 260 nm and 280 nm (Sambrook et ai, 1989). A value
between 1.7 and 1.9 indicated pure DNA, suitable for sequencing.
2.2.1.3b Sequencing
Sequencing was done on the ABI Prism 310 Genetic Analyzer (Applied
Biosystems, USA) using the BigDye ™ terminator cycle sequencing ready reaction
DNA sequencing kit (Applied Biosystems, UK). The BigDye ™ terminator cycle
sequencing is a PCR based system using AmpliTaq DNA Polymerase, FS, and




The manufacturer's instructions for sequencing plasm ids and PCR products were
used to prepare the sequencing reactions. Briefly, four III of the terminator ready
reaction mix, 400 ng of plasmid DNA and five pmol of the primer were added to a
final volume of 10 Ill. Seven primers were used to sequence the whole 1.5 kb gag.
Table 2.2 summarises the primers used for sequencing. The positions of T7 and
BGH reverse are also illustrated on the map of pCR@3.1 (Appendix A 1). A
minimum of four primers were used to sequence the whole gene. The cycle
sequencing was performed by repeating 25 cycles of 10 seconds denaturation at
96°C, annealing for five seconds at either 45°C or 59°C (depending on the primer)
and followed by a four minute elongation at 60°C. The reaction was cooled down
to 4°C until the purification was done. The unincorporated dye terminators
interfere with the analysis and must therefore be removed. The sequencing
reactions were purified through Centri-Sep ™ spin columns (Princeton Separations,
USA) and the manufacturer's instructions were used. The samples were allowed
to dry in a vacuum centrifuge and resuspended in 25 III of Template Suppression
reagent (Applied Biosystems, USA). The resuspended samples were denatured at
95°C for five minutes. The denatured sample were then loaded in the ABI Prism
310 Genetic Analyzer (Applied Biosystems, USA) according to the manufacturer's
instructions.
2.2.1.3c Sequencing Data Analysis
The ABI Prism 310 Genetic Analyzer sequence data was converted to an
electropherogram using the DNA Sequencing Analysis software, version 3.3
(Applied Biosystems, USA). The electropherogram was analysed in Chromas,
version 1.43 (McCarthy, Australia) and the nucleotide sequence analysed,
assembled and translated in DNAMAN, version 4.0 (Lynnon BioSoft, Canada). To
evaluate whether our subtype C sequences could be subtyped using a restriction
fragment length polymorphism (RFLP) analysis (Van Harmelen et ai, 1999b), the
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sequences were analysed for Alul and Accl recognition sites, which was performed
using DNAMAN, version 4.0 (Lynnon BioSoft, Canada). The clone sequences
were also analysed for unique, which only cut once, and non-cutting restriction
enzyme recognition sites.
The NCBI HIV-1 subtyping tool (http://www3.ncbi.nlm.nih.gov/retroviruses/subtype/
makepage.cgi?page=sub&type=O) was used to subtype the gag sequences, which
were compared to the set of reference sequences available in the database.
Possible recombinants were analysed by Bootscan analyses using the SimPlot,
version 2.5 software package (Ray, 1999). Sequences of clones identified as
possible recombinants in the subtyping tool were analysed against the subtype B
strains, K03455, M17451 , and our subtype B TV016 isolate.
Nucleotide sequences were aligned using the CLUSTAL X (1.8) software program
(Thompson et ai, 1997). The alignment of the nucleotide and predicted amino acid
sequences were viewed and analysed in GeneDoc (Nicholas & Nicholas, 1997).
Published mutational analyses and CTL epitopes were compared to the alignment
of the predicted amino acid sequences. Phylogenetic trees were constructed using
the nucleotide alignments. Kimura-2-parameter distance calculation, neighbour-
joining tree construction, and bootstrap analysis were done with TREECON for
Windows, version 1.3b (Van de Peer, 1994). Construction of a phylogenetic tree
with all the HIV-1 groups were done by comparing the gag clones to the reference
sequence set in the Los Alamos database and rooted with the HIV-1 group 0
strains. To construct a subtype C tree, the gag clone sequences were compared to
the full length HIV-1 subtype C gag sequences displayed in Table 2.3 and rooted
with the subtype B strains. Hydrophilic and hydrophobic graphs were constructed
in DNAMAN, version 4.0 (Lynnon BioSoft, Canada), using the predicted amino acid
sequences of the gag clones. The graphs were used to establish the maintenance
of the hydrophilic or hydrophobic profiles of different areas of the Gag protein
domains. The amphipathic a-helix of the MHR in the capsid domain, was
reconstructed using the predicted amino acid sequences of the gag clones, to
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establish whether the helix was maintained in our sequences. The original a-helix
was derived from a subtype B sequence (Clish et ai, 1996).
2.2.1.4 DNA Quality Assurance
RNA was isolated from the original patient plasma as well as from the earliest SNF
available. A -160 bp fragment was amplified by PCR using the primers GagA and
GagB (Table 2.2), and sequenced. Two Neighbour-joining phylogenetic trees were
constructed using the programs as described earlier (2.2.1.3c). The first tree was
constructed using all three codon positions, while the second tree was constructed
using synonymous substitutions. The tree was rooted with the sequences of the
subtype B isolates.
2.2.2 Expression Studies
2.2.2.1 In vitro transcription! translation
The TN~ Quick Coupled Transcription/ Translation System (Promega, USA)
together with the Transcend™ Non-Radioactive Translation Detection System
(Promega, USA) was used to verify whether the gag clones could produce
proteins.
The transcription/ translation master mix contained RNA polymerase, nucleotides,
salts, ribonuclease inhibitors and a reticulocyte lysate solution. The T7 RNA
polymerase was used as all the gag inserts were cloned into vectors, downstream
from a T7 promoter. DNA of the clones was prepared by the standard alkaline
lysis method (Sambrook et aI, 1989), the DNA concentration determined as
described earlier and a total of 1 Jlg of DNA was used in each reaction. Half of the
recommended volumes were used, therefore 20 JlI of TN~ Quick Master Mix was
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used and the final volume of each reaction was 25 ~1. The reactions were
incubated at 30°C for 90 minutes after which the detection was done.
The detection system used, incorporated biotinylated lysine residues into the
protein during translation. Five ~I of the translated mixture was added to 20 ~I of
SOS sample buffer (125 mM Tris, 4% SOS, 20% Glycerol, 1% 2-Mercaptoethanol)
and loaded on a 10% Tris-glycine SOS-polyacrylamide gel. The electrophoresis
was performed at a constant voltage of 150 Volts for two hours in a "Mighty Small"
slab gel electrophoresis unit SE 250 (Hoefer Scientific Instruments, Ca, USA)
containing electrophoresis buffer (0.025 M Tris pH 8.3, 0.192 M glycine, 0.1%
SOS) in both the upper and lower chambers. The proteins were transferred to a
Hybond ECl nitrocellulose membrane (Amersham Life Science, UK) using the
Mighty Small™ tank transfer unit (Hoefer Scientific Instruments, USA) filled with
the Towbin transfer buffer (25 mM Tris, 192 mM Glycine, 10% methanol) (Towbin
et ai, 1979) at 100 Volts for one hour. Non-specific binding sites on the membrane
were blocked by incubation with TBS-T (20 mM Tris-CI, pH 7.5, 150 mM NaCI,
0.5% Tween-20) and the rest of the detection was done according to the
manufacturer's instructions. The translated proteins were colorimetricly detected
after incubation with a streptavidin-alkaline phosphatase conjugate.
2.2.2.2 Screening for Mycoplasma contamination in cell lines
A nested PCR assay, to detect any mycoplasma contamination in the cell cultures
used for transfections, was performed by Ms M. Claasen or Mrs l. Wilsdorf. The
Mycoplasma detection kit (ATCC) was used to screen the cell cultures for
mycoplasma contamination. In a mycoplasma contaminated cell culture, the
detection kit produces a PCR product ranging in size from 236 bp to 365 bp,
depending on the Mycoplasma species present in the contaminated culture
(Harasawa et ai, 1993; Tang et ai, 2000). The supplier's instructions were followed.
Screening for mycoplasma contamination is performed routinely by technologists




2.2.2.3a Preparation of Endotoxin free plasmid DNA for transfections
The removal of endotoxins from DNA can improve transfection efficiency into
mammalian cells, especially in sensitive cells. The EndoFree plasmid Maxi
protocol (Qiagen, Germany) was used according to the manufacturer's instructions.
The DNA concentration and purity was determined as described earlier.
2.2.2.3b Transfection Techniques
2.2.2.b(i} Tfx™ Transfection (Promega, USA)
The Tfx™ reagents contain a synthetic cationic lipid molecule [N,N,N',N'-
tetramethyl-N,N'-bis(2-hydroxy-ethyl)-2,3,-di(0Ieoyloxy)-1 ,4-butanediammonium
iodide]. There are three different Tfx™ reagents available: Tfx™-10, Tfx™-20 and
Tfx™-50 and the manufacturer's instructions were used in the transfection
reactions. The Tfx™-10 reagents were used for transfecting Vero cells and Tfx™-
50 for CV-1 cells, which was according to the guidelines given in the Tfx™
reagents kit protocol (Promega, USA). A range of DNA concentrations was used,
ranging from 0.25 I1g to 1.0011gof endotoxin free plasmid DNA. The Tfx™ reagent
to DNA ratio was also optimized, using a 4: 1 and 2:1 ratio in reactions.
2.2.2.3b(ii} Calcium Phosphate (CaP04) Mediated Transfection
The standard protocol for CaP04 transfection of adherent cells as described in
(Sambrook et at, 1989) was followed. Briefly, cells were trypsinised and plated at 2
x 106 cells per 60 mm culture flask. The cultures were incubated for 24 hours at
37°C in a humidified incubator with 5% CO2 atmosphere. After 24 hours the cells
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were directly exposed to DNA precipitate containing 8.8 ).1gof endotoxin free
plasmid DNA, HEPES-buffered saline (HBS) (140 mM NaCI, 5 mM KCI, 0.75 mM
Na2HP042H20, 6 mM dextrose, 25 mM HEPES) and 124 mM CaCb for 15
minutes at room temperature. Seven ml of pre-warmed complete medium was
then added to the cells and incubated for 16 to 18 hours at 3rC in a humidified
incubator with a 5% CO2 atmosphere. After 18 hours the cells were washed once
with phosphate-buffered saline (PBS) (80 mM Na2HP04, 20 mM NaH2P04, 100
mM NaCI, pH 7.5) and seven ml of pre-warmed complete medium was added and
incubated for a further 60 hours in a humidified incubator with a 5% COz
atmosphere at 3rC.
2.2.2.3b(iii) Electroporation
The Gene Pulser II system (Bio-Rad, USA) with the Capacitance Extender PLUS
module (Bio-Rad, USA) was used for the electroporation. Cells were trypsinised
and seeded at 2 x 106 cells/ml in serum-free DMEM medium (Sigma-Aldrich, UK)
containing 100 units/ml penicillin and 100 ).1g/ml streptomycin. Five hundred ).11of
the cells were added together with 10 ).1gof endotoxin free plasmid DNA to a 0.4
cm cuvette and placed into the shocking chamber of the electroporator. An electric
pulse of 0.3 Volts was applied to the cuvette at a capacitance of 1000 ).1F. The
electroporated cells were immediately added to 1.5 ml warm complete medium in
one well of a six well plate and incubated for 72 hours at 3rC in a humidified
incubator with a 5% CO2 atmosphere.
2.2.2.3c Antigen preparation
The transfected cells were harvested 72 hours post transfection. The supernatant
fluid (SNF) was removed and the cells washed twice with ice cold PBS (80 mM
Na2HP04, 20 mM NaH2P04, 100 mM NaCI, pH 7.5). One ml or 500 ).11of lysis
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buffer (150 mM NaCI, 10 mM Tris-CI, pH 7.4, 1 mM EOTA, 1% NP-40, 1 mM
PMSF, 1% Sodium deoxycholate, 0.1% SOS, 0.02% Sodium azide) was added to
one 60 mm flask or one well of a 6 well plate respectively and incubated on ice for
30 minutes. The cell lysate was then centrifuged in a microcentrifuge at 15 000 x g
for 10 minutes, after which the clear SNF was placed into a clean microfuge tube
and stored at -20°C until used in further applications.
2.2.2.3d Evaluation of the Transfection Techniques
The levels of CAT expression in the transfected cells were determined by using a
CAT ELISA (Roche, Germany). The manufacturer's instructions were followed.
2.2.2.4 SOS-Polyacrylamide Gel Electrophoresis (SOS-PAGE)
Fifteen III of cell lysate was added to 15111of SOS sample buffer (125 mM Tris, 4%
SOS, 20% Glycerol, 1% 2-Mercaptoethanol), denatured and loaded on a 10% Tris-
glycine SOS-polyacrylamide gel. The full range Rainbow molecular weight marker
(Amersham Life Science, UK) was used as a size standard on the gel and HIV-
1111BP55Gagwas added as a positive control. The HIV-111IBP55Gagwas obtained
from Mr Steve Showalter and Ms Maria Garcia-Moll (BioMolecular Technology)
through the NIH AIDS Research and Reference Reagent Program, OIAOS, NIAIO,
NIH. The electrophoresis was performed at a constant voltage of 200 Volts for 1.5
hours in a Hoefer miniVE vertical electrophoresis system (Amersham Pharmacia
Biotech, USA) containing electrophoresis buffer (0.025 M Tris pH 8.3, 0.192 M




After the SDS-polyacrylamide electrophoresis was complete, the proteins were
transferred to a Hybond ECl nitrocellulose membrane (Amersham Life Science,
UK) using the Hoefer miniVE Blot module (Amersham Pharmacia Biotech, USA)
according to the manufacturer's instructions. Briefly, the module containing the gel
and membrane sandwich, was filled with the Towbin transfer buffer (25 mM Tris,
192 mM Glycine, 10% methanol) and the tank filled with chilled distilled water.
Transfer was performed at 25 Volts for one hour. Non-specific binding sites were
blocked with TBS-T (20 mM Tris-CI, pH 7.5, 150 mM NaCI, 0.5% Tween-20)
containing 5% skim milk for at least one hour at room temperature. The membrane
was washed twice in TBS-T (20 mM Tris-CI, pH 7.5, 150 mM NaCI, 0.5% Tween-
20) and incubated in either a 1/100 diluted human HIV-1 positive serum or a
1/1000 diluted sheep antiserum to HIV-1 p24 for at least one hour. The antiserum
to HIV-1 p24 was obtained from Dr. Michael Phelan through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH (Karacostas et ai,
1989). The membrane was washed three times for five minutes each with TBS-T
(20 mM Tris-CI, pH 7.5, 150 mM NaCI, 0.5% Tween-20) and incubated for an hour
with a 1/10 000 diluted either anti-sheep or anti-human secondary antibody. The
anti-sheep secondary antibodies were horseradish-peroxidase conjugated and the
anti-human antibodies were either alkaline phophatase- or horseradish-peroxidase
conjugated. The membrane was washed three times of five minutes each with
TBS-T (20 mM Tris-CI, pH 7.5, 150 mM NaCI, 0.5% Tween-20). For the
horseradish-peroxidase detection, the ECl Plus kit (Amersham Pharmacia biotech,
USA) was used according to the manufacturer's instructions. The Western Blue®
stabilized substrate (Promega, USA) was used according to the manufacturer's




Demographics of 18 HIV-1 infected patients
Genderl Risk CD4 Serotype Source of
Patient Age Clinical Symptoms
count infectionfactor
TV001 36 Male! Heta Dermatitis 196 C Unkown
TV002 35 Male! Het" Oral Candidiosis 309 C Unkown
TV003 38 Male! Het" Pulmonary TB 117 C Transkei! CTd
TV004 38 Female! Heta TB adenitis 435 C Unkown
TV005 36 Female! Heta Oral!tracheal Candidiosis 64 C Kraaifontein
TV006 26 Female! Het" TB pleuritis 116 C Bellville
TV007 24 Female! Het" Dermatitis 363 C Gauteng
TV008 31 Female! Het" Bladder infection 125 C Zimbabwe
TV009 31 Male! Heta Pulmonary TB 171 C Mfuleni
TV010 21 Female! Heta Lymphadenopathy 167 C Khayelitsha
TV012 32 Male! Heta Oral!nasopharyngeal 3
C Unkown
Candidiosis, diarrhea
TV013 43 Female! Heta Pneumonia 765 C Unkown
TV014 33 Male! Heta Pulmonary TB unknown C Namibia
TV015 28 Male! Horn" Wasting, stomach ulcers 420
No Unkown
reaction
TV016 39 Male! Bic Loose stools 421 B!D Unkown
TV017 22 Male! Heta Glandular fever, 200
B Unkown
Candidiosis, wasting
TV018 56 Male! Heta Pulmonary TB 201 C Transkei! CTd
TV019 37 Female! Het" Asymptomatic 100 C Unkown





Primer Sequence (5' - 3') Orientation Reference
GagF GCTAGAAGGTCTAGAATGGGT Forward Qiu et ai, 1999GCGAGAGCG
GagR AGTTGCCCCCGAATTCTTATT Reverse Qiu et ai, 1999GTGACGAGG
GagA AGAGAACCAAGGGGAAGTGA Forward Kemp et ai, 1989
GagB TCTCTAAAGGGTTCCTTTGG Reverse Kemp et ai, 1989
G40 GACACCAAGGAAGCTTTAGA Forward Sanders-Buell et ai, 1995
G60 CAGCCAAAATTACCCTATAGT Forward Sanders-Buell et ai, 1995
GCAG
G80 ATGAGAGAACCAAGGGGAAGT Forward Sanders-Buell et ai, 1995GA
Eukaryotic TA Cloning ® Kit
T7 primer TAATACGACTCACTATAGGG Forward (Bidirectional) Version H
BGH
Eukaryotic TA Cloning ® Kit





Reference sequences of full-length HIV-1 subtype C gag.
Name Acc. no. Description Year Reference
92BR025 U52953 HIV-1, isolate from Brazil 1992 Gao et ai, 1996
98BR004 AF286228 HIV-1 strain from Brazil 1998 Rodenburg et ai, 2001
96BW06H51 AF290027 HIV-1 isolate 96BW06 from Botswana 1996 Ndung'u et ai, 2000
BW.MJ4 AF321523 HIV-1 infectious molecular clone MJ4 Ndung'u et ai, 2001
from Botswana
96.BW01B03 AF110959 HIV-1 isolate 96BW01, clone B03 from 1996 Novitsky et ai, 1999
Botswana
96BW01B21 AF110960 HIV-1 isolate 96BW01, clone B21 from 1996 Novitsky et ai, 1999
Botswana
96BW01B22 AF110961 HIV-1 isolate 96BW01, clone B22 from 1996 Novitsky et ai, 1999
Botswana
96BW0402 AF110962 HIV-1 isolate 96BW04, clone 02 from 1996 Novitsky et ai, 1999
Botswana
96BW0407 AF110963 HIV-1 isolate 96BW04, clone 07 from 1996 Novitsky et ai, 1999
Botswana
96BW0408 AF110964 HIV-1 isolate 96BW04, clone 08 from 1996 Novitsky et ai, 1999
Botswana
96BW0409 AF110965 HIV-1 isolate 96BW04, clone 09 from 1996 Novitsky et ai, 1999
Botswana
96BW0410 AF110966 HIV-1 isolate 96BW04, clone 10 from 1996 Novitsky et ai, 1999
Botswana
96BW0504 AF110968 HIV-1 isolate 96BW05, clone 04 from 1996 Novitsky et ai, 1999
Botswana
96BW1104 AF110969 HIV-1 isolate 96BW11, clone 04 from 1996 Novitsky et ai, 1999
Botswana
96BW1106 AF110970 HIV-1 isolate 96BW11, clone 06 from 1996 Novitsky et ai, 1999
Botswana
96BW11B01 AF110971 HIV-1 isolate 96BW11, clone B01 from 1996 Novitsky et ai, 1999
Botswana




96BW15B03 AF110973 HIV-1 isolate 96BW15, clone 03 from 1996 Novitsky et ai, 1999
Botswana
96BW15C02 AF110974 HIV-1 isolate 96BW15, clone C02 from 1996 Novitsky et ai, 1999
Botswana
96BW15C05 AF110975 HIV-1 isolate 96BW15, clone C05 from 1996 Novitsky et ai, 1999
Botswana
96BW16B01 AF110976 HIV-1 isolate 96BW16, clone B01 from 1996 Novitsky et ai, 1999
Botswana
96BW16014 AF110977 HIV-1 isolate 96BW16, clone 014 from 1996 Novitsky et ai, 1999
Botswana
96BW1626 AF110978 HIV-1 isolate 96BW16, clone 26 from 1996 Novitsky et ai, 1999
Botswana
96BW17A09 AF110979 HIV-1 isolate 96BW17, clone A09 from 1996 Novitsky et ai, 1999
Botswana
96BW17B03 AF110980 HIV-1 isolate 96BW17, clone B03 from 1996 Novitsky et ai, 1999
Botswana
96BW17B05 AF110981 HIV-1 isolate 96BW17, clone B05 from 1996 Novitsky et ai, 1999
Botswana
96BW0502 AF110967 HIV-1 isolate 96BW05, clone 02 from 1996 Novitsky et ai, 1999
Botswana
96BW06K18 AF290030 HIV-1 isolate 96BW06, clone K18 from 1996 Ndung'u et ai, 2000
Botswana
96BW06J7 AF290029 HIV-1 isolate 96BW06, clone J7 from 1996 Ndung'u et ai, 2000
Botswana
96BW06J4 AF290028 HIV-1 isolate 96BW06, clone J4 from 1996 Ndung'u et ai, 2000
Botswana
86.ETH2220 U46016 HIV-1 isolate C2220 from Ethiopia 1986 Salminen et ai, 1996
981S002 AF286233 HIV-1 strain 981S002 from Israel 1998 Rodenburg et ai, 2001
IN.AF209990 AF209990 HIV-1 isolate C-Gag-221 from India Gupta et ai, 2001
931N904 AF067157 HIV-1 isolate 301904 from India 1993 Lole et ai, 1999
931N905 AF067158 HIV-1 isolate 301905 from India 1993 Lole et ai, 1999
931N101 AB023804 HIV-1 subtype C genomic RNA 1993 Mochizuki et ai, 1999
931N999 AF067154 HIV-1 isolate 301999 from India 1993 Lole et ai, 1999
941N476 AF286223 HIV-1 strain 941N476 from India 1994 Rodenburg et ai, 2001
941N11246 AF067159 HIV-1 isolate 11246 from India 1994 Lole et ai, 1999
951N21068 AF067155 HIV-1 isolate 21068 from India 1995 Lole et ai, 1999
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981N012 AF286231 HIV-1 strain 981N012 from India 1998 Rodenburg et ai, 2001
981N022 AF286232 HIV-1 strain 981N022 from India 1998 Rodenburg et ai, 2001
98TZ013 AF286234 HIV-1 strain 98TZ013 from Tanzania 1998 Rodenburg et ai, 2001
98TZ017 AF286235 HIV-1 strain 98TZ017 from Tanzania 1998 Rodenburg et ai, 2001
97ZA012 AF286227 HIV-1 strain 97ZA012from South Africa 1997 Rodenburg et ai, 2001
96ZM651 AF286224 HIV-1 strain 96ZM651 from Zambia 1996 Rodenburg et ai, 2001
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3.1.1 Amplification of gag
3.1.1.1 Optimisation of PCR conditions
To optimise the conditions of the PCR reactions, a titration of three different MgCI2
concentrations were used in reactions using the - 9 kb fragments of six different
HIV-1 isolates as templates. The PCR products were visualised on a 1% agarose
gel with two rows of 16 wells (Figure 3.1). All six PCR products in all three MgCI2
concentrations yielded a strong band of approximately 1.5 kb in length. All three
MgCI2 concentrations showed little or no visible background on the agarose gel.
The PCR product of the isolate TV013, displayed a smaller non-specific band with
a concentration ratio of 1:5 when compared to the - 1.5 kb band. The PCR
products produced in 3 mM MgCI2 (Mix 4) showed smearing possibly caused by
non-specific primer binding. Two mM MgCb produced PCR products with the least
amount of background. The subsequent PCR reactions were done using a MgCI2
concentration of 2 mM.
To confirm that the amplified PCR products were HIV-1 gag, a spot blot of the PCR
products of the 2 mM MgCb titration, were done and hybridised with an HIV-1 gag




3.1.1.2 peR results of the different templates
3.1.1.2a Near full-length - 9 kb fragment as template
PCR reactions, using the - 9 kb fragment as template were performed three times
on separate occasions. The purpose of the first set of reactions was to optimise
the PCR conditions (3.1.1.1). The second group of reactions was done to obtain
PCR products for cloning into pCR®3.1 (Figure 3.3). Two of the products displayed
smaller background bands, indicated by perforated arrows. The ratio of the non-
specific band to the - 1.5 kb band for the PCR product of the isolate TV003 was
1:2, while the ratios of the two non-specific bands compared to the - 1.5 kb band
for the product of the TV007 isolate, were 1:10 and 1:14 respectively. The third set
of PCR reactions was performed to obtain PCR products for cloning into pcDNA3.1
(Figure 3.4). The PCR product of the isolate TV007, displayed a larger band,
indicated by a perforated arrow, with a concentration ratio of 1:7 when compared to
the - 1.5 kb band. All PCR products of the three sets were positive upon
hybridisation with an HIV-1 gag specific probe (data not shown).
3.1.1.2b RNA as template
There were no suitable -9kb PCR products for the isolates TV009 and TV014, and
RNA was therefore used as templates. Faint bands, in the region of the - 1.5 kb
positive band of the positive control, were observed for both isolates (Figure 3.5).
Both PCR products were positive upon hybridisation with an HIV-1 gag specific
probe. The PCR products were used in directional cloning into pcDNA3.1.
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3.1.2 Cloning of gag
3.1.2.1 Cloning into pCR®3.1
3.1.2.1 a Screening for recombinants
Clones were screened for inserts by evaluating the size of their plasmids.
Plasm ids with inserts were larger than the 5 kb native pCR®3.1 and therefore
migrated slower on an agarose gel. Figure 3.6 is an example of such an
evaluation. A plasmid containing a 1.5 kb gag insert would be -6.5 kb in size. On
a 1% agarose gel, the difference in migration between a 5 kb plasmid and a 6.5 kb
plasmid is sufficient for selection. Figure 3.7 and Figure 3.8 are examples of the
two confirmation processes, which were used to identify HIV-1 gag positive clones.
Figure 3.7 illustrates an electrophoretic analysis of PCR confirmation, while Figure
3.8 illustrates confirmation by hybridisation. Table 3.1 displays the number of HIV-
1 gag positive clones obtained for the different isolates.
3.1.2.1 b Determination of the orientation of the inserts
The gag positive clones were digested with the restriction enzyme, Xbal to
determine the orientation of the inserts. The enzyme, Xbal cut in the forward
primer, GagF, and in the multiple cloning site, 43 bp downstream of the insert.
Clones with inserts in the forward orientation would give a restriction pattern of a
-5 kb band and a -1.5 kb band on a 1% agarose gel. Such patterns can be seen
in Figures 3.9 (A and B) in lanes 3, 6, 15, 16, 21, 22, 23, 24, 26, 28, 45 and 51,
which represent the following clones respectively: pTV012G34, pTV012G40,
pTV019G20, pTV019G51, pTV013G2, pTV013G8, pTV013G11, pTV013G15,
pTV001G8, pTV001G11, pTV009G97, pTV018G60. Clones with inserts in the
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reverse orientation display a Xbal restriction pattern of a -6.5 kb band without the
smaller band on a 1% agarose gel. The number of HIV-1 positive clones with
inserts in the forward orientation, in the vector pCR®3.1, is displayed in Table 3.1.
3.1.2.2 Cloning into pcDNA3.1(-)
3.1.2.2a Restriction digest for directional cloning
Purified PCR products of the isolates TV002, TV003, TV004, TV005, TV007,
TV008, TV009, TV010, and TV014, as well as the vector, pcDNA3.1 (-) were
digested with the restriction enzymes Xbal and EcoRI. The digested PCR product
of the isolate TV003 migrated faster through the agarose gel than the other
products (Figure 3.10), indicating that the TV003 product was smaller than the rest.
Figure 3.4 however showed that the undigested TV003 PCR product was the same
size as the rest of the PCR products, suggesting that TV003 contained an EcoRI
and/or Xbal cleavage site. To determine which of the restriction enzymes cleaved
the product of TV003, restriction digestions of both enzymes, separate and
together, were performed (Figure 3.11 ).
3.1.2.2b Screening for recombinants
Screening and confirmation of clones were done as described for pCR®3.1 (Figure
3.7 and Figure 3.8). The number of HIV-1 gag positive clones for the different
isolates is given in Table 3.2.
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3.1.1 Sequencing of gag
3.1.3.1 Sequencing Data
The full length gag sequences were assembled for the clones TV001 G8,
TVOO1G11, TVOO2G8, TVOO3G15, TVOO4G17, TVOO4G24, TVOO5G29,
TVOO5G36, TVOO6G11, TVOO6G97, TVOO7G59, TVOO8G65, TVOO8G66,
TVOO9G12, TV010G74, TV012G34, TV012G40, TV013G2, TV013G15,
TV014G73, TV018G60, TV019G20, TV019G25. The nucleotide and amino acid
sequences are listed in Appendix B1. All sequences, except for both clones of the
isolate TV006, contained a single open reading frame (ORF) with no early stop
codons. The clone TV006G11 contained a two nucleotide deletion in the beginning
of the gag sequence, resulting in a frame shift. The clone TV006G97 contained an
early stop codon, resulting in a truncated protein. Table 3.3 summarises the size
of the different gag clones and their nucleotide compositions, which will be used to
explain the instability of gag mRNA transcripts.
3.1.3.2 Sequencing Data Analyses
3.1.3.2a Nucleotide Sequence Analyses
3.1.3.2a(i) Restriction Digest Analyses
The sequences of the gag clones were analysed for recognition sites for the
restriction enzymes, Alul and Accl. The restriction maps for the different gag Clone
sequences are given in Appendix B2.1. The unique cutting restriction enzymes as
well as the non-cutting enzymes were identified for all the clone sequences. The





The results of the NCBI HIV-1 subtyping tool are given in Appendix B3, while
representative plots are given in Figure 3.12. Fifteen of the isolates were identified
as subtype C and one isolate, TV016 as subtype B. The similarity plot is colour
coordinated with subtype C being a green bar and subtype B a red bar. Figures
3.12 (A & B) are representatives of subtype C sequences. The similarity plots for
the isolate TV006 (Figures 3.12 C & D) are different from the rest of the subtype C
similarity plots, which shows one window of 300 bp that is more similar to a
subtype B. Bootscan graphs of the clones TV006G11 and TV006G97, constructed
in SimPlot, are given in Figures 3.13 (A-F). Each bootscan graph shows the
comparison of the TV006 sequence to two subtype C sequences (TV001 G8 and
TV004F17), and one subtype B sequence (K03455 or M17451 or TV016G95). A
recombination breakpoint can be seen in Figures 3.13 A and C, at positions 600 bp
to 1000 bp, where the subtype B sequence of K03455 in this region shows the
highest percentage of permuted trees and both the subtype C reference
sequences show a sharp drop in percentage permuted trees. This - 400 bp
recombination area is not seen in the other bootscan graphs where the subtype B
sequences are M17451 or TV016G95.
3.1.3.2a(iii) Phylogenetics
Phylogenetic analysis of the gag clone sequences compared to a set of HIV-1
reference sequences, is given in the form of a rooted phylogenetic tree (Figure
3.14). This tree confirms the NCBI subtyping, which shows that our 15 isolates
cluster with the reference subtype C sequences and the isolate, TV016, clusters
with the subtype B sequences. The rooted phylogenetic tree in Figure 3.15
displays the relationship between the different subtype C strains (Table 2.3) and
our isolates. The distance matrices are given in Appendix B for the complete gag
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gene (Appendix B4.1), the matrix (Appendix B4.2), the capsid (Appendix B4.3), the
region between the nucleocapsid and p6 (Appendix B4.4), as well as for the three
regions within the matrix containing published CTL epitopes (Appendix B4.5). The
distance matrices for the CTL epitope areas, were calculated on the amino acid
alignments of these areas. The rest of the matrices were calculated on the
nucleotide alignments. The data obtained from the distance matrices are also
summarised in Table 3.4, which shows the minimum and maximum variation found
within the different areas. The variation was calculated as the difference between
100% and the percentage identical residues between two sequences.
3.1.3.2b Predicted Amino Acid Sequence Analyses
The amino acid alignment (Appendix B5) shows the variation of the amino acid
sequences between the different subtype C strains, our isolates and two subtype B
strains, of which one is the clone of the isolate TV016. Dots indicate identical
sequence to the reference sequence, TV001 G11, while mismathes are indicated
by the amino acid at that particular position. Dashes indicate indels.
The hydrophilicity and hydrophobic graphs of the clones are displayed in Figures
3.16 (A & B) and Figures 3.16 (C & D) respectively. The hydrophatic helix of the
major homology region found in the capsid domain is displayed in Figure 3.17.
The amino acid sequence within the helix is as was found in the subtype C clones.
3.1.3.3 DNA Quality Assurance
A rooted phylogenetic tree (Figure 3.18 A & B) displays the relationship between
the clone sequences and the sequences of the plasma and/or SNF. Figure 3.18A
was calculated using all alignment positions, while Figure 3.18B was calculated
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only using the synonymous substitutions. Bootstrap values above 50 % are
indicated.
3.2 Expression studies
3.2.1 In vitro transcriptionl translation
To determine whether the clones with inserts in the forward orientation produced
proteins, an in vitro transcription/ translation was performed on them. The clones
TV001G8, TV001G11, TV002G8, TV003G15, TV004G24, TV005G36, TV006G11,
TV006G97, TV007G59, TV008G66, TV009G12, TV010G74, TV012G34,
TV012G40, TV013G2, TV013G15, TV014G73, TV016G95, TV018G60, and
TV019G20, were subjected to this translation system and the proteins were
detected by Western blot. Figures 3.19 (A-E) represent the blots. The Western
blots represented by Figures 3.19 (A) and (B) were done at the same time, while
(C) and (D) were done a week later. A coloured band in the region of 55 kDa was
considered as positive, and therefore the clones TV002G8, TV013G15,
TV004G24, TV008G66, TV001G11, TV009G12 and TV014G73 were considered to
be protein-producing clones. The in vitro transcription/ translation of the clone
TV001 G11 seen in Figure 3.20 (E) was performed with DNA that was older than
four months. All the other translations were performed with DNA that was not older
than two weeks.
3.2.2 Cell culture and screening for mycoplasma contamination
Both the Vero and CV-1 cell lines grew adherent. The Vero cells were fast growers
and a monolayer of cells was achieved within two days after subculture. The CV-1
cells grew slower and monolayers were only achieved by day three or four after
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subculture. All the cell lines used were negative for mycoplasma contamination and
remained negative with routine testing thereafter.
3.2.3 Evaluation of the transfection techniques
The cell lines, Vero and CV-1, were transfected with the vector pCR®3.1/CAT,
using the CaP04, Tfx™ and electroporation methods. The transfection methods
were evaluated on the concentration of the CAT protein produced. Table 3.5
summarises the results of the evaluation of the Tfx™ method, while Table 3.6
summarises the results of the evaluation of the CaP04 and electroporation
methods. The concentrations of the CAT production of the different transfection
techniques were also plotted on graphs (Figure 3.20 A & B).
3.2.4 Transfection
Endotoxin free DNA was prepared of the clones TV001 G11, TV002G8, TV004G24,
TV008G66, TV009G12, TV013G15, and TV014G73 and were transfected into the
Vero cell line, using the electroporation technique. A faint band above the 50 kDa
size marker and corresponding height to the positive control was observed in the
lanes representing the clones TV008G66 and TV013G8 (Figure 3.21 A). In a
following Western blot, the positive control failed to be detected (data not shown).
The positive in vitro transcription/ translation sample of the clone, TV009G12 was
used as a positive control in subsequent Western blots, which was
immunodetected with goat antibodies specific for HIV-1 Gag. The detection was
done using ECl detection (Figure 3.21 B). Both of the clones, TV009G12 and
TV014G73 were positive for production of a-55 kDa protein, which correlated to a










TV001 20 4 2
TV002 30 3 0
TV004 17 5 0
TV005 12 1 0
TV006 44 6 1
TV007 37 3 0
TV008 74 5 0
TV012 40 5 2
TV013 9 4 4
TV018 5 2 1




The number of HIV-1 gag positive pcDNA3.1 clones














The nucleotide and amino acid composition of the HIV-1 subtype C gag clones
Clone Size in bp" Ad Cd Gd Td No. aa" MW (Da)
pTV001G8 1494 37 20 24 19 497 55374
pTV001G11 1494 37 19 24 19 497 55404
pcTV002G8 1464 37 19 24 20 487 54503
pcTV003G15 1476 37 19 24 19 491 54812
pcTV004G17 1479 37 20 25 19 492 54889
pcTV004G24 1479 37 20 25 19 492 54793
pcTV005G29 1479 37 19 24 19 492 55109
pcTV005G36 1479 37 19 24 19 492 55052
pcTV006G11 1468 37 19 25 19 488 54593
pTV006G97 1460 37 19 24 19 485 54315
pcTV007G59 1500 37 20 24 19 499 55511
pTV008G65 1476 36 20 25 19 491 54695
pcTV008G66 1476 37 20 24 19 491 54899
pcTV009G12 1479 37 19 25 19 492 54769
pcTV010G74 1482 37 20 24 19 493 55088
pTV012G34 1491 36 20 24 19 496 55405
pTV012G40 1503 37 20 24 19 500 55951
pTV013G2 1527 37 20 24 19 508 56952
pTV013G15 1527 37 20 24 19 508 56910
pcTV014G73 1476 37 20 24 19 491 54857
pTV018G60 1479 37 19 24 20 492 55099
pTV019G20 1479 38 19 24 19 492 55105
pTV019G25 1479 37 19 24 19 492 54918
C The size of the gag insert. d The percentage occurrence of the nucleotide in the gag




The diversity of the HIV-1 gag gene
Region of sequence Groups compared Minimum variation (a) Maximum variation (a)
Subtype C gag clones 6 12
Gag (b)
Subtype C 191 6 13
Group M subtypes 8 19
M, N,O 28 36
Subtype C 191 6 15
Matrix (b) Group M subtypes 8 25
M,N,O 20 42
Subtype C \91 4 9
Capsid (b) Group M subtypes 5 15
M,N,O 21 28
Subtype C \91 3 14
Nucleocapsid, Spacer
Group M subtypes 5 19
peptides, p6 (b)
M,N,O 27 35
CTL area 1\01 in p17 ICI Subtype C gag clones 4 26
CTL area 21el in p17 \CJ Subtype C gag clones 0 18
CTL area 31TI in p17 \C) Subtype C gag clones 0 45
a Percentage diversity = 100% - percentage similarity (Distance matrix)
b Distance matrix calculated on nucleotide diversity
C Distance matrix calculated on amino acid diversity
d Matrix area from the amino acid KI8 to the amino acid E40
e Matrix area from the amino acid G7I to the amino acid LlOl
f Matrix area from the amino acid DI2l to the amino acid Y132
g Subtype C sequences in the Los Alamos HIV -1 gag reference subtypes set, plus the




Evaluation of the Tfx™ transfection technique
Tfx™ Tfx™:DNA [CAT] in
Cell line I1gDNA
Reagent ratio ng/ml



















Evaluation of the CaP04 and Electroporation techniques
Transfection method Culture growth Cell line [CAT] in ng/ml
area (cm2)
CaP04 21 CV-1 2.51
21 Vero 2.55





Mix 2 Mix 3
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Figure 3.1 PCR results for the optimisation of the MgCI2 concentration when
using the Expand High Fidelity PCR System to amplify HIV-1 gag. The
lanes marked 1 to 7 are the same for all three mixes. Lanes: 1, TV016; 2,
TV012; 3, TV015; 4, TV008; 5, TV019; 6, TV016; 7, TV013. Mix 2 had a




Figure 3.2 A spot blot of 6 gag PCR products for the optimisation of the PCR
conditions. The numbers 1 to 4 represent the spot below the number. The
number 5 represents the spot to right and number 6 the spot to the left of it.
Spot 1, TV016; spot 2, TV012; spot 3, TV015; spot 4, TV008; spot 5, TV019;
spot 6, TV013. The negative control is marked neg. A coloured spot is an





Figure 3.3 Agarose gel electrophoretic analyses of the peR products to be used
in TA cloning. Lanes: 1, Lambda/Hind III Molecular weight marker; 2,
TV016; 3 and 4, TV013; 5, TV001; 6, TV006; 7, TV004; 8, TV002; 9, TV007;
10, TV003; 11, TV006; 12 and 13, lV005; 14 and 15, TV018. The




Figure 3.4 Agarose gel electrophoretic analyses of the amplified -1.5 kb gag
peR product after purification for cloning into pcDNA3.1. Lanes: 1,
Lambda/Hind III Molecular Weight Marker; 2, TV002; 3, TV003; 4, TV004; 5,
TV005; 6, TV006; 7, TV007; 8, TV008; 9, TV010; 10, TV016. The




Figure 3.5 PCR results on RT-PCR products. Lanes: 1, Lambda/Hind III





Figure 3.6 Agarose gel electrophoretic analyses of miniprep DNA for screening
of clones. This is an example of how positive clones were distinguished from
negative clones. Lane 1 displayed the Lambda/Hind III molecular weight
marker. Lanes 2,4,5,7,8,10,11,12,13,14,15, and 16 are examples of
negative clones, and lanes 3, 6, and 9 were considered to be positive
clones. Negative clones, without inserts, were -5 kb in size, while positive
clones, with inserts, were -6.5 kb in size.
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160 bp
Figure 3.7 Agarose gel electrophoretic analyses of the PCR assay for
confirmation of HIV-1 gag positive clones. This is an example of how the
positive clones were distinguished from the negative clones. A positive
clone would produce a 160 bp fragment after PCR. The smallest band of
the 1 kb DNA ladder is 250 bp long. Lane 1 displayed the 1 kb DNA Ladder
(Promega, USA) molecular weight marker. Lanes 3, 4, 5, 6, 7, 9, 10, 12, 14,




Figure 3.8 A spot blot assay for the confirmation of HIV-1 gag positive clones.
This is an example of how the positive clones were distinguished from the
negative clones. A positive clone is identified as a coloured spot on the
membrane, while a negative clone would have no coloration. A7, A8, A9,
B2, B3, and B4 were considered to be positive, while B1 and B9 were
considered as weak positives. A1 to A6, B5 to B8 and C1 to C9 were





Figure 3.9 (A & 8) Orientation determination of clones in the vector pCR ®3.1, by restriction
enzyme digestion with Xba1. The Lambda/Hind III molecular weight markers were loaded
in the lanes 1,17,33, and 49. The pCR ®3.1 clones were loaded as follows: lanes: 2,
TV012G19; 3, TV012G34; 4, TV012G35; 5, TV012G38; 6, TV012G40; 7, TV008G59; 8,
TV008G60;9, TV008G62; 10, TV008G65; 11, TV008G70; 12, TV019G25; 13, TV019G10; 14,
TV019G17; 15, TV019G20; 16, TV019G51; 18, TV016G61, 19, TV016G63; 20, TV016G67; 21,
TV013G2; 22, TV013G8; 23, TV013G11; 24, TV013G15; 25, TV001G2; 26, TV001G8; 27,
TV001G10; 28, TV001G11; 29, TV004G11; 30, TV004G12; 31, TV004G13; 32, TV004G16; 34,
TV004G17; 35, TV002G1; 36, TV002G2; 37, TV002G16; 38, TV007G10; 39, TV007G11; 40,
TV007G12; 41, TV006G71; 42, TV006G78; 43, TV006G88; 44, TV006G93; 45, TV006G97; 46,
TV006G98; 47, TV005G29; 48, TV018G59; 50, blank; 51, TV018G60.
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EcoR1iXha1 Digest of GAGpeR Products
1 2 3 4 5 6 7 8 9 10
I
-=1M ...... .... W!! - '..... ~ ~ ,= -1.5 kb
Figure 3.10 Agarose gel electrophoretic analyses of peR products of gag after
digestion with the restriction enzymes Xbal and EcoRI. Lanes: 1,
Lambda/Hind III Molecular Weight Marker; 2, TV002; 3, TV003; 4, TV004; 5,
TV005; 6, TV006; 7, TV007; 8, TV008; 9, TV010; 10, TV016. Although the
lower end of the gel is not shown in this figure, no visible bands were
observed beyond these borders when the photograph was taken.
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Figure 3.11 Restriction digest of the gag PCR product of the isolate TV003.
Lanes: 1, Lambda/Hind III Molecular Weight Marker; 2, blank; 3, digestion with
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Figure 3.12 (A & B)The similarity plot of the NCBI HIV-1 subtyping database for the
clones TV002G8 (A) and TV003G15 (B). The right hand legend indicates the different
reference subtypes, which the query sequence was compared to. The solid bar at the top
of the graph represents the sybtype most similar to the query sequence. The X-axis
represents the nucleotide position, while the Y-axis represents the score of identity
obtained when comparing the query sequence to the individual reference sequences. The
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Figure 3.12 (C & O)The similarity plot of the NCBI HIV-1 subtyping database for the clones
TV006G11 (C) and TV006G97 (D). The right hand legend indicates the different reference
subtypes, which the query sequence was compared to. The solid bar at the top of the graph
represents the sybtype most similar to the query sequence. The X-axis represents the
nucleotide position, while the Y-axis represents the score of identity obtained when comparing
the query sequence to the individual reference sequences. The similarity between the query and
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Figure 3.12 E The similarity plot of the NCBI HIV-1 subtyping database for
the clone TV0016G95. The right hand legend indicates the different reference
subtypes, which the query sequence was compared to. The solid bar at the top of
the graph represents the sybtype most similar to the query sequence. The X-axis
represents the nucleotide position, while the Y-axis represents the score of identity
obtained when comparing the query sequence to the individual reference
sequences. The similarity between the query and reference sequences increases
with an increase in score.
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Figure 3.13 (A & 8)The bootscan graph drawn in SimPlot for the comparison of
the sequence of TV006G11 to the sequences of TV001G8, TV004G17 and
K03455 (A) or M17451 (8). The right hand legend indicates the sequences
that the sequence of TV006G11 was compared to. Similarity increases on
the Y-axis, while the X-axis shows the nucleotide position.
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BootScan - Query: Tv006g97
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Figure 3.13 (C & O)The bootscan graph drawn in SimPlot for the comparison of
the sequence of lV006G97 to the sequences of lV001G8, lV004G17 and
K03455 (A) or M17451 (8). The right hand legend indicates the sequences that
the sequence of lV006G97 was compared to. Similarity increases on the Y-axis,
while the X-axis shows the nucleotide position.
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Figure 3.13 (E & F) The bootscan graph drawn in SimPlot for the comparison of
the sequence of TV006G11 (E) and TV006G97 (F) to the sequences of TV001G8,
TV013G15 and the clone of the subtype B isolate TV016. The right hand legend
indicates the sequences that the sequence of the TV006 clones were compared to.























Figure 3.14 A neighbour-joining phylogenetic tree, constructed in TREECON, comparing the
complete gag DNA sequences of the clones and the Los Alamos HIV-1 gag reference
subtypes, with bootstrap values (shown as percentage) greater than 75 % indicated. The
South African clones are indicated in bold, blue letters. The horizontal scale indicates the
percentage variation, represented by the horizontal branch lengths between OTUs. Six
clusters and the representing subtypes within group M are indicated by the brackets on the








































Figure 3.15 A neighbour-joining phylogenetic tree, constructed in TREECON, comparing the
complete gag sequences of the South African clones and the 47 HIV-1 subtype C gag
sequences in the Los Alamos databank (Table2.3). The tree is rooted with three subtype B
sequences. The South African clones are indicated in bold, blue letters. The horizontal
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Figure 3.16 (A & B) The hydophilicity profiles of the predicted amino acid sequences of
the HIV-1 subtype C gag clones. In the right hand legend, Tvxxgxx represents
TVxxGxx, as DNAMAN, which was used to construct the graphs, do not allow
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Figure 3.16 (C &0) The hydrobhobicity profiles of the predicted amino acid sequences
of the HIV-1 subtype C gag clones. In the right hand legend, Tvxxgxx represents
TVxxGxx, as DNAMAN, which was used to construct the graphs, do not allow









Figure 13.17 The amphipathic a.-helix of the major homology region (MHR) in the
capsid domain (Clish et ai, 1996), as found in the predicted amino acid
sequence of the HIV-1 subtype C gag clones. Each corner within the helix
represents an amino acid, which is written in the single letter code, followed
by the position of the amino acid in the MHR. A24-TV013 and V24-TV014,





















































Figure 3.18A A neighbour-joining phylogenetic tree analysis, constructed in
TREECON, of the quality control performed on the sequences of the clones, using all three
codon positions in the alignment. The SNF at the back of sequence names indicates that
the origin of the sequence is the earliest supernatant fluid available. The P indicates that
























I I ~ TV003Gl5

























Figure 3.188 A neighbour-joining phylogenetic tree analysis, constructed in
TREECON, of the quality control performed on the sequences of the clones, using only the
synonymous substitutions in the alignment. The SNF at the back of sequence names
indicates that the origin of the sequence is the earliest supernatant fluid available. The P
indicates that the sequence is from the RNA isolated from the original plasma. Bootstrap
values above 50% are indicated.
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Figure 3.19 (A & 8) A Western blot analyses of the in vitro transcriptionl
translation assays. Lanes: 1, Rainbow marker; 2, Negative control; 3, TV002G8; 4,
TV013G15; 5, TV007G59; 6, TV005G36; 7, TV019G20; 8, Luciferase control; 9,
TV016G95; 10, TV004G24; 11, TV010G74; 12, TV008G66; 13, Negative control;
14, Rainbow marker. Dashed arrows indicate the position of a-55 kDa protein.
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Figure 3.19 (C & 0) A Western blot analyses of the in vitro transcription!
translation assays. Lanes: 15, Luciferase control; 16, TV013G2; 17, TV006G97;
18, TV005G36; 19, TV003G15;20, TV001G8;21,TV001G11;22, TV006G11;23,
Negative control; 24, Rainbow marker; 25, Rainbow marker; 26, TV012G34; 27,
TV010G74; 28, TV012G40; 29, TV016G95; 30, TV018G60; 31, TV019G20; 32,
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Figure 3.19 E A Western blot analyses of the in vitro transcription/ translation
assays. Lanes: 35, TV009G12; 36, TV014G73; 37, TV001G11; 38, Luciferase
control; 39, Blank; 40, Rainbow marker. Dashed arrows indicate the position of a
-55 kDa protein.
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Figure 3.20A A graphical analyses of the production of the CAT protein in
the Tfx transfection method and cell lines. The cell lines and ratio of
transfection reagents to DNA used in the transfection are portrait on the X-
axis, while the concentration of CAT protein is indicated on the Y-axis. The






Figure 3.208 A graphical analyses of the production of the CAT protein in
the CaP04 and electroporation transfection methods and cell lines. The cell
lines are portrait on the X-axis, while the concentration of CAT protein is
indicated on the Y-axis. The legend on the right indicates the transfection
methods.
100






Figure 3.21 A A Western blot analyses of the harvested transfected vero
cells. The cells were transfected with different HIV-1 subtype C gag clones.
Blot A was detected by alkaline phophatase. Lanes: 1, Pr55gag positive
control; 2, negative control; 3, TV001G11; 4, TV008G66; 5, TV004G24; 6,
TV013G8; 7, TV002G8; 8, Rainbow marker. The dashed arrows indicate
faint -55 kDa bands in lanes 4 and 6.
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Figure 3.22 B A Western blot analyses of the harvested transfected vero
cells. The cells were transfected with different HIV-1 subtype C gag clones.
Blot B was detected by ECL. Lanes: 1, The positive in vitro transcription!
translation reaction ofTV009G12; 2, pCR@3.1;3, TV009G12; 4, TV014G73.
The Rainbow molecular weight size markers are indicated on the right hand
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4. Discussion and Conclusion
4.1 Discussion
4.1.1 Characterisation Studies
4.1.1.1 Amplification of gag
The Expand High Fidelity peR System (Roche, Germany) was used for the
amplification of gag. The system uses an enzyme mix containing thermostable
Taq -and Pwo DNA polymerases. Due to the Taq DNA polymerase, the system
generates peR products containing either single 3' deoxyadenosine residues or
blunt ends. The Pwo DNA polymerase, which has a 3'-5' exonuclease
proofreading activity, causes the system to increase the fidelity of DNA synthesis
three fold, thus introducing less peR induced mutations.
The peR cycle was designed with the length of the fragment to be amplified in
mind. Longer starting denaturing and annealing times were required due to the
large size of the starting template (-9kb). When the concentration of the smaller
fragment (-1.5 kb) increased the time was reduced. The elongation time was kept
long to reduce the risk of peR mediated recombination, which can happen when
the elongation process is terminated before completion (Paabo et ai, 1989,
Overbaugh et ai, 1990).
To ensure a high efficiency of cloning, it is important to use a peR product that is
homogenous in size. The less background bands visible on an agarose gel, after
electrophoresis, the more specific the peR reactions were. A single band of DNA,
-1.5 kb in length with no visible background bands, as seen in Figure 3.1, Mix 2,
lanes one to six, was perceived to be homogenous enough for cloning. All the
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PCR products of the isolate TV013 (Figure 3.1) displayed a smaller DNA band,
which might have been produced by non-specific amplification. The ratio between
the concentration of specific DNA to non-specific DNA (5:1) was not big enough to
ignore the non-specific band. When cloning, the presence of non-specific DNA,
especially shorter pieces, will result in clones with non-specific inserts, favouring
the incorporation of the shorter piece of DNA (Sambrook et ai, 1989). The PCR
product of the isolate TV013 was discarded and the PCR repeated at a later stage,
where the PCR product produced, was of high concentration and the non-specific
band not visible by ethidium bromide staining (Figure 3.3).
It is also important to know the origin of the PCR product before cloning, as this will
simplify the screening process thereafter. The origin of the PCR products of the
isolates TV016, TV012, TV015, TV008, TV019, and TV013 were confirmed to be
HIV-1 gag, by hybridisation with an HIV-1 gag specific probe (Figure 3.2). The
probe is detected for by an alkaline phospatase conjugated antibody, which causes
a colour reaction in the presence of the substrate, 5-bromo-4-chloro-3-indolyl
phosphate/ nitro blue tetrazolium (NBT/ BCIP). The presence of the conjugated
antibody is identified as a coloured spot. Although non-specific background
coloration is also possible, the colour development is not as strong as for the
specific reaction. A positive reaction is therefore identified as a coloured spot,
more intense in colour than the negative background stain.
The remainder of the subtype C isolates were amplified, using the optimised
conditions (Figure 3.3). All the products, except for the product of TV003, were
used for cloning. The PCR product of the isolate TV003 contained a smaller non-
specific band of significant amount when compared to the -1.5 kb band (2:1). The
same reason for exclusion was used for TV003 as was used for the isolate TV013
(Figure 3.1). Although the PCR products of the isolates TV002 and TV007
contained several smaller non-specific bands, the products were used for cloning.
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The PCR products of the isolates TV002, TV003, TV004, TV005, TV006, TV007,
TV008, TV010 and TV016 (Figure 3.4), produced for cloning into pcDNA3.1, were
all considered to be homogenous enough for cloning. Although the PCR product of
the isolate TV007 displayed a larger non-specific DNA band (Figure 3.4), the
product was used for cloning, as the -1.5 kb band was smaller and would be
favoured for incorporation during cloning. Although the isolate TV016 was an HIV-
1 subtype B isolate, it was used to generate a clone for use as a subtype B
reference. All the PCR products were confirmed to be of HIV-1 gag origin, by
hybridisation with an HIV-1 gag specific probe.
The amplification of gag from RT-PCR products resulted in - 1.5 kb products that
were visible as very weak bands after electrophoresis on an agarose gel (Figure
3.5). The products were however used to clone into the vector pcDNA3.1. The
weak products were probably due to low concentration of starting template, as the
RNA was only converted to DNA, without any amplification and the non-amplified
DNA used as starting template in the PCR. The amplification of the other 13
subtype C gag genes used an amplified template and was therefore a nested PCR.
4.1.1.2 Cloning of gag
The reagents used in the PCR reaction, like free dNTPs, can interfere in the
cloning reactions and must therefore be removed from the amplified DNA. The
products were purified by using the Qiagen kit, which uses spin columns containing
silica gel membranes that bind nucleic acids larger than 100 bp and efficiently
remove unincorporated nucleotides, primers smaller than 40 bp and enzymes.
Adjusting the pH on the silica membrane elutes the DNA. The sephadex columns
used to purify the restriction digested PCR products worked on the same principle
as the Qiagen cloumns.
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The orientation of the insert was not important for the characterisation studies and
gag was firstly cloned into the pCR@3.1vector, using TA-cloning, where the insert
could be inserted in the forward or reverse orientation. For the expression studies
however, the insert needed to be in the forward orientation for expression of the
gene. The isolates of which there was no pCR@3.1clones with inserts in the
forward orientation, were directionally cloned into the pcDNA3.1(-) vector. The
vector pcDNA3.1(-) contained an Xbal recognition site upstream of the recognition
site for the restriction enzyme, EcoRI, which correlates to the orientation of these
two enzymes on the PCR products. Cleavage with Xbal and EcoRI results in
incompatible ends, limiting the possibility of self-ligation of the vector onto itself and
ensuring that the insert, cleaved with these two restriction enzymes, is cloned in
only one possible orientation.
4.1.1.3 Sequencing of gag
4.1.1.3a Nucleotide Sequencing Analyses
4.1.1.3a(i} Sequencing Data
Sequencing analyses of clones from all 15 HIV-1 subtype C isolates showed that
the cloned gag differed in size ranging from 1.464 kb to 1.527 kb, with an average
size of 1.485 kb (Table 3.3). The difference in size is largely due to inserts found in
the Gag p6 domain, at the C-terminal of the Gag polyprotein (Appendix 85). The
nucleic acid composition of the gag clones correspond to the nucleic acid
composition of lentiviruses with a composition of 36% A, 18% C, 24% G and 22%
T (Foley, 2000). The gag clones had a slightly lower thymine percentage (19-
20%). The highest occurring nucleotide in the cloned gag is adenosine (36-38%).
It has been shown that elevated levels of AU content in human mRNAs resulted in
instability and low expression levels (Hentze, 1991). The AT content in the gag
clones, which corresponds to the AU content in their mRNA transcripts, was found
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to range between 55-58% (Table 3.3), which accounts for the dependency of gag
expression on the viral protein, Rev.
The two nucleotide deletion in the sequence of the clone TV006G11 seems to be
an artefact of cloning, because the clone TV006G97 of the same isolate does not
contain this deletion. The clone TV006G97 contained an early stop codon,
resulting in a truncated protein. This early stop codon was the result of a single
nucleotide change from G to A. These two clones, TV006G97 and TV006G11,
were not cloned from the same PCR product and the deletion and mutation could
have been produced at PCR level as well.
4.1.1.3a(ii) Restriction Digest Analyses
Subtyping of HIV-1 subtype C viruses by RFLP was previously described (Van
Harmelen et ai, 1999b), which looks at the restriction patterns of p17 after digestion
with the restriction enzyme Alul. According to this study, subtype C strains have
two Alul recognition sites, resulting in 3 fragments of which two can be seen on a
4% agarose gel and can be distinguished from subtypes A, Band 0 by the size of
the upper band after digestion. They found that the size of the largest fragment
after Alul digestion was -240 bp for subtype C, while subtypes A, Band 0
produced a - 160 bp fragment. According to the restriction digest analyses of our
subtype C clone sequences, only one isolate, TV018, as well as one clone of the
isolate TV019 contained two Alul recognition sites, while 10 isolates plus the
remaining clone of the isolate TV019 contained three recognition sites and three
isolates contained four. Restriction digest of the p17 fragment with Alul of the
subtype C isolate containing two recognition sites, as well as all of the subtype C
isolates with three recognition sites, except for both clones of the isolate TV006,
would produce a - 270 bp fragment as the largest fragment. The difference
between - 240 bp and - 270 bp is probably negligible on a 4% agarose gel. The
smallest fragment produced by the subtype C isolates containing three recognition
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sites, is however 10 bp long, which would result in a restriction pattern close to
what was observed in the RFLP study and would therefore have subtyped these
clones as subtype C sequences. The clones of the isolate TV006, with three A/ul
recognition sites, would produce a slightly different restriction pattern with a largest
fragment of - 240 bp and a smallest fragment of - 70 bp, but would still result in a
similar pattern on a 4% agarose gel to the pattern observed in the RFLP study.
Similar restriction digest patterns on a 4% agarose gel would also have been
observed for the clones of the isolates TV001 and TV012, with four A/ul recognition
sites. Erroneous subtyping would however have been done on the clone of the
isolate TV003, where the largest fragment produced after A/ul digestion would
have been - 170 bp in length, grouping this isolate with the subtypes A, B, and D.
The 650 bp fragment, which includes the p17 region and a part of the p24, used to
subtype the A, Band 0 subtypes in the RFLP study, would have identified the
TV003 isolate as a subtype 0 sequence after digestion with the restriction
enzymes Accl and Swal, which would have produced an uncut fragment after both
digestion reactions. To identify a subtype 0 sequence, the final Xmnl restriction
digest of the 650 bp fragment would result in a two fragment pattern, not observed
in the TV003 isolate, which would probably have resulted in this clone not being
able to be subtyped. The subtype B isolate TV016 contained all the A/ul and Accl
recognition sites at the appropriate positions necessary for the identification of
subtype B sequences.
Sequencing analyses confirmed the finding that the isolate TV003 had a cleavage
site for the restriction enzyme Xbal and not for EcoRI. None of the other 14
isolates contained a recognition site for Xbal. The restriction enzymes, EcoRI,
Hgal, Kpnl, Nar1, Ndel, Notl, Sacl, Sacll, Sail, Smal, Xhol and Xmal, had no
recognition sites in any of the 15 isolates, which is useful information when
designing primers for directional cloning, or when sub cloning and making use of
the multiple cloning site of the vector. Unique recognition sites for different
restriction enzymes differed between the isolates as well as between clones from
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the same isolate, giving less confidence to the use of restriction analyses for HIV
identification.
4.1.1.3a(iii) Subtyping
All the sequences were submitted to the NCBI HIV-1 subtyping database and
confirmed their HIV-1 subtype C status, and also the subtype B status of the
TV016 clone (Appendix B3). The two clones of the isolate TV006, however
showed a sequence stretch, between nucleotides 501 and 800, which was most
similar to a subtype B strain (Figure 3.12 C & D), suggesting recombination in this
area. On closer inspection of this region on the similarity plot, it became clear that
the TV006 sequences in the region between 501 and 800, are most similar to only
one subtype B sequence and was also quite similar to sequences of other
subtypes as well.
Bootscanning is a procedure for the identification of HIV-1 recombinants and for
the mapping of their recombination breakpoints (Salminen et ai, 1995). The
bootscanning tool in SimPlot delivered similar results for both clones of the isolate
TV006 (Figure 3.13). Although the region 100 bp to 400 bp in the bootscan graph
showed a similarity to the subtype B strains, this was not considered as a
recombination point, because there was no sharp drop in the similarity to one of
the subtype C reference strains. In the boots can graphs, where the subtype B
reference strain is K03455 (Figures 3.13 A & C), a definite recombination
breakpoint can be seen in the region between 600 bp and 1000 bp, with both
remaining reference sequences dropping sharply. This recombination breakpoint
corresponds to the region of recombination seen in the similarity plots (Figures
3.12 C & D). When compared to the other subtype B reference strains, M17451
and TV016G95 (Figures 3.13 B, D, E, F), however, no recombination is observed
in this region, suggesting that the TV006 sequences in that region were only similar
to the subtype B strain, K01455 and not to the subtype B strains, M17451 or
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TV016G65. The strain, K03455 is the lab strain, HXB2, which is not found in our
laboratory and it is highly unlikely that there could have been recombination
between the TV006 isolate and HXB2. The region between 600 bp and 1000 bp
lies within the capsid domain, which is very conserved. It might be that the
sequence of TV006 in this region is not typical subtype C, but similar to a range of
subtypes, which is supported by the Alul and Accl restriction maps in this region of
the TV006 clones that is comparable to the Alul and Accl restriction map for the
subtype B isolate TV016. It was previously found that the Alul restriction pattern
for the first - 700 bp of gag were similar for the subtypes A, Band D (Van
Harmelen et ai, 1999b). The sequence of TV006 was therefore not considered as
a recombinant sequence, but a subtype C sequence with a small region of - 400
bp not typical subtype C, and would not lie as an outlier sequence on a
phylogenetic tree comparing the subtype C sequences.
4.1.1.3a(iv} Phylogenetic Analyses
The phylogenetic tree, comparing the full-length gag DNA sequences of our
subtype C isolates and the Los Alamos reference subtypes (Figure 3.14) also
confirmed the NCBI HIV-1 subtyping. All of our isolates, except for the isolate
TV016, clustered with the subtype C reference strains. As was expected, the
isolate TV006 clustered with the rest of the subtype C strains, confirming that this
sequence was indeed not a recombinant. In previous studies involving the South
African subtype C isolates, it was established that the accessory genes (Scriba et
ai, 2001), the env gene (Engelbrecht et ai, 2001) and the LTRs (Scriba et ai, in
press) of these isolates were all subtype C, strongly suggesting that the isolates
are not recombinants. The isolate TV016 clustered with the subtype B strains.
Although the different subtypes all formed clusters, which were supported by high
bootstrap values, there appears to be only six main subclusters within the M group
for the gag sequences (Figure 3.14). Several subtypes formed clusters with other
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subtypes, which were supported by high bootstrap values. The subtypes F and K
formed a cluster, as well as subtypes Band D. The CRF05 OF formed a
subcluster within the subtype 0 cluster, suggesting that the gag region of the
CRF05_OF strains is strictly subtype O. The two sub-subtypes F1 and F2 formed
subclusters within the subtype F cluster, indicating two definite subgroups of the F
subtype. The subtypes G, A and CRFs 06_CPX, 03_AB, 02_AG, 04_CPX, and
01_AE are all part of one cluster with the subtype G forming a separate subcluster
from the rest. The CRFs clustering with the subtype A strains are all recombinant
forms containing subtype A sequences (Kuiken et ai, 2000), which explains this
clustering with subtype A. All however formed definite subclusters of their own,
which were supported by high bootstrap values. The CRF 02_AG strain, G829,
does however not cluster with the rest of the CRF 02_AG strains, suggesting that
the recombination breakpoints in the G829 sequence might differ from that of the
other CRF 02_AG sequences.
The clustering of different subtypes (Figure 3.14) indicate that these groups of
subtypes have more recent common ancestors than the common ancestor for the
Group M subtypes. The subtype C strains however form a single cluster, with the
Brazilian and Ethiopian strains forming a separate subcluster within the subtype C
cluster.
A tree was also constructed with our isolates and all the HIV-1 subtype C gag
sequences available in the Los Alamos database and rooted with the subtype B
strain, HXB2 and our isolate TV016 (Figure 3.15). Most of the high bootstrap
values were on branches connecting clones. A significant clustering was however
seen in the strains from India (931N101, 931N905, 931N904, 941N11246, AF209990
and 951N21068), which are from different isolates, suggesting a single introduction
which spread and resulted in this clustering. There are however two strains from
India (981N012 and 941N476), which fall into a different subcluster, although not
supported by high bootstrap values, indicating a different ancestor to the ancestor
responsible for the majority of the Indian strains in the Los Alamos database.
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Significant clustering was also seen between the clones from the isolates TV014
and TV008 and between the clones of the isolates TV001 and TV006 (Figure
3.15). Such clustering suggest a common ancestor more recent than the ancestor
for all the subtype C strains. The only thing that the isolates TV014 and TV008
have in common is that they were infected outside the borders of South Africa. It is
however impossible to make further assumptions with the available patient data.
The South African subtype C isolates lie scattered between the other subtype C
strains with no particular clustering with any of the countries represented by
sequences on this tree. These data suggest multiple introductions of the HIV-1
subtype C virus into South Africa.
A distance matrix was calculated for the different alignments of the gag sequence.
The nucleotide sequence of gag showed a variation of 6-12% between the clones
and 6-13% within subtype C. The diversity between the clones is therefore
comparable to the diversity seen between the the gag sequences of all the different
strains of HIV-1 subtype C. An intersubtype variation of 8-19% was seen, while the
inter-group variation was calculated between 28-36%, confirming that Gag is
relatively conserved when compared to other viral proteins. The most variation
was seen in the p17 matrix protein, which correlates to the finding that this protein
is not essential for viral replication (Reil et ai, 1998), as the most variable regions
are usually dispensable regions.
4.1.1.3b Predicted Amino Acid Sequence Analyses
4.1.1.3b(i) Matrix
The HIV-1 matrix protein is involved in various processes in the viral life cycle.
Freed and his colleagues did a series of analyses to establish the effects of single
amino acid mutations on viral particle formation (Freed et ai, 1994). The N-
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terminal glycine residue (G1), involved in N-myristoylation (G6ttlinger et ai, 1989;
Bryant & Ratner, 1990), was present in all the isolates except in the one clone of
the isolate TV006 (TV006G11) (Appendix B5). All except two of the amino acid
residues that Freed found to playa role in viral replication or particle production
were conserved in all our isolates. The valine (V7) residue at position seven was
present in only three of our isolates (TV002, TV005 and TV008). Freed found that
a mutation at this position to a basic arginine residue resulted in a ten day delay of
reverse transcriptase production (Freed et ai, 1994). The remainder of the isolates
contained an isoleucine (17) residue at this position, with the exception of the clone
TV006G97, which contained a threonine (T7). Both valine and isoleucine are
aliphatic amino acids and are two of the most hydrophobic amino acids, with
isoleucine the more hydrophobic of the two. The isoleucine at position seven was
also found in all the subtype C strains, except for the strain of Botswana
(96BW15C02), which had an arginine (R7) (Appendix B5). The Botswana strain,
96BW15C02, was a clone of the same patient as the strains, 96B15C05 and
96BW15B03 (Novitsky et ai, 1999), which contained an isoleucine residue (17),
suggesting that the mutation might have been PCR induced. The Isoleucine (17)
was also found in both the HIV-1 subtype J reference strains, SE7022 and SE7887
(Kuiken et ai, 2000). It can be postulated that if a mutation in position seven to a
basic, hydrophilic residue like arginine, results in a delay in viral replication, then a
mutation to a more hydrophobic residue could hasten viral replication. Isoleucine
and valine are most probably too similar in their hydrophobic nature to result in any
detectable difference, as was observed by Ono and his colleagues (Ono et ai,
1997).
Two nuclear localisation signals (NLS) NLS-1 e4GKKKYKLKH) (Bukrinsky et ai,
1993; von Schwedler et ai, 1994) and NLS-2 C1OKSKKKAQ) (Haffar et ai, 2000)
have been found within the matrix protein. The amino acid sequences of the
published NLS regions are those of the HIV-1 subtype B strain, HXB2. Although
only the isolate TV005 contained a lysine (K28) in NLS-1, the remaining isolates,
except TV007 and TV009, contained either arginine or histidine residues (Appendix
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B5), which are both basic amino acids. The isolate TV007 contained a threonine
residue, which has a hydroxyl-containing side chain, while the isolate TV009 had
the least hydrophobic, aliphatic amino acid, Glycine at the position 28. NLS-2,
which contain a series of basic amino acids, was less conserved in all the isolates.
The basic amino acid confers a hydrophilic property to this region and although the
amino acid sequence was not conserved, the hydrophilic nature of this area was
certainly maintained in all of the isolates (Figure 3.16).
The Leucine residues at positions 13 and 31, as well as the valine residue at
position 35, all three critical for the incorporation of the HIV-1 transmembrane
envelope glycoprotein into virion particles (Freed and Martin, 1995, 1996), were
maintained in all our isolates (Appendix B5).
4.1.1.3b(ii) Capsid
The amino acid positions, mentioned below are as found within the capsid, starting
from the first amino acid in the capsid domain as position one. The single mutation
of a deoxyguanosine to a deoxyadenosine at position 551 found in clone
TV006G97, resulting in a glycine to arginine mutation at position 89 of the capsid
domain (G89R) (Appendix B5), could have been induced by either PCR or cloning.
The clone TV006G11 does not contain this mutation. It was previously found that
a mutation of the proline residue at position 90 (P90) or the glycine residue (G89)
immediately preceding it in the capsid domain, disrupts the incorporation of
cyclophilin A (CypA) into the virions (Braaten et ai, 1996; Thali et ai, 1994; Luban,
1996). All the clones of all the isolates contained a proline at position 90 in the
capsid domain. Two additional sites, both containing the glycine-proline motif, for
cyclophilin incorporation was found at positions 157 and 224 in the capsid domain
(Endrich et ai, 1999). The glycine-proline motifs at these two positions were
conserved in all our isolates.
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It was previously found that the phosphorylation of three serine residues at
positions 109, 149 and 178 was essential for the viral uncoating process (Cartier et
ai, 1999). All our isolates contained serine residues at positions 109 and 149, but
only the isolate TV002 contained a serine at position 178. The remainder of the
isolates all contained a threonine (T178) at this position. Although six subtype B
strains also contained threonine residues at position 178, the majority of 69 HIV-1
subtype B strains and all of the six subtype D strains in the Los Alamos database
contained a serine (8178) residue at this position (Kuiken et ai, 2000). The
threonine residue was also the dominant amino acid at position 178 in the majority
strains of the subtypes A, G, H, J and K. Both phosphoserines and
phosphothreonines were previously found in the capsid protein, suggesting that
both serine and threonine could be phosphorylated on their hydroxyl groups (Di
Marzo Veronese et ai, 1988).
The major homology region (MHR) in the capsid domain was well conserved in all
of our subtype C isolates (Appendix B5), with the critical glutamine (0), glutamic
acid (E), and argine (R) residues at positions 155, 159 and 167 respectively
(Mammano et ai, 1994), 100% conserved in all. At position 164, all the isolates
contained the aromatic amino acid tyrosine, which correlated to the finding that
different retroviruses contained an aromatic residue at this. Residues 161 to 173
of the capsid protein, which falls in the MHR, forms an amphipathic a-helix
containing both an hydrophobic and hydrophilic side (Clish et ai, 1996). Our
isolates maintain this amphipathic helix-wheel model (Figure 3.17 and Appendix
B5), with substitutions in the residues joining the hydrophilic- and hydrophobic
sides (residues 22 and 24 in Figure 13.17), still maintaining the amphipathic
character of the helix.
The stretch of amino acids 209 to 213 (ATLEE) and 218 and 219 (CO) were found
to be essential for the formation of HIV-1 particles (von Poblotzki et ai, 1993).
These regions were well conserved in our isolates, except for the residue at the
position 210, which was either a threonine or serine (Appendix B5). Both amino
116
acids, threonine and serine contains an hydroxyl group in their side chains and are
similar in structure, suggesting that particle formation would occur with a serine at
position 210. The isolate TV003, however displayed a glycine residue at position
213, which is not similar to the preferred glutamate residue. Unfortunately there
was only one clone sequenced for this isolate, but as this glutamate to glycine
change was not observed in any of the other subtype C strains or of the other
reference subtypes, this mutation can be seen as an artefact of cloning or PCR.
4.1.1.3b(iii) Nucleocapsid
The C-X2-C-~-H-~-C motif of the zinc finger in the nucleocapsid (Berg, 1986) was
maintained at both sites in all our isolates (Appendix B5). The cysteine to tyrosine
change, seen in clone TV019G20 was seen to be a cloning artefact, as the other
clone of this isolate did not contain this change. The consensus peptide sequence
connecting the two zinc-binding domains was RAPRKKG. This sequence of the
linker peptide was previously found to be important for virion formation and
infectivity, possibly due to the spatial proximity it renders to the two zinc fingers
(Morellet et ai, 1994). Similar to the finding with the mutation in the clone
TV019G20, the mutation in the linker peptide found in the clone TV012G34 was
seen as a cloning artefact or PCR.
4.1.1.3b(iv) Spacer Peptides and p6
Amino acid alignments showed that four isolates (TV001, TV007, TV012 and
TV013) contained a seven to ten amino acid repeat and one isolate (TV013)
displayed a further four amino acid extension in the Gag p6 region (Appendix B5).
These amino acid repeats were also observed previously (Barrie et ai, 1996) and
might also have a significant effect on protease function, as the domain upstream
of the protease sequence influence the protease autoprocessing (Zybarth & Carter,
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1995). The exact function of the sequence repeats or the influence it has is
however not known.
4.1.1.3b(v) Protease cleavage sites
The matrix-capsid protease cleavage site (SQNY*PIVQN) was well conserved in all
the isolates, except in the isolate TV005, where the C-terminal aromatic tyrosine
was replaced with another aromatic amino acid, phenylalanine (Appendix 85).
This correlates to the finding that the matrix-capsid cleavage site falls in the class I
category where an aromatic amino acid and a proline residue flank the site of
cleavage (Griffiths et ai, 1992; Pettit et ai, 1991). The proline residue at position
one of the capsid domain, which is important in the refolding of the N-terminal into
a ~-hairpin/helix structure after proteolysis (von Schwedler et ai, 1998) was
conserved in all the isolates. This ~-hairpin/helix structure is stabilised by the
formation of a salt bridge between the proline residue and an aspartate residue at
position 51, which was conserved in all the isolates. The second cleavage site
between the capsid protein and the p2 spacer protein (KARVL *AEAMS) was also
well conserved in the isolates, except for the one clone of TV012, TV012G34,
which had a valine to alanine substitution at the C-terminal region of the capsid
domain. The other TV012 clone did not have this change, suggesting that the
alanine residue is not the natural occurring amino acid at this position, although
both the amino acids valine and alanine are similar hydrophobic, aliphatic amino
acids. The Gag p2-p7 nucleocapsid cleavage site was less conserved, especially
in the p2 region. The Gag p2 region was also previously found to be variable in
sequence and composition in different HIV-1 isolates (Louwagie et ai, 1993.). The
IM*MQ motif was however maintained in 11 of the 15 isolates. The
hydrophobic/hydrophobic character of the cleavage site (Griffiths et ai, 1992; Pettit
et ai, 1991) was also maintained in all the clones of the isolates TV012 (VM*MQ/
VM*IQ), TV008 (IL*MQ/ IF*MQ), TV006 (IL*MQ), and TV001 (IL*VQ). The p7-p1
and p1-p6 cleavage sites were further well conserved.
118
4.1.1.3b(vi) ell Epitopes
Several studies have indicated the importance of HIV-specific and more
specifically, Gag-specific CTL for controlling the virus in infected individuals. There
are three major areas in the matrix domain in which published CTL epitopes fall.
These three areas display a great percentage variation in their amino acid
sequences (4-26%, 0-18%, 0-45%), with the most variation seen in the C-terminal
area. Variation in CTL epitopes result in viral escape from the cell mediated
immune response. Epitopes that are well conserved are therefore more desirable
to include into a vaccine. The p24 capsid domain is quite conserved with the
different HIV-1 groups varying between 21% and 28% from each other, while the
subtype C strains varied between 4% and 9%. CTL epitopes have been described
for almost the whole capsid domain, except for a 10 amino acid region at the C-
terminal. The dominant CTL epitopes found in South African adults and children
are also situated in the capsid (Goulder et ai, 2000). The three p24 epitopes were
SALSEGATPODLNTMLNTVG, FRDYVDRFFKTLRAEOA, and SILDIKOGKEPFR
DY, of which the last two epitopes shared four amino acids. All three epitopes
were well conserved in all our isolates, as well as in the rest of the subtype C
strains. Interestingly 64 out of the 65 subtype C sequences in the predicted amino
acid alignment (Appendix 85) contained a threonine in the first position of the first
epitope (TALSEGATPQDLNTMLNTVG), but the remainder of the amino acids in
the epitope were identical to the consensus subtype 8 sequence. The Gag p2-p6
region contains three published CTL epitopes. The first region lies within the
second CCHC motif of the zinc finger and is well conserved in all of our isolates.
The second CTL epitope lies in the proline rich area where several repeat amino
acid sequences occur and is therefore vary variable. The third area is again quite
conserved. The recognition of CTL epitopes is dependent on the histocompatibilty
leukocyte antigen (HLA) haplotype of an individual cell and varies from person to
person. The HLA recognises degraded peptides and displays the peptide on the
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surface of the infected cell, where the peptide or epitope is recognised by the
immune system. Each person would therefore recognise different epitopes and it
would therefore be wise to include as many different epitopes especially of
conserved regions in a vaccine. Inclusion of Gag in a vaccine would present 187
published epitopes, including the highly conserved 127 epitopes within the capsid
domain, to the immune system (Korber et ai, 2000).
4.1.1.4 DNA Quality Assurance
Careful lab work is not sufficient to prove that no contamination occurred and it is
therefore important to include a sequence quality control to screen for possible
contamination (http://hiv-web.lanl.gov/seq-db.html). A phylogenetic tree was
constructed using the sequences of the gag clones and a 160 bp sequence within
gag from the most original patient RNA available (Figure 3.18A). The gag clone
sequences clustered with the corresponding patient RNA sequences. The
branching order of 10 out of the 15 subtype C isolate clusters were supported by
high bootstrap values. For conserved regions with little variation, the Los Alamos
HIV sequence quality control protocol (http://hiv-web.lanl.gov/CONTAM/
contam_main.html) suggests the construction of a Neighbour-joining tree, based
on synonymous substitutions (Figure 3.188). The phylogenetic tree based on
synonymous substitutions delivered a tree with a similar topology as the tree based
an all substitutions. The clustering of the isolates TV008 and TV014 was not seen
as proof of contamination, as these two isolates were isolated and stored at
different time points. The clustering of all of the sequences of these two isolates
suggests that the contamination occurred at the time of virus isolation, which is
very unlikely as these two samples were isolated four months apart from each
other (data not shown). The variation between the full length gag sequences of the
clones of the isolates TV008 and TV014 (6%) is significant enough to rule out
contamination. Also, the fact that the phylogenetic tree was constructed with such
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a small sequence length gives greater confidence to the areas with high bootstrap
values. The branching orders with lower bootstrap values were accepted.
4.1.2 Expression Studies
4.1.2.1 In vitro transcriptionl translation
Surprisingly only seven of all the clones could produce a-55 kDa protein (Figure
3.19). One would expect that clones with such similar sequences would all be able
to produce proteins. One would especially have expected the sister clones of
TV013G15 and TV001 G11, namely TV013G2 and TV001 G8, to produce proteins
as they are so similar in sequence. Two of the clones were in the vector pCR®3.1
and the remaining five were in the vector pcDNA3.1, suggesting that both vectors
are capable of producing proteins, although pcDNA3.1 appears to be the better
vector for protein production. The DNA quality might be considered a culprit in the
low percentage of clones producing proteins. Although the protocol does not call
for high quality DNA, it does warn to be mindful of RNAse that can destroy the
transcribed RNA. The normal mini prep DNA used in the in vitro transcription/
translation assay was prepared in a laboratory where the use of RNAse is common
practise and this might have contaminated certain tubes of DNA. There are also
many bacterial proteins present in miniprep DNA, which might have some influence
on either the transcription or translation processes. An indirect indication that DNA
quality might playa role in outcome of in vitro transcription/ translation is the fact
that the clone TV001 G11 produced a protein with fresh DNA, but failed to do so
again when repeated with older DNA. Some of the negative clones were repeated
(Figure 3.19 D), but unfortunately with the same DNA and the outcome was the
same.
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4.1.2.2 Evaluation of the transfection techniques
Although the highest concentration of the CAT protein was produced in Vero cells
transfected by using the CaP04 method, the electroporation of Vero cells was
decided to be best method to continue with (Figure 3.20). The electroporated cells
are plated on a smaller flask area than cells transfected by CaP04. The 2.26
ng/ml of CAT was therefore produced by fewer cells than the amount of cells that
produced the 2.55 ng/ml of CAT (Table 3.5 and 3.6). The Vero cells produced the
higher amount of protein in all of the transfection techniques tested (Figure 3.20).
This correlates to the cell growth properties of the two cell lines where the Vero
cells were the faster growing cells.
4.1.2.3 Gag protein production in cell culture
Four of seven protein producing clones showed production of a-55 kDa protein in
cell culture that was detectable by Western blot (Figure 3.21). The expression was
very weak, which was however not a surprise as the native gag sequence contains
various inhibitory sequences (Maldarelli et ai, 1991; Olsen et ai, 1992; Schneider et
ai, 1997), which decreases the stability of gag transcripts and translation efficiency,
making the expression dependant of the viral protein Rev. Studies have shown
that cellular proteins interact with these inhibitory sequences on the mRNA
transcripts, forming a protein-mRNA complex, which is retained in the nucleus and
degraded. As discussed earlier, the AT content of the cloned gags ranged
between 55% and 58% (Table 3.3). For highly expressed genes a G or C is
generally preferred over an A or T. Several studies have made gag constructs,
involving the elimination of the inhibitory sequences and/ or codon optimising (Qiu
et ai, 1999; Kotsopoulou et ai, 2000; Zur Megede et ai, 2000), which increased the
expression of Gag several fold. Although codon optimisation would have
significantly improved expression of Gag, the process of codon optimising a 1.5 kb
construct is quite expensive and we did not consider this for this study.
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4.2 Conclusion
The full length gag gene of 23 gag clones of 15 HIV-1 subtype e isolates as well as
one clone of one HIV-1 subtype B isolate was amplified, cloned and sequenced.
The cloned gag genes varied between 1.464 kb to 1.527 kb in length and
contained a nucleotide composition comparable to that of the different lentiviruses.
The sequences of clones from 14 HIV-1 subtype e isolates contained intact open
reading frames, while the clones of the isolate TV006 contained either a frame shift
deletion at the beginning of the clone or an early stop codon resulting in a
truncated protein. Phylogenetics confirmed that the 15 subtype e isolates were
indeed HIV-1 subtype e strains. Subtyping by RFLP (Van Harmelen et ai, 1999a)
would have correctly subtyped 14 of the HIV-1 subtype e isolates as well as the
HIV-1 subtype B strain. The clone of the isolate TV003 would have been
erroneously subtyped using the RFLP method.
The sequences of the isolate TV006 showed a region, -400 bp in length, of
probable recombination, which could be described as a region atypical of subtype
C, but similar to a range of subtypes. The greater part of the TV006 sequences
was however typical HIV-1 subtype e sequences. When comparing the predicted
amino acid sequences of the two clones of the isolate TV006 to previously
published mutational analyses of different regions of Gag, the two sequences gave
in more than one cases inconsistent results. This might be due to fact that the
clones were generated from two different peR products. One could also postulate
that the patient, from whom the isolate TV006 was isolated, contained
quasispecies, resulting in a virus culture containing diverse strains within the
culture. When a clone is established, an homogenous population is isolated and
when compared to other clones obtained from the same culture, the diversity
between the clones can be determined. The two clones of the isolate TV006
varied 98% between each other, which is not significantly different. The gag gene
is however well conserved and it would be interesting to look at less conserved
regions of the HIV-1 genome to establish the homogeneity of the TV006 culture.
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The South African HIV-1 subtype C strains do not form a cluster with any of the
other subtype C strains from various countries and therefore suggest multiple
introduction of the subtype C strain into South Africa. The strains from Brazil and
Ethiopia fall in a different subtype C subcluster as the South African strains,
suggesting that these strains are more distantly related than the strains from
Botswana, India, Israel, Tanzania and Zambia.
The native gag gene does not elicit good expression of a protein, due to the high
AT content and the presence of inhibitory sequences within the gene. Sequence
modification whereby the GC content is increased without altering the amino acid
sequence, have been shown to increase protein expression several times (Zur
Megede et ai, 2000; Qiu et ai, 1999; Kotsopoulou et ai, 2000). It has also been
shown that good CTL responses can be induced in humans by immunisation with a
plasmid based DNA vaccine (Calarota et ai, 1998, 1999; MacGregor et ai, 1998).
The sequence of any of the subtype C strains can be used to modify for use as a
Southern African DNA vaccine, as the diversity between the South African strains
are comparable to the diversity between all the different subtype C strains. It
would also be wise to include the full length modified gag gene in the DNA vaccine,
as this would present 187 published CTL epitopes to the immune system. In such
a racially heterogeneous country as South Africa, it would be important to include
as many CTL epitopes in the vaccine, as people with different HLA haplotypes,
recognise different epitopes, and limiting the number of epitopes would limit the
range and efficiency of the vaccine.
The second aim of this study was to establish the transfection technique and
Western blot protocol in our laboratory. Since the completion of this study, other
cloned HIV-1 genes have successfully been transfected into mammalian cells
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A1. Map and summary of pCR®3.1
11~. 1Dj! PI' '~ll "f! ~i!
'!'ll'J'~ CAC'lAt.1D'3 ~c 'TIXlcr':.tEU·! TTAAAC!'Tll aCT'l'3G'1'AL~ az..o._...."!'C'():J:;:T




PutaUve Itansoriptional &!art; bases 620-625
T7 ptQrnOlaripriming~: ba$$$ ~~7
M~ OIoning $Ita: ba$$$ $7Q..OO1
fA CIoniI1!f $iIe: 737C738
BGH re"erwprinW!g~I&: ~813-831
BGH poIy'9den)falion siIe: ba6es812-1026
pVC origin: ~ 1116-1r69
SV.w ~ano:Il)ttgin: bGsas 31904-3S32 (complement)
Naomycif1ikanamydn r~ gene (ORf): bGses 2371-315\} (com~f)
~e Idna:sI> poIyadoo}4a6on site: b_ 1926-2196 (ClOiTIplemMl)
Ampdin r~rq ~ (ORl'): bases 3611-4471 (complement)
II origin: ba&e$ <Ul02~0513
(Eukaryotic TA Cloning Kit Catalog, Invitrogen)
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A2. Map and summary of pcDNA3.1
Comments for pe0NA3.1 (+)
5428 ~oti<i$$
C*',V prOl'l1OlEr: bas$'!; 232-a19
T7 ~rrprtming site: 1)asI)$ 003-002
MuI~pI&cloning site: b_ &95-H)1Q
rx:ONA3.1fBGH r_rseprVning SiIe: ~ 1(l22-1()39
BGH poIyaden~EIti<ln $G(JIGI"ICa: bases 1028-1252
11 orign: ~ 129&-1726
SV40 prQmOlerMd origin: basell Hll-W74
NeomY<¥l rasjt;lance ~ (ORF'): ~$ 2136-2930
SV4Q PoIYadenyla(iOn signal: ~ 3t(l.4-3234
pMB1 origii'l (pUC-<Iat1I19d): bases 3617-4287
~1ii1 tl)i$i~ gene (bI;i): 00$$s ~-542a (C)
ORF: 1l\1&e$ 4432-5292 (C)
~ binding site: baSe$ 5300-5:).0.4 (Cl




pc0NA3.1 (+) and pc:!)NA.3.1(-~ have been comp!e1ely sequenoed. It I'OIJ $USPect an errcK ill tOO sequooces.
plea6G r;ontact Invill'ogell'$ Tec:tl~ ServIt;aS DepartmooL
(pcDNA3.1 catalog, Invitrogen)
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A3. Map and summary of pCR®3.1/CAT
Comments f(W pCR"3. fiCA T
5aoo~de$
CMV promoter: W$e$ 1-596
PWldva ItM$Q1J)1iOnai $tIi'C b~ 62f}.625
T7 promOO;i1primfng $ita: ba$e$~7
CAT OAF: bases 738:-1400
BGH ri')W)IW pti~ $i~: b$se$ 1$2-1579
BGH potyaden~ site: baGel> 156'1-1715
pUC origin: i:la$a!; 1900-2489
SVM/ pi'omoter Md origin: bases 394H281 (eomplemenll
N<;!Qmyclru'lcJ;ln~n ~ gene (ORF): ba&a$ 3120-3908 (complement)
1'hymid1rIa kinase poIy&~~ $ill): b(I$Q$ 2675-2945 «()QttlJllemEll'ltj
Ampidiln r9$i$1a~ gena (ORE'): l)a(;as 4360-5220 (comPI9l1l(!l'lt)
fl Qrigin: ba$i;)$ 5351-5001
(Eukaryotic TA Cloning Kit Catalog, Invitrogen)
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A4. List of genotypes and corresponding phynotypes of bacterial strains
to
Prcmega
Table 13. Genetic Markers in Frequently Used E. coli Strains.
Symbol Description
Blocks arabinose catabolism.Grtl-14 Mutation in arabinose metabolism
Adenine methylase mutation
Blocks methylation of cytosine in the sequence 3'...CmCAGG ..3' or
5' ...CmCTGG ...3'.
datu
dOll Cytosine methylase mutation
Regulatory gene mutation allo\\·ing
constitutive expression of genes for
deoxyribose synthesis
Endonuclease m u tation
Galactokinase mutation
DNA gyrase mutation
Mutation leading to a high
frequency of lysogeny






11,£1S20 (rB-, m 1\-) Restriction minus, modification
minus










Blocks methylation of adenine residues in the sequence §'...GmATC ..3'.
AIIOl\·s uptake of large plasrnids.
Improves qualitv of plasmid O~A isolations.
Blocks catabolism of galactose.
Confers resistance to nalidixic acid.
Leads to greatly enhanced frequency of lysogeny in t. phages
containinganorma_lrep~e5s3_r(~!)gen~(1) _
Allows cloning without cleavage of transformed 0:\.'\ by endogenous
restriction endonucleases. O\JA prepared from this strain can be
used to transform rl(' E. coli strains.
Allows cloning without cleavage of transformed O,,\A by
endogenous restriction endonucleases. O!,\A prepared from
this strain is unrnethvlated by thelz:id 5]0 met_h;-l~ses




Allows complementation of ~-galactosidase acti\-it~~ b)-
o-cornplernentation sequence in pGE'..! :-Z vectors. Allows blue/
whitt.' selection for recombinant colonies when plated on X-Gal.
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A4. List of genotypes and corresponding phynotypes of bacterial strains
Symbol Description Effect
IluB ~-isopropyl malate dehydrogenase Requires leucine for growth on minimal media.
mutation
A_(_10_11,-) Deletion of lOll protease ~duces p_roteolysis of expressed fusion proteins.
merA Mutation in restriction system Blocks restriction of DNA methylated at the sequence 5' ..C,:,CGc..3'.
!lcrB ~~ltat~n in restriction system _~oc~~ restrjction of D~A methylated ~t the sequence 5' ..AGmCT.}':_
__ Cystat_~~onine y-synthase mutati~ __ !equir~~J"llet~oni!2.~. fO~l?.?_\~t~~n m_inim~! _r:n_edia..: .__~_ ...lIel B
1111-1 Mutation in mannitol metabolism Blocks catabolism of mannitol.
ml!I~ ._~is~_!~~!ep~i_~r:n!~~~~ p!~_\·~l1ts_r~p_air ClL!h_e:nE'wlx.~r~the~~zed,~rl~~t~y~~~ec!._s.!_ra~d:.
P2 bacteriophage lysogen A phages containing the red and gal/l genes of )" are groy\·th
.rresel1~ iI1__I1.?~t_. ~r:J:l!lJit_~~bXP2_I_y~(lgen5.(2)..:_ . _
P2
~~A! _Ivl~~~~ns_il1.P_r:?!i_~~_~e~~_C?'ism__ ___ _ R_e_q~~ire_sr~ol_il1e~(lr g-r~l',~~hinminin~al ~e90:_ .. __.. _
Mutation in recombination Prevents recombination of introduced D\:A with host Di'JA, ensuring
stabilitv of inserts. Inserts are more stable in rt'tA 1 than rec A 13 hosts.
't'CAI, ref A 13
Relaxed phenotype; mutation Allows RNA synthesis in the absence of protein synthesis .
. eli_min~ti~~ s!ri~gel1t~a~tor
'lcB, rrr C Exonuclease V mutations Reduces general recombination and affects repair of radiation damage.
- . - -
Mutation in subunit 512 of 305
ribosome
Confers resistance to streptomycin.





Suppressor mutations Suppress ochre (UAA) and amber (UAG) mutations,
~I'D,slIpE,
'I'F
Suppressor mutations Suppress amber (UAG) mutations.
Mutation in thiamine metabolism Thiamine required for growth in minimal media.
Transposon Encodes resistance to kanamycin.
'~lO Trarisposon Encodes resistance to tetracvcline.
Mutation in outer membrane protein Confers resistance to bacteriophage Tl.
',1036 Transfer factor mutation Prevents transfer of F' episome. ---------------
Blocks catabolism of xvlose.Mutation in xylose metabolism
(!fe~ences
Hoyt, A. (198:2) Cell 31, 563 .
. Kaiser, K. and Murray, 1'\. (1983) In: DSA Cloning, Vol. 1, Clover, D., ed., IRL Press Ltd, Oxford, LK
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AS. DNA Molecular Weight Markers
o
Promega

























AG. Protein Molecular Weight Markers
Rainbow Molecular Weight Markers
The ladder 01 proteins in the Full-Range
Rainbow markers on a 12% SDS-PAGE gel.
LMW HMW-SDS HMW-Native
220- -
97.0 - 170 - ,,'W
66.0 -
116 - --450 - 669 -
76 - -- 440 -30.0 -
232 -
20.1 - 53- -












.'LMW: A 3 ~I aliquot 01 a two-told dilution 01 LMW Marker Kit was separated on a 15%
:T, 2.7% C polyacrylamide gel.
) HMW·SDS: A 10 ~I aliquot 01 a two-told dilution of HMW-SDS Marker Kit was separated
ton 7.5% T, 2.7% C polyacrylamide gel.
l.·HMW·Native: A 10 ~I aliquot 01 a two-told dilution of HMW Marker Kit was separated
~on 5-12.5% polyacrylamide gradient gel. All gels were stained with PhastGel Blue R.
~;Numbers represent molecular weights (M,l in thousands.
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Appendix B
B1. Nucleotide and Amino Acid Sequences of the HIV-1 gag clones
B2. Restriction Digest
B2.1 Retsriction Digest Maps of the gag clones for the Restriction enzymes,
Alul and Accl
B2.2 Unique cutting and Non-Cutting restriction enzymes
B3. Similarity Pots of the gag clones obtained from the NCBI subtyping tool
B4. Distance matrices calculated for:
B4.1 Nucleotide sequence alignment of the whole gag for the gag clones
and reference subtype sequences
B4.2 Nucleotide sequence alignment of the p17 matrix domain for the gag
clones and reference subtype sequences
B4.3 Nucleotide sequence alignment of the p24 capsid domain for the gag
clones and reference subtype sequences
B4.4 Nucleotide sequence alignment of the region from the nucleocapsid to
p1 spacer peptide for the gag clones and reference subtype
sequences
B4.5 Amino acid sequence alignment of the three areas in p17 containing
published CTL epitopes
B5. Predicted amino acid sequence alignment of the complete gag
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81. Nucleotide and AminoAcid Sequencesof gag clones
Translation of TVOOIG8(1-1494)
Universal code
Total amino acid number: 497, MW=55374
















































M GAR A S L S G G K L D K W ERR
TTAAGGCCAGGGGGAAAGAAACATTATATGTTAAAACATCTAGTATGGGCAAGCAGGGAG
L R P G G K K H Y M L K H L V WAS R E
CTGGAAAGATTTGCACTTAACCCTGGCCTGTTAGAAACATCAGAAGGCTGTAAACAAATA
L E R F A L N P G L LET S E G C K Q I
ATAAAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATTCAAC
K Q L Q PAL Q T GTE E L R S L F N
ACAGTAGCAACTCTCTATTGTGTACATAAAGGGATAAAGGTACGAGACACCAAGGAAGCC
TVA T L Y C V H K G K V R D T K E A
TTAGACAAGATAGAGGAAGAACAAAACAAATGTCAGCAAAAAGCACAGCAGGCAAAAGCG
L D K E E E Q N K C Q Q K A Q Q A K A
GCTGACGAAAAGGTCAGTCAAAATTATCCTATAGTACAGAATGCCCAAGGGCAAATGGTA
A D E K V S Q N Y P V Q N A Q G Q M V
CACCAAGCTATATCACCTAGAACATTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
H Q ASP R T L N A W V K VIE E K A
TTCAACCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
F N P E VIP M F TAL S EGA T P Q D
TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
L N T M L N T V G G H Q A A M Q M L K D
ACCATCAATGAGGAGGCTGCAGAATGGGATAGGACACATCCAGTGCATGCAGGGCCTGTT
TIN E E A A E W D R T H P V HAG P V
GCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
A P G Q M REP R G S D I A G T T S T L
CAGGAACAAATAGCATGGATGACAAGTAATCCACCTATTCCAGTAGGAGACATCTATAAA
Q E Q A W M T S N P PIP V G DIY K
AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
R W I L G L N K V R M Y S P V S L
GACATAAAACAAGGGCCAAAAGAACCCTTTAGAGATTATGTAGATCGGTTCTTTAAAACT
D K Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q D V K N W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTTCATTA
Q NAN P D C K TIL R A L G P GAS L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCATAAAGCAAGGGTGTTG
E E M M T A C Q G V G G P S H K A R V L
GCTGAGGCAATGAGCCAAACAAACAGTAACATACTAGTGCAGAGAAGCAATTTTAAAGGC
A E A M S Q T N S N L V Q R S N F K G
CCTAACAGAATTGTTAAATGTTTCAACTGTGGCAAAGTAGGGCACATAGCCAGAAAGTGC
P N R V K C F N C G K V G H ARK C
AGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGACAGGAAGGGCACCAAATGAAAGAC
RAP R K K G C W K C G Q E G H Q M K D
TGTACTGAGAGGCAGGCTAATTTTTTAGGGAAAATCTGGCCTTCCCACAAGGGGAGGCCA
C T E R Q A NFL G K I W P S H K G R P
GGGAATTTCCTCCAGAACAGACCAGAGCCAACAGCCCCACCAGCAGAGCCAACAGCCCCA
G NFL Q N R PEP TAP P A E PTA P
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E P L T S L K S L F G S D P S S Q
Translation of TVOOlGll(1-1494)
Universal code
Total amino acid number, 497, MW=55404
Max ORF, 1-1491, 497 AA, MW=55404
1 ATGGGTGCGAGAGCGTCAATATTAAGCGGCGGAAAATTAGATAAATGGGAAAGAATTAGG
1 MGARAS LSGGKLDKWER R
61 TTAAGGCCAGGGGGAAAGAAACATTATATGTTAAAACATTTAGTATGGGCAAGCAGAGAG
21 L R P G G K K H Y M L K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTGTTAGAGACAGCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET A E G C K Q
181 ATAAAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATTCAAC
61 I K Q L Q PAL Q T GTE E L R S L F N
241 ACAGTAGCAACTCTCTATTGTGTACATAAAGGAATAGAGGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H K G E V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAATGTCAACAAAAGGCACAACAGGCAAAAGCG
101 L D K E E E Q N K C Q Q K A Q Q A K A
361 GCTGATGAAAAGGTCAGTCAAAATTATCCTATAGTACAGAATGCCCAAGGGCAAATGGTA
121 A D E K V S Q N Y P V Q N A Q G Q M V
421 CACCAAGCTATATCACCTAGAACATTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q A I S P R T L N A W V K VIE E K A
481 TTCAACCCAGAGGTGATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F N P E V P M F TAL S EGA T P Q D
541 TTAAACACAATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCAGAATGGGATAGGACACATCCAGTGCATGCAGGGCCTGTT
201 TIN E E A A E W D R T H P V HAG P V
661 GCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q M REP R G S D I A G T T S T L
721 CAGGAACAAATAGCATGGATGACAAGTAATCCACCTATTCCAGTAGGGGACATCTATAAA
241 Q E Q A W M T S N P PIP V G D Y K
781 AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTTAGCATTTTG
261 R W L G L N K I V R M Y S P V S I L
841 GACATAAAACAAGGGCCAAAAGAACCCTTTAGAGATTATGTAGATCGGTTCTTTAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
301 L RAE QAT Q D V K N W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTTCATTA
321 Q NAN P D C K TIL R A L G P GAS L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCATAAAGCAAGGGTGTTG
341 E E M M T A C Q G V G G P S H K A R V L
1081 GCTGAGGCAATGAGCCAAACAAACAGTAACATACTAGTGCAGAGAAGCAATTTTAAAGGC
361 A E A M S Q T N S NIL V Q R S N F K G
1141 TCTAACAGAATTGTTAAATGTTTCAACTGTGGCAAGGTGGGGCACATAGTCAGAAATTGC
381 S N R I V K C F N C G K V G H I V R N C
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E P L T S L K S L F G N D P S S Q
Translation of TV002G8(1-1464)
Universal code
Total amino acid number: 487, MW=54503
Max ORF: 1-1461, 487 AA, MW=54503
ATGGGTGCGAGAGCGTCAGTATTGAAAGGGAAAAAATTAGATACATGGGAAAGAATTAGG
M GAR A S V L K G K K L D T W ERR
61 TTAAGGCCAGGGGGAAAGAAACACTATATGCTAAAACACCTAGTATGGGCAAGCAGGGAG
21 L R P G G K K H Y M L K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAAACAGCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET A E G C K Q
181 ATGCAACAGCTACAATCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATATAAC
61 M Q Q L Q SAL Q T GTE E L R SLY N
241 ACAGTAGCAACTCTCTATTGTGTACATAAAGAGATAGATGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H K E I D V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAATAAGAGTCAGCAAAAAACACAGCAAGCAGAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A E A
361 GCTGACAAAGGAAAGGTCAGTCAAAATTATCCAATAGTGCAGAATCTCCAAGGGCAAATG
121 A D K G K V S Q N Y P V Q N L Q G Q M
421 GTACACCAGGCCATATCACCGAGAACTTTAAATGCATGGGTAAAAGTAATAGAAGAGAAG
141 V H Q ASP R T L N A W V K VEE K
481 GCTTTCAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCTACCCCACAA
161 A F S P E VIP M F TAL S EGA T P Q
541 GATTTAAACACCATGTTAAATACAGTGGGGGGACACCAAGCAGCCATGCAAATGTTAAAA
181 D L N T M L N T V G G H Q A A M Q M L K
601 GATACCATCAATGAGGAGGCTGCAGAATGGGATAGGTTACATCCAGTGCATGCAGGGCCT
201 D T NEE A A E W D R L H P V HAG P
661 ATTGCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACC
221 A P G Q M REP R G S D A G T T S T
721 CTTCAAGAACAAATAGCATGGATGACAAGTAACCCACCTATTCCGGTGGGAGACATCTAT
241 L Q E Q I A W M T S N P P P V G D Y
781 AAAAGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATT
261 K R W I L G L N K I V R M Y S P V S
841 TTGGACATAAAACAAGGGCCAAAAGAACCCTTTAGAGACTATGTAGACCGATTCTTTAAA
281 L D I K Q G P K E P F R D Y V D R F F K
901 ACTTTAAGGGCTGAACAATCTTCACAAGAGGTAAAAAATTGGATGACAGACACCTTGTTG
301 T L RAE Q S S Q E V K N W M T D T L L
961 GTCCAAAATGCAAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACA
321 V Q NAN P D C K TIL R A L G P GAT
1021 TTAGAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTT
341 LEE M M T A C Q G V G G P G H K A R V
161




























G S D P S S Q
Translation of TV003G15(1-1476)
Universal code
Total amino acid number: 491, MW=54812




21 L R P G G K K R Y M I K H L V WAS R E
121 CTGGAAAAATTCGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGATGTAAACAGATA
41 L E K F A L N P G L LET S E G C K Q
181 ATGAAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATTCAAC
61 M K Q L Q PAL Q T GTE E L R S L F N
241 ACCATAGCAGTTCTCTATTGTGTACATGAAAAGATAGAGGTACAAGACACCAAGGAAGCC
81 T I A V L Y C V H E K lEV Q D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAGCAGCA
101 L D K lEE E Q N K S Q Q K T Q Q A A A
361 GCTGACGGAAAAGTCAGTCAAAATTATCCTATAGTGCAGAATGCCCAAGGGCAAATGGTG
121 A D G K V S Q N Y P V Q N A Q G Q M V
421 CACCAGAGCATATCACCTAGGACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q SIS P R T L N A W V K VIE E K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCTCACAAGAC
161 F S P E VIP M F TAL S EGA T S Q D
541 TTAAACACCATGCTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCAGAATGGGATAGAATACATCCAGTACATGCGGGGCCTATT
201 TIN E E A A E W D R I H P V HAG P I
661 GCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q M REP R G S D A G T T S T L
721 CAGGAACAAATAGCATGGATGACAAGTAATCCACCTATCCCAGTGGGAGACATCTATAAA
241 Q E Q I A W M T S N P PIP V G DIY K
781 AGATGGATAATTTTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
261 R W I L G L N K V R M Y S P V S L
841 GACATAAAACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACAGGTTCTTTAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGAAACCTTGTTGGTC





















Nucleotide and Amino Acid Sequences of gag clones
CAAAATGCAAACCCAGATTGTAAGACCATTTTAAGAGGGTTAGGAACAGGGGCTACATTA
Q NAN P D C K T L R G L G T GAT L
GAGGGAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCATAAAGCAAGAGTGTTA
E G M M T A C Q G V G G P G H K A R V L
GCTGAAGCAATGAGCCAAGCAACATATAACATAATGATGCAGAGAAGCAATTTTAAAGGC
A E A M S QAT Y N M M Q R S N F K G
TCTAGAAAAATTGTTAAATGTTTCAACTGTGGCAGGAAAGGGCACATAGCCAGAAATTGC
S R K V K C F N C G R K G H A R N C
AGGGCCCCTAGAAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAGAGAA
RAP R K K G C W K C G KEG H Q M R E
TGTACTGAAAAGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGGCCA
C T E K Q A NFL G K W P S H K G R P
GGGAATTTCCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAGGTTC
G NFL Q S R PEP TAP P A E S F R F
GAGGAGACACCCCCCGCGATGAAGCAGGAACCGAAAGACAGGGAACCCTTAACTTCCCTC
E E T P PAM K Q E P K D REP L T S L
AAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
K S L F G S D P S S Q
Translation of TV004G17(1-1479)
Universal code
Total amino acid number, 492, MW=54889




21 L R P G G K K H Y M K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACAGCAGAGGGCTGTAAACAAATA
41 L E R F A L N P G L LET A E G C K Q
181 ATAAAACAGCTACATCCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATACAAC
61 K Q L H PAL Q T GTE E L R SLY N
241 ACCGTGGTAACTCTTTATTGCGTACATGCAGAGATAGAGGTACGAGACACCAAGGAAGCC
81 T V V T L Y C V H A E E V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A K A
361 GCTGACGGAAAAGTCAGTCAAAATTATCCTATAGTACAGAATCTCCAAGGGCGAATGGTA
121 A D G K V S Q N Y P I V Q N L Q G R M V
421 CACCAAGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAAAAGGCT
141 H Q ASP R T L N A W V K VIE E K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCCCAAGAC
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAACGAGGAGGCTGCAGAATGGGATAGATTACATCCAGCACAGGCAGGGCCTGTT
201 TIN E E A A E W D R L H P A Q A G P V
661 GCACCAGGCCAAATAAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q IRE P R G S D I A G T T S T L
721 CAGGAACAAATAACATGGATGACAAGTAACCCACCTGTTCCAGTGGGAGAAATCTATAAA
241 Q E Q I T W M T S N P P V P V GEl Y K
781 AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGGATGTATAGCCCTGTCAGCATTTTG

























Nucleotide and Amino Acid Sequences of gag clones
GACATAAAACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
D K Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAGGCTACACAAGAAGTAAAAGGCTGGATGACAGACACCTTATTGGTC
L RAE QAT Q E V K G W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACACTA
Q NAN P D C K T L R A L G P GAT L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAGGCAAGAGTGTTG
E E M M T A C Q G V G G P S H K A R V L
GCTGAGGCAATGAGCCAAACAAACAGTGCAAGCATAATGATGCAGAAAAGCAATTTTAAA
A E A M S Q T N S A S M M Q K S N F K
GGAGCCAAAAGAATTGTTAAATGCTTCAACTGTGGCAAGGAGGGGCACATAGCCAGAAAT
G A K R V K C F N C G KEG H A R N
TGCAGGGCCCCTAGGAAAAAAGGCTGTTGGAAATGTGGACAGGAAGGACACCAAATGAAA
C RAP R K K G C W K C G Q E G H Q M K
GACTGTACTGAGAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAAGGAAGG
D C T E R Q A NFL G K I W P S H K G R
CCAGGGAATTTCCTTCAGAACAGACCAGAGCCAACAGCACCACCAGCAGAGAGCTTCAGG
P G NFL Q N R PEP TAP P A E S F R
TTCGAGGAGACAACACCCACTCCGAAGCAGGAGCCGAAGGACAGGGAACCTTTAACTTCC
FEE T T P T P K Q E P K D REP L T S
CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
L K S L F G S D P S S Q
Translation of TV004G24 (1-1479)
universal code
Total amino acid number: 492, MW=54793




21 L R P G G K K H Y M K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACAGCAGAGGGCTGTAAACAAATA
41 L E R F A L N P G L LET A E G C K Q
181 ATAAAACAGCTACATCCAGCTCTTCAGACAGGAACAGAGGAACTTAGATCATTATATAAC
61 K Q L H PAL Q T GTE E L R SLY N
241 ACCGTGGCAACTCTTTATTGCGTACATGCAGAGATAGAGGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H A E lEV R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A K A
361 GCTGACGGAAAAGTCAGTCAAAATTATCCTATAGTACAGAATCTCCAAGGGCAAATGGTA
121 A D G K V S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAAAAGGCT
141 H Q ASP R T L N A W V K VIE E K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCCCAAGAC
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAACGAGGAGGCTGCAGAATGGGATAGATTACATCCAGCACAGGCAGGGCCTGTT
201 TIN E E A A E W D R L H P A Q A G P V
661 GCACCAGGCCAAATAAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q REP R G S D A G T T S T L
164
81. Nucleotide and Amino Acid Sequences of gag clones
721 CAGGAACAAATAACATGGATGACAAGTAACCCACCTGTTCCAGTGGGAGAAATCTATAAA
241 Q E Q I T W M T S N P P V P V GEl Y K
781 AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGGATGTATAGCCCTGTCAGCATTTTG
261 R W I I L G L N K I V R M Y S P V S I L
841 GACATAAAACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAGGCTACACAAGAAGTAAAAGGCTGGATGACAGACACCTTATTGGTC
301 L RAE QAT Q E V K G W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACACTA
321 Q NAN P D C K TIL R A L G P GAT L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAGGCAAGAGTGTTG
341 E E M M T A C Q G V G G P S H K A R V L
1081 GCTGAGGCAATGAGCCAAACAAACAGTGCAAGCATAATGATGCAGAAAAGCAATTTTAAA
361 A E A M S Q T N S A S I M M Q K S N F K
1141 GGAGCCAAAAGAATTGTTAAATGCTTCAACTGTGGCAAGGAGGGGCACATAGCCAGAAAT
381 G A K R I V K C F N C G KEG H A R N
1201 TGCAGGGCCCCTAGGAAAAAAGGCTGTTGGAAATGTGGACAGGAAGGACACCAAATGAAA
401 C RAP R K K G C W K C G Q E G H Q M K
1261 GACTGTACTGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAAGGAAGG
421 D C T E R Q A NFL G K W P S H K G R
1321 CCAGGGAATTTCCTTCAGAACAGACCAGAGTCAACAGCACCACCAGCAGAGAGCTTCAGG
441 P G NFL Q N R PES TAP P A E S F R
1381 TTCGAGGAGACAACACCCACTCCGAAGCAGGAGCCGAAGGACAGGGAACCTTTAGCTTCC
461 FEE T T P T P K Q E P K D REP LAS
1441 CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
481 L K S L F G S D P S S Q
Translation of TVOOSG29(1-1479)
Universal code
Total amino acid number: 492, MW=55109




21 L R P G G KKK Y M L K H V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGTCTTTTAGAAACATTAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET LEG C K Q
181 ATGCAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAGTCATTATACAAC
61 M Q Q L Q PAL Q T GTE ELK SLY N
241 ACAGTAGCAACTCTCTATTGTGCACACAAAAGGATAGATGTACGAGACACCAAGGAAGCC
81 TVA T L Y C A H K R D V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGACAAAAACG
101 L D K lEE E Q N K S Q Q K T Q Q T K T
361 GCTGACGAAAAGGTCAGTCAAAATTTCCCTATAGTGCAGAATCTTCAAGGGCAAATGGTA
121 A D E K V S Q N F P V Q N L Q G Q M V
421 CATCAAGCCATATCACCTAGAACCTTGAATGCATGGGTAAAGGTAATAGAGGAAAAGGCT
141 H Q A I S P R T L N A W V K VEE K A
481 TTTAGCCCAGAGGTAATACCTATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E VIP M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACGGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT

































Nucleotide and Amino Acid Sequences of gag clones
ACCATCAATGAAGAGGCTGCAGAATGGGATAGATTACATCCAGTACATGCGGGGCCTATT
TIN E E A A E W D R L H P V HAG P
GCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
A P G Q M REP R G S D A G T T S T L
CAGGAACAAATAGCATGGATGACAAACAACCCACCTGTTCCAGTGGGAGACATCTATAAA
Q E Q I A W M T N N P P V P V G D Y K
AGATGGATAATTTTGGGGCTAAATAAAATAGTGAGAATGTATAGCCCTGTCAGCATTTTG
R W L G L N K V R M Y S P V S L
GATATAAGACAAGGGCCAAAGGAACCTTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
D R Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGAGGTAAAAAATTGGATGACAGACACCTTGTTGATC
L RAE QAT Q E V K N W M T D T L L
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTAGTTTA
Q NAN P D C K T L R A L G P GAS L
GAAGAAATGATGACAGCATGTCAAGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTGTTG
E E M M T A C Q G V G G P G H K A R V L
GCTGAGGCAATGAGCCAGGCAAACAATGCACACATAATGATGCAAAGAAGCAATTTTAAA
A E A M S Q ANN A H M M Q R S N F K
GGCTCAAAAAGAATTGTTAAATGCTTCAACTGCGGCAAGGAAGGGCACATAGCAAAAAAT
G S K R V K C F N C G KEG H I A K N
TGCAGAGCCCCCAGGAAAAAAGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
C RAP R K K G C W K C G KEG H Q M K
GATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGG
D C T E R Q A NFL G K I W P S H K G R
CCAGGGAATTTCCTTCAGAGCAGGCCAGAGCCAACGGCCCCACCAGCAGAGAGCTTCAGG
P G NFL Q S R PEP TAP P A E S F R
TTCGAGGAGACAACATCAGCTCCACAGCAGGAGCCGAAAGACAGGGAACCCTTAACTTCC
FEE T T SAP Q Q E P K D REP L T S
CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
L K S L F G S D P S S Q
Translation of TVOOSG36 (1-1479)
Universal code
Total amino acid number: 492, MW=55052




21 L R P G G KKK Y M L K H V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGTCTTTTAGAAACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q I
181 ATGCAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAGTCATTATACAAC
61 M Q Q L Q PAL Q T GTE ELK SLY N
241 ACAGTAGCAACTCTCTATTGTGTACACAAAGGGATAGATGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H K G D V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAACG
101 L D K lEE E Q N K S Q Q K T Q Q A K T
361 GCTGACGAAAAAGTCAGTCAAAATTTCCCTATAGTGCAGAATCTTCAAGGGCAAATGGTA
121 A D E K V S Q N F P V Q N L Q G Q M V
421 CATCAAGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAAAAGGCT





































Nucleotide and Amino Acid Sequences of gag clones
TTTAGCCCAGAGGTAATACCTATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
F S P E V P M F TAL S EGA T P Q D
TTAAACACCATGTTAAATACGGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
L N T M L N T V G G H Q A A M Q M L K D
ACCATCAATGAAGAGGCTGCAGAATGGGATAGATTACATCCAGTACATGCGGGGCCTATT
TIN E E A A E W D R L H P V HAG P
GCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
A P G Q M REP R G S D A G T T S T L
CAGGAACAAATAGCATGGATGACAAACAACCCACCTGTTCCAGTGGGAGACATCTATAAA
Q E Q I A W M T N N P P V P V G DIY K
AGATGGATAATTTTGAGGCTAAATAAAATAGTGAGAATGTATAGCCCTGTCAGCATTTTG
R W I L R L N K V R M Y S P V S L
GATATAAGACAAGGGCCAAAGGAACCTTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
D R Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGAGGTAAAAAATTGGATGACAGACATCTTGTTGGTC
L RAE QAT Q E V K N W M T D ILL V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTAGTTTA
Q NAN P D C K T L R A L G P GAS L
GAAGAAATGATGACAGCATGTCAAGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTGTTG
E E M M T A C Q G V G G P G H K A R V L
GCTGAGGCAATGAGCCAGGCAAACAATGCACACATAATGATGCAGAGAAGCAATTTTAAA
A E A M S Q ANN A H M M Q R S N F K
GGCTCAAAAAGAATTGTTAAATGCTTCAACTGTGGCAAGGAAGGGCACATAGCCAAAAAT
G S K R V K C F N C G KEG H A K N
TGCAGAGCCCCCAGGAAAAAAGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
C RAP R K K G C W K C G KEG H Q M K
GATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGG
D C T E R Q A NFL G K I W P S H K G R
CCAGGAAATTTCCTTCAGAGCAGGCCAGAGCCAACGGCCCCACCAGCAGAGAGCTTCAGG
P G NFL Q S R PEP TAP P A E S F R
TTCGAGGAGACAACATCAGCTCCAAAGCAGGAGCCGACAGACAGGGAACCCTTAACTTCC
FEE T T SAP K Q E P T D REP L T S
CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
L K S L F G S D P S S Q
Translation of TV006Gll(1-1468)
Universal code
Total amino acid number: 488, MW=54593






W V R A S L K G G K L D AWE R R L
AAGGCCAGGGGGAAAGAAACACTATATGATAAAACATTTAGTATGGGCAAGCAGGGAGCT
121 GGAAAGATTTGCACTTAACCCTGGCCTGTTAGAGACATCAGAAGGATGTAAACAAATAAT
41 E R F A L N P G L LET S E G C K Q I M
R P G G K K H Y M K H L V WAS R E L
181 GAACCAGCTACAACCATCTCTTCAGACAGGAACAGAAGAACTTAGATCATTATACAACAC
61 N Q L Q P S L Q T GTE E L R SLY N T
241 AGTAGCAACTCTCTATTGTGTACATGAAAAGATAGAGGTACGAGACACCAAGGAAGCCTT
81 VAT L Y C V H EKE V R D T K E A L
301 AGACAAGATAGAGGAAGAACAAAACAAAAGCCAGCAAAAAACACAACAGGCAAAAGCGGC
101 D K E E E Q N K S Q Q K T Q Q A K A A
167
B1. Nucleotide and Amino Acid Sequences of gag clones
361 TGGCGAAAAGGTCAGTCAAAATTATCCTATAGTGCAGAATGCCCAAGGGCAAATGGTACA
121 G E K V S Q N Y P V Q N A Q G Q M V H
421 CCAAGCTATATCACCTAGAACGTTAAATGCATGGGTAAAAGTAATAGAGGAGAAGGCTTT
141 Q A I S P R T L N A W V K VIE E K A F
481 CAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGATTT
161 S P E VIP M F TAL S EGA T P Q D L
541 AAACACCATGTTAAATACAGTGGGAGGACATCAAGCAGCCATGCAAATGTTAAAAGATAC
181 N T M L N T V G G H Q A A M Q M L K D T
201
601 CATCAATGAGGAAGCTGCAGAATGGGATAGGGTACATCCAGTGCATGCAGGGCCTGTTGC
I NEE A A E W D R V H P V HAG P V A
661 ACCAGGACAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTGCA
221 P G Q M REP R G S D I A G T T S T L Q
721 GGAACAAATAGCATGGATGACAAGTAATCCACCTATTCCAGTAGGAGAAATTTATAAAAG
241 E Q A W M T S N P P P V G E Y K R
781 ATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATCTTGGA
261 W I I L G L N K I V R M Y S P V S I L D
841 CATAAAACAAGGGCCAAAGGAACCCTTTAGGGACTATGTAGACCGGTTCTTTAAAACTTT
281 K Q G P K E P F R D Y V D R F F K T L
901 AAGAGCCGAACAGGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTCCA
301 RAE QAT Q D V K N W M T D T L L V Q
321
961 AAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTTCATTAGA

















NAN P D C K T
AGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAAGCAAGAGTGTTGGC
E M M T A C Q G V G G P S H K A R V L A
TGAGGCAATGAGCCAAGCAAACAATATAAACATACTGATGCAGAGAAGCAATTTTAAGGG
E A M S Q ANN I NIL M Q R S N F K G
CTCTAAGAGAATTGTTAAATGCTTCAACTGTGGCAAGGAAGGGCACATAGCCAGAAATTG
S K R I V K C F N C G KEG H I A R N C
CAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATAAAAGA
RAP R K K G C W K C G KEG H Q I K D
CTGTACTGAGAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCGCAAGGGGAGGCC
C T E R Q A NFL G K I W P S R K G R P
AGGGAATTTCCTTCAGAACAGGCCAGAGCCAACAGCCCCACCAGCAGAAAGCTTCAGGTT
G NFL Q N R PEP TAP P A E S F R F
CGAGGAGACAACCCCTGCGCCGAAGCAGGACAAGGAACCCTTAACTTCCCTCAAATCACT
E E T T PAP K Q D K E P L T S L K S L
CTTTGGCAGCGACCCCTCGTCACAATAA
F G S D P S S Q
Translation of TV006G97 (1-1460)
Universal code
Total amino acid number: 485, MW=54316




21 L R P G G K K H Y M K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTGTTAGAGACATCAGAAGGATGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q
181 ATGAACCAGCTACAACCATCTCTTCAGACAGGAACAGAAGAACTTAGATCATTATACAAC
61 M N Q L Q P S L Q T GTE E L R SLY N
168
B1. Nucleotide and AminoAcid Sequencesof gag clones
81
241 ACAGTAGCAACTCTCTATTGTGTACATGAAAAGATAGAGGTACGAGACACCAAGGAAGCC









































TVA T L Y C V H E K
TTAGACAAGATAGAGGAAGAACAAAACAAAAGCCAGCAAAAAACACAACAGGCAAAGGCG
L D K E E E Q N K S Q Q K T Q Q A K A
GCTGGCGAAAAGGTCAGTCAAAATTATCCTATAGTGCAGAATGCCCAAGGGCAAATGGTA
AGE K V S Q N Y P V Q N A Q G Q M V
CACCAAGCTATATCGCCTAGAACGTTAAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
H Q ASP R T L N A W V K VEE K A
TTCAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
F S P E VIP M F TAL S EGA T P Q D
TTAAACACCATGTTAAATACAGTGGGAGGACATCAAGCAGCTATGCAAATGTTAAAAGAT
L N T M L N T V G G H Q A A M Q M L K D
ACCATCAATGAGGAAGCTGCAGAATGGGATAGGGTACATCCAGTGCATGCAAGGCCTGTT
TIN E E A A E W D R V H P V H A R P V
GCACCAGGACAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTG
A P G Q M REP R G S D I A G T T S T L
CAGGAACAAATAGCATGGATGACAAGTAATCCACCTATTCCAGTAGGAGAAATTTATAAA
Q E Q I A W M T S N P PIP V G E Y K
AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATCTTG
R W I L G L N K I V R M Y S P V S L
GACATAAAACAAGGGCCAAAGGAACCCTTTAGGGACTATGTAGACCGGTTCTTTAAAACT
D I K Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q D V K N W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGGCCAGGGGCTTCATTA
Q NAN P D C K TIL R A L G P GAS L
GAAGAAATGATAACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAAGCAAGAGTGTTG
E E M T A C Q G V G G P S H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAATATAAACATACTGATGCAGAGAAGCAATTTTAAG
A E A M S Q ANN N L M Q R S N F K
GGCTCTAAGAGAATTGTTAAATGCTTCAACTGTGGCAAGGAAGGGCACATAGCCAAAAAT
G S K R I V K C F N C G KEG H I A K N
TGCAGAGCCCCTAGGAAAAAGGGCTGTTGAAAATGTAGAAAAGAAAGACACCAAATGAAA
C RAP R K K G C K C R K E R H Q M K
GACTGTACTGAAAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGG
D C T E R Q A NFL G K W P S H K G R
CCAGGGAATTTCCTTCAGAACAGGCCAGAGCCAACAGCCCCACCAGCAGAAAGCTTCAGG
P G NFL Q N R PEP TAP P A E S F R
TTCGAGAAGACAACCCCTGCGCCGAAGCAGGACAAGGAACCCTTAACTTCCCTCAAATCA
F E K T T PAP K Q D K E P L T S L K S
CTCTTTGGCAGCGACCCCTC
L F G S D P
Translation of TV007G59(1-1500)
Universal code
Total amino acid number, 499, MW=55511






M GAR A S I L R G G K L D K WEE I R
TTAAGGCCAGGGGGAAAGAAAACCTATAGGCTAAAACATCTAGTATGGGCAAGCAGGGAG
L R P G G K K T Y R L K H L V WAS R E
169
81. NucleotideandAminoAcid Sequencesof gag clones
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACAGCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET A E G C K Q
181 ATAAGACAGCTACACCCAGCTCTTCAGACAGGAACGGAGGAACTTAGATCATTATACAAC
61 IRQ L H PAL Q T GTE E L R SLY N
81
241 ACAGTAGCAACTCTCTATTGTGTACATGCAAACATAGAGGTAAAAGACACCAAGGAAGCC
E V K D T K E ATVA T L Y C V HAN
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAATCAGAGCAGGCAAAAGTA
101 L D K E E E Q N K S Q Q K SEQ A K V
361 GGTAACGAAAAGATCAGTCAAAATTATCCTATAGTGCAGAATCTCCAAGGGCAAATGGTA
121 G N E K S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCTTATCACCTAGAACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q A L S P R T L N A W V K VIE E K A
481 TTCAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAACACAGTGGGGGGGCATCAAGCAGCCATGCAAATGTTAAAAGAC
181 L N T M L N T V G G H Q A A M Q M L K D
201
601 ACCATCAATGAAGAGGCTGCAGAATGGGATCGATTACACCCAGTACATGCAGGGCCTATT































A P G Q M REP R G S D I A G T T S T L
CAGGAACAAATAGCATGGATGACAAGTAACCCACCTATTCCGGTGGGAGATATCTATAAA
Q E Q I A W M T S N P PIP V G D Y K
AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
R W I I L G L N K I V R M Y S P V S I L
GACATTAAACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
D I K Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q D V K N W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGATCATTTTAAGAGGATTAGGACCAGGGGCTACATTA
Q NAN P D C K L R G L G P GAT L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAAGCAAGAGTGTTG
E E M M T A C Q G V G G P S H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAGTGGAAACATAATGATGCAGAAAAGCAATTTTAGA
A E A M S Q A N S G N M M Q K S N F R
GGCTCTAAAAGAATTATTAAATGTTTTAACTGTGGCAAGGAAGGGCACATAGCCAAAAAT
G S K R K C F N C G KEG H A K N
TGTAAGGCCCCTAGGAAAAGAGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
C K APR K R G C W K C G KEG H Q M K
GACTGTACTGAAAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCTGCAAGGGGAGG
D C T E R Q A NFL G K W P S C K G R
CCAGGGAATTTCCTTCAGAACAGGCCAGAGCCAACAGCCCCACCAGCAGAGCCAACAGCC
P G NFL Q N R PEP TAP P A E PTA
CCACCAGCAGAGAGCCTCAGGATCGAGGAAACAACCCCCGCTCCGAAGCCGGAGCCGAGG
P P A E S L R lEE T T PAP K PEP R
GACAGGGAACCCTTAATCTCCCTCAAATCACCCTTTGGCAGCGACCCCTCGTCACAATAA
D REP LIS L K S P F G S D P S S Q
Translation of TV008G65(l-1476)
Universal code
Total amino acid number: 491, MW=54695
Max ORF: 1-1473, 491 AA, MW=54695
170
81. Nucleotide and Amino Acid Sequences of gag clones
1 ATGGGTGCGAGAGCGTCAGTATTAAGAGGCGAAAAATTAGATACATGGGAAAAAATTAGG




L R P G G K K R Y M L K H V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q
181 ATACAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCGTTATTCAAC
61 Q Q L Q PAL Q T GTE ELK S L F N
241 ACAGTAGCAACTCTCTATTGTGTACATAAAAAGATAGAGGTTCGAGACACCAAGGAAGCC
81 TVA T L Y C V H K K E V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAGAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A E A
361 GCTGACAAAAAGGTCAGTCAAAATTATCCTATAGTACAGAACCTCCAAGGGCAAATGGTA
121 A D K K V S Q N Y P I V Q N L Q G Q M V
421 CACCAAGCCCTATCACCTAGAACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q A L S P R T L N A W V K VEE K A
481 TTTGGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCAGCAGAT
161 F G P E V P M F TAL S EGA T PAD
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAGGCAGCCATGCAGATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCAGAATGGGACAGATTACACCCAGTACATGCAGGGCCTACT
201 TIN E E A A E W D R L H P V HAG P T
661 GCACCAGGCCAAATGAGAGAACCTAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q M REP R G S D A G T T S T L
721 CAGGAACAAATAGCTCGGATGACAAGTAACCCACCTGTCCCAGTGGGAGACATCTATAAA
241 Q E Q ARM T S N P P V P V G D Y K
781 AGATGGATAATTCTAGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
261 R W I I L G L N K I V R M Y S P V S L
841 GACATAAAACAGGGGCCAAAAGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAAGCTACACAAGAGGTAAAAGGTTGGATGACAGACACCTTGTTGGTC
301 L RAE QAT Q E V K G W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACATTA
321 Q NAN P D C K TIL R A L G P GAT L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCCAGAGTGTTG
341 E E M M T A C Q G V G G P G H K A R V L
1081 GCTGAGGCAATGAGCCAAGCAAACAGTAACATACTTATGCAGAGAAGCAATTTTAAAGGC
361 A E A M S Q A N S N L M Q R S N F K G
1141 TCTAAAAGAATTGTTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCGGAAATTGC
381 S K R V K C F N C G KEG H I A G N C
1201 AGGGCCCCTAGAAAAAAGGGCTGTTGGAAATGTGGAAAAGAAGGACACCAAATGAAAGAA
401 RAP R K K G C W K C G KEG H Q M K E
1261 TGTACTGAAAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGGCCA
421 C T E R Q A NFL G K W P S H K G R P
1321 GGGAATTTCCTCCAGAGCAGACCAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAGGTTC
441 G NFL Q S R PEP TAP P A E S F R F
1381 GAGGAGACAACCCCCGCTCCGAAGCAGGAGTCGAAAGACAGGGAGCCCTTAACTTCCCTC
461 E E T T PAP K Q E S K D REP L T S L
1441 AGATCACTCTTTGGCAACGACCCCTCGTCACAATAA
481 R S L F G N D P S S Q
171
81. Nucleotide and Amino Acid Sequences of gag clones
Translation of TVOOBG66 (1-1476)
Universal code
Total amino acid number: 491, MW=54899




21 L R P G G K K R Y M L K H V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q I
181 ATACAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATTCAAC
61 Q Q L Q PAL Q T GTE ELK S L F N
81
241 ACAGTAGCAACTCTCTATTGTGTACACAGAAAGATAGAGGTACGAGACACCAAAGAAGCC
E V R D T K E ATVA T L Y C V H R K
301 TTAGACAAGATAGAGGAAGAACGAAACAAAAGTCAGCAAAAAACACAGCAGGCAGAAGCG
101 L D K lEE ERN K S Q Q K T Q Q A E A
361 GCTGACAAAAAGGTCAGTCAAAATTATCCTATAGTACAGAATCTCCAAGGGCAAATGGTA
121 A D K K V S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCCTATCACCTAGAACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q A L S P R T L N A W V K VIE E K A
161
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCAGCAGAT
F S P E V P M F TAL S EGA T PAD
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAGATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
201
601 ACCATCAATGAGGAGGCTGCAGAATGGGACAGATTACACCCAGTACATGCAGGGCCTGCT


























A P G Q M REP R G S D A G T T S T L
CAGGAACAAATAGCATGGATGACAAGTAACCCACCTGTCCCAGTGGGAGACATCTATAAA
Q E Q A W M T S N P P V P V G D Y K
AGATGGATAATTCTAGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
R W I L G L N K V R M Y S P V S I L
GACATAAAACAGGGGCCAAAAGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
D I K Q G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGAGGTAAAAGGTTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q E V K G W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACATTA
Q NAN P D C K T L R A L G P GAT L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCCAGAGTATTG
E E M M T A C Q G V G G P G H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAGTAACATATTTATGCAGAGAAGCAATTTTAAAGGC
A E A M S Q A N S N F M Q R S N F K G
TCTAAAAGAATTGTTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCAAAAATTGC
S K R V K C F N C G KEG H A K N C
AGGGCCCCTAGAAAAAAGGGCTGTTGGAAATGTGGAAAAGAAGGACACCAAATGAAAGAC
RAP R K K G C W K C G KEG H Q M K D
TGTACTGAAAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGGCCA
C T E R Q A NFL G K W P S H K G R P
GGGAATTTCCTCCAGAGCAGACCAGAGCCAACAGCCCCACCAGCAGAGAACTTCAGGTTC
G NFL Q S R PEP TAP P A E N F R F
172
81. Nucleotide and Amino Acid Sequences of gag clones
1381 GAGGAGACAACCCCCGCTCCGAAGCAGGAGTCGAAAGACAGGGAGCCCTTAACTTCCCTC
461 E E T T PAP K Q E S K D REP L T S L
1441 AGATCACTCTTTGGCAACGACCCCTCGTCACAATAA
481 R S L F G N D P S S Q
Translation of TV009G12(1-1479)
Universal code
Total amino acid number: 492, MW=54769
Max ORF: 1-1476, 492 AA, MW=54769
ATGGGTGCGAGAGCGTCAATATTAAGAGGGGGAAAATTAGATAAATGGGAAAAAATTAGG
M GAR A S L R G G K L D K W E K I R
61 TTAAGGCCAGGGGGAAAGAAAGGATATATGATAAAACACTTAGTATGGGCAAGCAGGGAG
21 L R P G G K K GYM K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACTCTGGCCTTTTAGAAACAGCAGACGGCTGTAAACAAATA
41 L E R F A L N S G L LET A D G C K Q I
181 CTACAACAGCTACAACCAGCTCTCCAGACAGGGACAGAGGAACTTAGATCATTATATAAC
61 L Q Q L Q PAL Q T GTE E L R SLY N
241 ACAGTGGCAACTCTCTATTGTGTACATAGCAATATTGGGGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H S N I G V R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAGCG
101 L D K lEE E Q N K S Q Q K T Q Q A K A
361 GCTGAAGGAAAGGTCAGTCAAAATTATCCTATAGTGCAGAATCTTCAAGGGCAGATGGTA
121 A E G K V S Q N Y P V Q N L Q G Q M V
421 CATCAGGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q A I S P R T L N A W V K VIE E K A
481 TTCAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E VIP M F TAL S EGA T P Q D
541 CTAAACACTATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCGGAATGGGATAGGTTACATCCAGTACAGGCAGGGCCTATT
201 T NEE A A E W D R L H P V Q A G P
661 GCACCAGGCCAAATAAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q IRE P R G S D A G T T S T L
721 CAGGAACAAATAGCATGGATGACAGGTAACCCAGTTATTCCAGTGGGAGACATCTATAAA
241 Q E Q A W M T GNP V P V G D Y K
781 AGATGGATAATTATGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
261 R W M G L N K V R M Y S P V S L
841 GACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTTAAAACT
281 D IRQ G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAAGCTACCCAAGAAGTAAAAAATTGGATGACAGACACCTTGTTGGTC
301 L RAE QAT Q E V K N W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACATTA
321 Q NAN P D C K T L R A L G P GAT L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTTTTG
341 E E M M T A C Q G V G G P G H K A R V L
1081 GCTGAGGCAATGAGCCAAGTAAACAATGCAAACATAATGATGCAAAGAAGTAATTTTAAA
361 A E A M S Q V N NAN M M Q R S N F K
1141 GGCTCCAAAAGAATTGTTAAATGTTTCAACTGTGGCAAAGAAGGGCACATAGCCAGAAAT
381 G S K R I V K C F N C G KEG H I A R N
1201 TGCAGGGCCCCTAGGAAAAAAGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
401 C RAP R K K G C W K C G KEG H Q M K
173
















L K S L F G S D P S S Q
Translation of TV010G74 (1-1482)
Universal code
Total amino acid number: 493, MW=55088
Max ORF: 1-1479, 493 AA, MW=55088
1 ATGGGTGCGAGAGCGTCAATATTAAGAGGCGGAAAATTAGATAAATGGGAAAAAATTAGA
1 MGARAS LRGGKLDKWEK R
61 TTAAGGCCAGGGGGAAAGAAACACTATATGTTAAAACACATAGTATGGGCAAGCAGGGAG
21 L R P G G K K H Y M L K H I V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q I
181 ATACAACAGCTACACACAGCTCTTAAGACAGGAACAGAGGAACTTACATCATTATACAAC
61 I Q Q L H TAL K T GTE E L T SLY N
241 ACAGTAGCAACTCTCTACTGTGTACATGCAGGGATAGAGGTACGAGACACCAAGGAGGCC
81 TVA T L Y C V HAG E V R D T K E A
301 TTAGACAAGATAGAGGAGGAGCAAAACAAAAGTCAGAAAAAAATGCAGCAAGCAGAAGTG
101 L D K E E E Q N K S Q K K M Q Q A E V
361 GCTGACAAAAAGAAGGTCAGTCAAAATTATCCTATAGTACAGAATCACCAAGGGCAAATG
121 A D KKK V S Q N Y P I V Q N H Q G Q M
421 GTACACCAGAACATATCACCAAGAACTTTAAATGCATGGGTAAAAGTAATAGAGGAGAAG
141 V H Q N I S P R T L N A W V K VIE E K
481 GGTTTCAACCCAGAGGTAATACCCATGTTTACAGCATTATCAGAGGGAGCCACCCCTTCT
161 G F N P E V P M F TAL S EGA T P S
541 GATCTGAACACCATGTTAAATATAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAA
181 D L N T M L N I V G G H Q A A M Q M L K
601 GATACCATCAATGAGGAGGCTGCAGAATGGGATAGATTACACCCAGCACAGGCAGGGCCT
201 D T NEE A A E W D R L H P A Q A G P
661 GTTGCACCAGGCCAAATCAGAGATCCAAGGGGAAGTGACATAGCAGGAACTACTAGTACC
221 V A P G Q R D P R G S D A G T T S T
721 CTTCAGGAACAAGTAACATGGATGACAAATAACCCACCTATTCCAGTAGGAGACATCTAT
241 L Q E Q V T W M T N N P P P V G D Y
781 AAAAGATGGATAATTCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATT
261 K R W I L G L N K V R M Y S P V S
841 TTGGACATTAGACAAGGACCAAAGGAGCCTTTTAGAGACTATGTAGATCGGTTCTTTAAA
281 L D IRQ G P K E P F R D Y V D R F F K
901 ACTTTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTG
301 T L RAE QAT Q D V K N W M T D T L L
961 GTCCAAAATGCAAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACA
321 V Q NAN P D C K T L R A L G P GAT
1021 TTAGAAGAAATGATGACAGCATGTCAAGGAGTGGGAGGACCTAGCCACAAAGCAAGAGTC
341 LEE M M T A C Q G V G G P S H K A R V
1081 TTGGCTGAGGCAATGAGCCAAGCAGGCAATACAAACATAATGATGCAGAAAAGCAATTTC
361 L A E A M S Q A G N T N M M Q K S N F
174
























S L K S L F G G D P S S Q
Translation of TV012G34 (1-1491)
Universal code
Total amino acid number, 496, MW=55405
Max ORF, 1-1488, 496 AA, MW=55405
1 ATGGGTGCGAGAGCGTCAATATTAAGAGGGGGAAAATTAGATAAATGGGAAAAAATTAGG
M GAR A S I L R G G K L D K W E K I R
61 TTAAGGCCAGGGGGGAAAAAACACTATATGCTAAAACACCTAGTATGGGCAAGCAGAGAG
21 L R P G G K K H Y M L K H L V WAS R E
121 CTGGAAAGATTTGCAGTTAACCCTGGCCTTTTAGAGACATCAGACGGATGTAGACAAATA
41 L E R F A V N P G L LET S D G C R Q
181 ATAAAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAAATTAGATCATTATTTAAC
61 I K Q L Q PAL Q T GTE E IRS L F N
241 ACAGTAGCAACTCTCTATTGTGTACATGAAGGGATAGATGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H E G I D V R D T K E A
301 TTAGACAAGTTGGAGGAGGAACAAAACAAATGTCAGCAAAAAACACAGCAGGCAGAAGCG
101 L D K LEE E Q N K C Q Q K T Q Q A E A
361 GCTGACAAAAAGGTCAGTCAAAATTATCCTATAGTGCAGAACCTCCAAGGGCAAATGGTA
121 A D K K V S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q ASP R T L N A W V K VEE K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCCGAATGGGATAGGTTACATCCAGTACATGCAGGGCCTGTT
201 TIN E E A A E W D R L H P V HAG P V
661 GCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGAAACTACTAGTACCCTT
221 A P G Q M REP R G S D A E T T S T L
721 CAAGAACAAATAGCATGGATGACAAGTAACCCACCTATCCCAGTAGGAGACATCTATAAA
241 Q E Q I A W M T S N P P P V G D Y K
781 AGGTGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTACAGCCCTGTCAGCATTTTG
261 R W I L G L N K V R M Y S P V S L
841 GACATAAAACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTCAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCTGAACAATCTACACAAGAGGTAAAAAATTGGATGACAGACACCTTGTTAGTC
301 L RAE Q S T Q E V K N W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTTCATTA



















Nucleotide and Amino Acid Sequences of gag clones
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAAGCAAGAGCTTTG
E E M M T A C Q G V G G P S H K A R A L
GCTGAGGCAATGAGCCAAGCAAACAATGCAAGTGTAATGATGCAGAAAAGCAATTTTAAA
A E A M S Q ANN A S V M M Q K S N F K
GGCCCTAGAAGTACTGTTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCAGGAAT
G P R S T V K C F N C G KEG H A R N
TGCAGGGCCCCTAGGAAAAAGGACTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
C RAP R K K D C W K C G KEG H Q M K
GACTGTACTGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGG
D C T E R Q A NFL G K W P S H K G R
CCAGGGAATTTCCTTCAGAGCAGGCCAGAGCCAACAGCCCCACCACTAGAGCCAACAGCC
P G NFL Q S R PEP TAP P L E PTA
CCACCAGCAGAGAGCTTCAAGTTCGAGGAGACTCCGAAGCGGGAGCCGAAAGACAGGGAA
P P A E S F K FEE T P K REP K D R E
CCCTTAACTTCCCTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
P L T S L K S L F G S D P S S Q
Translation of TV012G40(1-1503)
universal code
Total amino acid number: 500, MW=55961
Max ORF: 1-1500, 500 AA, MW=55961
ATGGGTGCGAGAGCGTCAATATTAAGAGGGGGAAAATTAGACAAATGGGAAAAAATTAGG
1 MGARAS LRGGKLDKWEK R
61 TTAAGGCCAGGGGGGAAAAAACGCTATATGCTAAAACACCTAGTATGGGCAAGCAGAGAG
21 L R P G G K K R Y M L K H L V WAS R E
121 CTGGACAGATTTGCAGTTAACCCTGGCCTTTTAGAGACATCAGACGGATGTAGACAAATA
41 L D R F A V N P G L LET S D G C R Q
181 ATAAAACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAAATTAGATCATTATTTAAC
61 K Q L Q PAL Q T GTE E IRS L F N
241 ACAGTAGCAACTCTCTATTGTGTACATAAAGGGATAGATGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H K G D V R D T K E A
301 TTAGACAAGATAGAGGAGGAACAAAACAAATGCCAGCAAAAAACACAGCAGGCGGAAGCG
101 L D K lEE E Q N K C Q Q K T Q Q A E A
361 GCTGACAAAAAGGTCAGTCAAAATTATCCTATAGTGCAGAACCTCCAAGGGCAAATGGTA
121 A D K K V S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q ASP R T L N A W V K VEE K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCCGAATGGGATAGGTTACATCCAGTACATGCAGGGCCTGTT
201 T NEE A A E W D R L H P V HAG P V
661 GCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGAAACTACTAGTACCCTT
221 A P G Q M REP R G S D A E T T S T L
721 CAAGAACAAATAGCATGGATGACAAGTAACCCACCTATCCCAGTAGGAGACATCTATAAA
241 Q E Q I A W M T S N P PIP V G DIY K
781 AGGTGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTACAGCCCTGTCAGCATTTTG
261 R W I I L G L N K I V R M Y S P V S L
841 GACATAAAACAAGGACCAAAAGAACCTTTTAGAGACTATGTAGACCGGTTCTTCAAAACT
281 D I K Q G P K E P F R D Y V D R F F K T
176
81. Nucleotideand AminoAcid Sequencesof gag clones
901 TTAAGAGCTGAACAATCTACACAAGAGGTAAAAAATTGGATGACAGACACCTTGTTAGTC
301 L RAE Q S T Q E V K N W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTTCATTA
321 Q NAN P D C K T L R A L G P GAS L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTACCCACAAAGCAAGAGTTTTG
341 E E M M T A C Q G V G G P T H K A R V L
1081 GCTGAGGCAATGAGCCAAGCAAACAATACAAGTGTAATGATACAGAAAAGCAATTTTAAA
















G P R R A V K C F N C G KEG H
TGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAA
C RAP R K K G C W K C G KEG H Q M K
GACTGTACTGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGAAGG
D C T E R Q A NFL G K W P S H K G R
CCAGGGAATTTCCTTCAGAGCAGACCAGAGCCAACAGCCCCACCACTAGAACCAACAGCC
P G NFL Q S R PEP TAP P L E PTA
CCACCAGCAGAGAGCTTCAAGTTCGAGGAGACTCCGAAGCAGGAGCCGAAAGACAGGGAA
P P A E S F K FEE T P K Q E P K D R E
CCCTACAGGGAACCCTTAACTTCCCTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAA




Total amino acid number: 508, MW=56952
























M GAR A S L R G T K L D AWE K I R
TTAAGGCCAGGGGGAAAGAAACATTATATGTTAAAACACCTAGTATGGGCAAGCAGGGAG
L R P G G K K H Y M L K H L V WAS R E
CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAAACATCGGAAGGCTGTAAACAAATA
L E R F A L N P G L LET S E G C K Q
ATGAAACAGCTACACCCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATACAAC
M K Q L H PAL Q T GTE ELK SLY N
ACAGTAGCAACTCTCTATTGTGTACATGAAAGCATAAAGGTACGAGACACCAAGGAAGCC
TVA T L Y C V H E S I K V R D T K E A
TTAGACAAGATAGAGGAAGAACAAAACAAAATTAAAAGTCAGCAAAAAACACAGCAGGCA
L D K E E E Q N K K S Q Q K T Q Q A
AAAGCGGCTGACGAAAAAGTCAGTCAAAATTATCCTATAGTGCAGAATCTTCAAGGGCAA
K A A D E K V S Q N Y P I V Q N L Q G Q
ATGGTACATCAGAACCTATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAG
M V H Q N L S P R T L N A W V K VEE
AAGGCTTTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCA
K A F S P E V P M F TAL S EGA T P
CAAGATTTAAACACCATGTTAAATACGGTGGGGGGACATCAAGCAGCCATGCAAATGTTA
Q D L N T M L N T V G G H Q A A M Q M L
AAAGATCCCATCAATGAAGAGGCTGCAGAATGGGATAGATTACACCCAGTCCATGCGGGG
K D PIN E E A A E W D R L H P V HAG
661 CCTATGGCACCAGGCCAATTGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGT



























Nucleotide and Amino Acid Sequences of gag clones
ACCCTTCAGGAACAAATAGCATGGATGACAAGTAATCCACCTATCCCAGTGGGAGACATC
T L Q E Q I A W M T S N P PIP V G D
TATAAAAGATGGATAATTCTGGGGTTAAATAAAATAGTGAGAATGTATAGCCCTATCAGC
Y K R W L G L N K V R M Y S P S
ATTTTGGACATAAGACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTT
L D IRQ G P K E P F R D Y V D R F F
AAAGCCTTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGAAACCTTG
K A L RAE QAT Q D V K N W M T E T L
CTGGTCCAAAATGCGAACCCAGATTGTAAGACCATTTTAAAAGCATTAGGAATAGGGGCT
L V Q NAN P D C K T L K A L G G A
ACATTGGAAGAAATGATGACAGCATGTCAGGGAGTGGGGGGACCTAGTCACAAAGCAAGA
T LEE M M T A C Q G V G G P S H K A R
GTGTTAGCTGAGGCAATGAGCCAAGCAAACAATACAAACATAATGATGCAGAGAAGCAAT
V L A E A M S Q ANN T N M M Q R S N
TTTAAAAGCTCAAAAAGAATTGTTAAATGTTTCAACTGTGGCAAGGAAGGGCATATAGCC
F K S S K R V K C F N C G KEG H I A
AGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAA
R NCR APR K K G C W K C G KEG H Q
ATGAAAGATTGTACTGAGAGGCAGGCAAATTTTTTAGGGAAAATTTGGCCTTCCCACAAG
M K D C T E R Q A NFL G K W P S H K
GGGAGGCCAGGGAATTTCCTTCAGAACAGACCAGAGCCAACAGCCCCACCAGCAGAGAGT
G R P G NFL Q N R PEP TAP P A E S
TTCAGGAACAGACCAGAGCCAACGGCTCCACCAGCAGAGAGCTTCAGGTTCGAGGAGACA
F R N R PEP TAP P A E S F R FEE T
1441 ACCCCCACTCCGAAGCAGGAGCCGAAAGACAGGGATCCCTTAACTTCCCTCAAATCACTC
481 T P T P K Q E P K D R D P L T S L K S L
1501 TTTGGCAGCGACCCCTCGTCACAATAA
501 F G S D P S S Q
Translation of TV013GlS(1-lS27)
Universal code
Total amino acid number: 508, MW=56910
Max ORF: 1-1524, 508 AA, MW=56910
ATGGGTGCGAGAGCGTCAATATTAAGAGGGACGAAATTAGATGCATGGGAAAAAATTAGG
1 MGARAS LRGTKLDAWEK R
61 TTAAGGCCAGGGGGAAAGAAACATTATATGTTAAAACACCTAGTATGGGCAAGCAGGGAG
21 L R P G G K K H Y M L K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAAACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q
181 ATGAAACAGCTACACCCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATACAAC
61 M K Q L H PAL Q T GTE ELK SLY N
81
241 ACAGTAGCAACTCTCTATTGTGTACATGAAAACATAAAGGTACGAGACACCAAGGAAGCC
K V R D T K E ATVA T L Y C V HEN
301 TTAGACAAGATAGAGGAAGAACAAAACAAAATTAAAAGTCAGCAAAAAACACAGCAGGCA
101 L D K E E E Q N K K S Q Q K T Q Q A
361 AAAGCGGCTGACGAAAAAGTCAGTCAAAATTATCCTATAGTGCAGAATCTTCAAGGGCAA
121 K A A D E K V S Q N Y P I V Q N L Q G Q
421 ATGGTACATCAGAACCTATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAG
141 M V H Q N L S P R T L N A W V K VEE
481 AAGGCTTTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCA
161 K A F S P E VIP M F TAL S EGA T P
178
81. Nucleotide and Amino Acid Sequences of gag clones
541 CAAGATTTAAGCACCATGTTAAATACGGTGGGGGGACATCAAGCAGCCATGCAAATGTTA
181 Q D L S T M L N T V G G H Q A A M Q M L
201
601 AAAGATACCATCAATGAAGAGGCTGCAGAATGGGATAGATTACACCCAGTCCATGCGGGG

































P MAP G Q L REP R G S D A G T T S
ACCCTTCGGGAACAAATAGCATGGATGACAAGTAATCCACCTATCCCAGTGGGAGACATC
T L R E Q I A W M T S N P P P V G D I
TATAAAAGATGGATAATTCTGGGGTTAAATAAAATAGTGAGAATGTATAGCCCTGTCAGC
Y K R W I I L G L N K I V R M Y S P V S
ATTTTGGACATAAGACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTTT
L D R Q G P K E P F R D Y V D R F F
AAAGCCTTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGAAACCTTG
K A L RAE QAT Q D V K N W M T E T L
CTGGTCCAAAATGCGAACCCAGATTGTAAGACCATTTTAAAAGCATTAGGAATAGGGGCT
L V Q NAN P D C K TIL K A L GIG A
ACATTGGAAGAAATGATGACAGCATGTCAGGGAGTGGGGGGACCTAGTCACAAAGCAAGA
T LEE M M T A C Q G V G G P S H K A R
GTGTTAGCTGAGGCAATGAGCCAAGCAAACAATACAAACATAATGATGCAGAGAAGCAAT
V L A E A M S Q ANN T N I M M Q R S N
TTTAAAAGCTCAAAAAGAATTGTTAAATGTTCCAACTGTGGCAAGGAAGGGCATATAGCC
F K S S K R I V K C S N C G KEG H I A
AGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGACACCAA
R NCR APR K K G C W K C G KEG H Q
ATGAAAGATTGTACTGAGAGGCAGGCAAATTTTTTAGGGAAAATTTGGCCTTCCCACAAG
M K D C T E R Q A NFL G K W P S H K
GGGAGGCCAGGGAATTTCCTTCAGAACAGACCAGAGCCAACAGCCCCACCAGCAGAGAGT
G R P G NFL Q N R PEP TAP P A E S
TTCAGGAACAGACCAGAGCCAACGGCTCCACCAGCAGAGAGCTTCAGGTTCGAGGAGACA
F R N R PEP TAP P A E S F R FEE T
ACCCCCACTCCGAAGCAGGAGCCGAAAGACAGGGATCCCTTAACTTCCCTCAAATCACTC
T P T P K Q E P K D R D P L T S L K S L
TTTGGCAGCGACCCCTCGTCACAATAA
F G S D P S S Q
Translation of TV014G73 (1-1476)
Universal code
Total amino acid number, 491, MW=54857




21 L R P G G R K H Y M L K H L V WAS R E
121 CTGGAAAGATTCGCACTTAACCCTGGCCTTTTAGAGACATCACAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S Q G C K Q I
181 ATAAAACAGCTACACCCAGCTCTTAAGACAGGAACAGAGGAACTTAGGTCATTATACAAC
61 K Q L H PAL K T GTE E L R SLY N
241 ACAGTAGCAACTCTCTATTGTGTACATGAAAACATAGAGGTACGAGACACCAAGGAGGCC
81 TVA T L Y C V HEN lEV R D T K E A
301 TTAGACAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A K A
179
81. Nucleotideand AminoAcid Sequencesof gag clones
361 GCTGACGAAGGAGTCAGTCAAAATTATCCCATAGTGCAGAATCTCCAAGGGCAAATGGTA
121 A D E G V S Q N Y P V Q N L Q G Q M V
421 CACCAGGCCATATCACCTAGAACTTTGAATGCATGGGTGAAAGTAATAGAGGAGAAGGCT
141 H Q A I S P R T L N A W V K VIE E K A
481 TTTAGCCCAGAAGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E VIP M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACAGTAGGGGGACATCAAGCAGCCATGCAGATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
201
601 ACCATCAATGAGGAGGCTGCAGAATGGGATAGATTACATCCAGTCCATGCAGGGCCTGCT






























A P G Q M REP R G S D I A G T T S T L
CAGGAACAAATAGCATGGATGACAGGTAACCCACCTGTCCCAGTGGGAGACATCTATAAA
Q E Q I A W M T GNP P V P V G D Y K
AGATGGATAATTCTGGGGTTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
R W I I L G L N K V R M Y S P V S L
GACATAAAACAAGGGCCAAAGGAACCCTTTAGAGACTATGTAGATCGGTTCTTTAAAGTT
D K Q G P K E P F R D Y V D R F F K V
TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGATC
L RAE QAT Q D V K N W M T D T L L
CAAAATGCGAACCCAGATTGTAAGACCATCTTAAAGGCATTGGGACCAGCGGCTTCATTA
Q NAN P D C K T L K A L G P A A S L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTGTTG
E E M M T A C Q G V G G P G H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAGTAACATAATGATGCAGAGAAGCAATTTTAAAGGA
A E A M S Q A N S N M M Q R S N F K G
TCTAAAAGAATTGTTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCAGAAATTGC
S K R I V K C F N C G KEG H A R N C
AGGGCCCCTAGAAAAAAGGGCTGTTGGAAATGTGGACAAGAAGGACACCAAATGAAAGAC
RAP R K K G C W K C G Q E G H Q M K D
TGTACTGAAAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGGCCA
C T E R Q A NFL G K I W P S H K G R P
GGGAATTTCCTCCAGAGCAGGCCAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAGGTTC
G NFL Q S R PEP TAP P A E S F R F
GAGGAAACAACCCCCGCTCCGAAACAGGAGTCGAAGGACAGGGAACCCTTAATTTCCCTC
E E T T PAP K Q E S K D REP LIS L
AAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
K S L F G S D P S S Q
Translation of TV018G60(1-1479)
universal code
Total amino acid number: 492, MW=55099




21 L R P G G K K H Y M L K H I V WAS R E
121 TTGGAAAAATTTGCACTTAACCCTGGCCTTTTAGAAACAGCAGAAGGCTGTAATCAAATA
41 L E K F A L N P G L LET A E G C N Q
181 ATGAACCAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATTCAAC
61 M N Q L Q PAL Q T GTE ELK S L F N
180
81. Nucleotideand AminoAcid Sequencesof gag clones
81
241 ACAGTAGCAACTCTCTATTGTGTACATAAAAAGATAGATGTACGAGACACCAAGGAAGCC
D V R D T K E ATVA T L Y C V H K K
301 TTAGATAAGATAGAGGAAGAACAAAACAAAAGTCAGCAAAAAACACAGCAGGCAAAAGCG
101 L D K E E E Q N K S Q Q K T Q Q A K A
361 GCTGACGAAAAGGTCAGTCAAAATTATCCTATAGTACAAAATCTCCAAGGGCAAATGGTA
121 A D E K V S Q N Y P I V Q N L Q G Q M V
421 CATCAAGCCATATCACCTAGAACCTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCC
141 H Q A I S P R T L N A W V K VIE E K A
481 TTTAGCCCAGAGGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E V P M F TAL S EGA T P Q D
541 TTAAACACCATGTTAAATACGGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
201
601 ACCATCAATGAGGAGGCTGCAGAATGGGATAGATTACATCCAGTACATGCGGGGCCTGTT






























A P G Q M REP R G S D I A G T T S T L
CAGGAACAAATAGCATGGATTACAGCTAACCCACCTATTCCAGTAGGAGAAATCTATAAA
Q E Q I A W TAN P PIP V G E Y K
AGATGGATAATTCTGGGGTTAAATAAAATAGTGAGAATGTATAGCCCTGTCAGCATTTTG
R W I L G L N K V R M Y S P V S L
GACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGATCGGTTCTTTAAAACT
D IRQ G P K E P F R D Y V D R F F K T
TTAAGAGCTGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q D V K N W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGACCATTTTAAGAGCATTAGGACCAGGGGCTACATTA
Q NAN P D C K TIL R A L G P GAT L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTAGCCACAAAGCAAGAGTTTTG
E E M M T A C Q G V G G P S H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAATGCAGTCATAATGATGCAGAAAAGCAATTTTAAA
A E A M S Q ANN A V M M Q K S N F K
GGTCCTAGAAAAATTATTAGATGTTTCAACTGTGGTAAGGAAGGGCACATAGCCAGAAAC
G P R K I R C F N C G KEG H A R N
TGCAGGGCCCCTAGGAAAAAAGGCTGTTGGAAATGTGGAAAGGAGGGACACCAAATGAAA
C RAP R K K G C W K C G KEG H Q M K
GACTGTACTGAAAGGCAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGGAGG
D C T E R Q A NFL G K W P S H K G R
CCAGGGAATTTCCTTCAGAACAGACCAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAAG
P G NFL Q N R PEP TAP P A E S F K
TTCGAGGAGACAACCCCCACTCCGAGGCAGGAGTCGAAAGACAGGGAACCCTTAACTTCC
FEE T T P T P R Q E S K D REP L T S
CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
L K S L F G S D P S S Q
Translation of TV019G20(1-1479)
Universal code
Total amino acid number: 492, MW=55105





M GAR A S L R G G K L D T W E K R
TTAAGGCCAGGGGGAAAGAAACACTATATGCTAAAACATCTAGTATGGGCAAGCAGGGAG

















































Nucleotide and Amino Acid Sequences of gag clones
CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGCTGTAAACAAATA
L E R F A L N P G L LET S E G C K Q
ATAAGACAGCTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATATAAC
R Q L Q PAL Q T GTE ELK SLY N
ACAGTAGCAACTCTCTATTGTGTACATGCAAAGATAGAGGTACGAGACACCAAGGAAGCC
TVA T L Y C V H A K E V R D T K E A
TTAGACAGGATAGAGGAAGAACAGAAAAAATGTCAGCAAAAAACACAGCAGGCAAAAGAG
L D R E E E Q K K C Q Q K T Q Q A K E
GCTGACGGGAAGATCAGTCAAAATTATCCTATAGTGCAGAATCTTCAAGGGCAAATGGTA
A D G K S Q N Y P V Q N L Q G Q M V
CACCAGGCCATATCACCTAGAACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
H Q ASP R T L N A W V K VEE K A
TTTAGCCCAGAAGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
F S P E VIP M F TAL S EGA T P Q D
TTAAACACCATGCTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
L N T M L N T V G G H Q A A M Q M L K D
ACCATCAATGAGGAGGCTGCAGAATGGGACAGAATACATCCAGTACATGCAGGGCCTATT
T NEE A A E W D R I H P V HAG P
GCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
A P G Q M REP R G S D A G T T S T L
CAGGAACAAATAGCATGGATGACAAGTAACCCACCTGTTCCAGTGGGAGAAATCTATAAA
Q E Q I A W M T S N P P V P V G E Y K
AGATGGATAATTCTGGGCCTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
R W L G L N K V R M Y S P V S L
GACATAAAACAAGGACCAAAGGAACCCTTTAGAGATTATGTAGATCGGTTCTTTAAAACT
D K Q G P K E P F R D Y V D R F F K T
TTAAGAGCCGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
L RAE QAT Q D V K N W M T D T L L V
CAAAATGCGAACCCAGATTGTAAGATCATTTTAAGAGGATTAGGACCAGGGGCTACATTA
Q NAN P D C K L R G L G P GAT L
GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTGTTG
E E M M T A C Q G V G G P G H K A R V L
GCTGAGGCAATGAGCCAAGCAAACAGTACAAATATAATGATGCAGAGAGGCAATTTTAAA
A E A M S Q A N S T N M M Q R G N F K
GGCCCTAAAAGAAACATTAAATGTTTTAACTGTGGCAAGGAAGGGCACCTAGCCAGAAAT
G P K R N I K C F N C G KEG H L A R N
TACAGGGCCCCTAGGAAAAAAGGTTGTTGGAAATGTGGAAAAGAAGGACACCAAATGAAA
Y RAP R K K G C W K C G KEG H Q M K
GACTGTACAGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGAAGG
D C T E R Q A NFL G K W P S H K G R
CCAGGGAACTTCCTTCAGAACAGAACAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAGG
P G NFL Q N R T E PTA P P A E S F R
TTCGAGGAGACAAACCCTGCTCCGAAGCAGGAGCCGAAAGACAGGGAACCCTTAACTTCC
FEE T N PAP K Q E P K D REP L T S
CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
L K S L F G S D P S S Q
182
81. Nucleotideand AminoAcid Sequencesof gag clones
Translation of TV019G25(1-1479)
universal code
Total amino acid number: 492, MW=54918




21 L R P G G K K H Y M L K H L V WAS R E
121 CTGGAAAGATTTGCACTTAACCCTGGCCTTTTAGAGACATCAGAAGGCTGTAAACAAATA
41 L E R F A L N P G L LET S E G C K Q I
181 ATAAGACAACTACAACCAGCTCTTCAGACAGGAACAGAGGAACTTAAATCATTATACAAC
61 IRQ L Q PAL Q T GTE ELK SLY N
241 ACAGTAGCAACTCTCTATTGTGTACATGCAAAGATAGAGGTACGAGACACCAAGGAAGCC
81 TVA T L Y C V H A K E V R D T K E A
301 TTAGATAAGATAGAGGAAGAACAGAAAAAATGTCAGCAAAAAACACAGCAGGCAAAAGAG
101 L D K E E E Q K K C Q Q K T Q Q A K E
361 GCTGACGGGAAGATCAGTCAAAATTATCCTATAGTGCAGAATCTTCAAGGGCAAATGGTA
121 A D G K I S Q N Y P I V Q N L Q G Q M V
421 CACCAGGCCATATCACCTAGAACTTTGAATGCATGGGTAAAAGTAATAGAGGAGAAGGCT
141 H Q ASP R T L N A W V K VEE K A
481 TTTAGCCCAGAAGTAATACCCATGTTTACAGCATTATCAGAAGGAGCCACCCCACAAGAT
161 F S P E VIP M F TAL S EGA T P Q D
541 TTAAACACCATGCTAAATACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAT
181 L N T M L N T V G G H Q A A M Q M L K D
601 ACCATCAATGAGGAGGCTGCAGAATGGGACAGAATACATCCAGTACATGCAGGGCCTATT
201 T NEE A A E W D R I H P V HAG P
661 GCACCAGGCCAAATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTT
221 A P G Q M REP R G S D A G T T S T L
721 CAGGAACAAATAGCATGGATGACAAGTAACCCACCTGTTCCAGTGGGAGAAATCTATAAA
241 Q E Q A W M T S N P P V P V G E Y K
781 AGATGGATAATTCTGGGCCTAAATAAAATAGTAAGAATGTATAGCCCTGTCAGCATTTTG
261 R W I L G L N K V R M Y S P V S L
841 GACATAAAACAAGGACCAAAGGAACCCTTTAGAGATTATGTAGACCGGTTCTTTAAAACT
281 D K Q G P K E P F R D Y V D R F F K T
901 TTAAGAGCCGAACAAGCTACACAAGATGTAAAAAATTGGATGACAGACACCTTGTTGGTC
301 L RAE QAT Q D V K N W M T D T L L V
961 CAAAATGCGAACCCAGATTGTAAGATCATTTTAAGAGGATTAGGACCAGGGGCTACATTA
321 Q NAN P D C K L R G L G P GAT L
1021 GAAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCTGGCCACAAAGCAAGAGTGTTG
341 E E M M T A C Q G V G G P G H K A R V L
1081 GCTGAGGCAATGAGCCAAGCAAACAGTACAAATATAATGATGCAGAGAGGCAATTTTAAA
361 A E A M S Q A N S T N M M Q R G N F K
1141 GGCCCTAAAAGAAACATTAAATGTTTTAACTGTGGCAAGGAAGGGCACCTAGCCAGAAAT
381 G P K R N I K C F N C G KEG H L A R N
1201 TGCAGGGCCCCTAGGAAAAAGGGTTGTTGGAAATGTGGAAAAGAAGGACACCAAATGAAA
401 C RAP R K K G C W K C G KEG H Q M K
1261 GACTGTACAGAGAGACAGGCTAATTTTTTAGGGAAAATTTGGCCTTCCCACAAGGGAAGA
421 D C T E R Q A NFL G K I W P S H K G R
1321 CCAGGGAACTTCCTTCAGAACCGAACAGAGCCAACAGCCCCACCAGCAGAGAGCTTCAGG
441 P G NFL Q N R T E PTA P P A E S F R
1381 TTCGAGGAGACAAACCCTGCTCCGAAGCAGGAGCCGAAAGACAGGGAACCCTTAACTTCC
183
81. Nucleotide and Amino Acid Sequences of gag clones
461
1441 CTCAAATCACTCTTTGGCAGCGACCCCTCGTCACAATAA
481 L K S L F G S D P S S Q
FEE T N PAP K Q E P K D REP L T S
Translation of TV016G95 (1-1508)
Universal code
Total amino acid number: 502, MW=55966













































M GAR A S V L S G GEL D R W E K R
TTGAGGCCAGGGGGAAAGAAAAAGTATCAATTAAAACATATAGTATGGGCAAGCAGGGAG
L R P G G KKK Y Q L K H I V WAS R E
CTAGAACGCTTCGCAGTTAACCCTGGCCTGTTAGAAACATCAGAAGGTTGTAGACAAATA
L E R F A V N P G L LET S E G C R Q
CTGGGACAGCTACAGCCAGCCCTTCAGACAGGATCAGAAGGACTTAGATCATTATATAAT
L G Q L Q PAL Q T G S E G L R SLY N
ACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGGTAAAAGACACCAAGGAAGCT
TVA T L Y C V H Q REV K D T K E A
TTAGAGAAAATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAGGCACAGCAAGCAGCCGCT
L EKE E E Q N K S KKK A Q Q A A A
GACACAGGAAACAGTAGCAGCAGCCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATG
D T G N S S S S Q V S Q N Y P I V Q N M
CAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTA
Q G Q M V H Q A I S P R T L N A W V K V
GTGGAAGAGAAGGCTTTTAGTCCAGAAGTAATACCCATGTTTGCAGCATTATCAGAAGGA
VEE K A F S P E V P MFA A L S E G
GCCACCCCACAAGATTTGAACACCATGCTAAATACAGTGGGGGGACATCAGGCAGCCATG
A T P Q D L N T M L N T V G G H Q A A M
CAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGAATGGGATAGAATGCATCCAGTG
Q M L K E T NEE A A E W D R M H P V
CATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAGCCAAGGGGAAGCGACATAGCAGGG
HAG PAP G Q M REP R G S D A G
ACTACTAGTACCCTTCAGGAACAGATAAACTGGATGACAGCTAATCCACCTACCCCAGTA
T T S T L Q E Q I N W M TAN P P T P V
GGAGAAATCTATAAAAGATGGATAATCCTGGGACTAAATAAAATAGTAAGGATGTATAGT
G E Y K R W L G L N K V R M Y S
CCTACTAGCATTCTGGACATAAGACAAGGACCAAAAGAACCCTTTAGAGATTATGTAGAC
P T S I L D R Q G P K E P F R D Y V D
CGGTTCTATAAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACA
R F Y K T L RAE Q A S Q E V K N W M T
GAAACCTTGTTAGTCCAGAATGCAAACCCAGATTGTAAGACTATTTTAAAAGCGTTGGGA
E T L L V Q NAN P D C K TIL K A L G
CCAGCAGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAGGAGGACCCGGCCAT
P A A T LEE M M T A C Q G V G G P G H
AAAGCAAGAGTGTTAGCTGAAGCAATGAGCCAAGTAACAAATTCAGCTACCATAATGATG
K A R V L A E A M S Q V T N SAT M M
CAGAAAGGCAATTTTAGGAACCAAAGAAAAATTGTTAAGTGCTTCAATTGTGGCAAAGAA
Q K G N F R N Q R K V K C F N C G K E
GGGCACATAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAG
G H A R NCR APR K K G C W K C G K
GAAGGACACCAAATGAAAGATTGTACTGAGAGACAAGCTAATTTTTTAGGGAAAATCTGG
184
81. Nucleotide and Amino Acid Sequences of gag clones
421 E G H Q M K D C T E R Q A NFL G K w
1321 CCTTCCCACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCA
441 P S H K G R P G NFL Q S R PEP TAP
1381 CCAGAAGAGAGCTTCAGGTTTGGGGAGGAGACAACAACCCCCTCTCAGAAGCAGGAGACG
461 PEE S F R F GEE T T T P S Q K Q E T
1441 GTAGACAAGGACCTGTATCCTTTAGTTTCCCTCAAATCACTCTTTGGCAACGACCCCTCG

















































Alu! 1373) Alu! (1435)
1479
Tv004g24
Alu! (907) Alu! (1399)







82.1 Restriction Digest Maps for Alul and Accl on the gag clone sequences
TV006G11
Alul (118)

























































































82.1 Restriction Digest Mapsfor Alul and Accl on the gag clone sequences
TV019G20





Alul (120) Alui (199)
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Appendix 82.1 A restriction enzyme recognition site map of the gag clone
sequences for the enzymes, Alul and Accl. The names of the maps are
indicated under the line representing the sequence. The horizontal scale
indicates the nucleotide length in 100 bp units. The lines on top of the
sequence line indicate the recognition sites, and the position of the
recognition site is shown in brackets.
191
82.2 Unique cutting and non-cutting Restriction Digest Enzymes for the gag clones
Restriction analysis on TVOO1G8
Enzymes with >1 sites are not shown
16 sites found
List by Site Order
20 SspI 425 HphI 649 SphI 1206 ApaI
206 Sap I 453 NsiI 655 AlwNI 1207 AvrIl
261 Bsp14071 478 XmnI 1054 ppuMI 1244 BanI
370 DrdI 621 Pst I 1206 BanII 1400 TaqI
Non Cut Enzymes
AatII Acc651 AccI AccII AccIlI AclI
Acyl AflIl AflIlI Agel Alw441 ApaBI
ApaLI AscI Asp7181 AsuIl AvaI Ball
BamHI BbeI BbvIl BclI BglI BglIl
Bpull021 BsaHI BsaOI Bsc911 BsiI BspHI
BspMI BspMII BssHIl BstD1021 BstEIl BstXI
Bsu361 Cfr101 CfrI ClaI Csp451 CspI
CvnI DraIIl EagI Ec1136Il Eco31I Eco47Il1
Eco521 Eco561 Eco721 EcoHI EcoICRI EcoNI
EcoRI EcoRV EheI EspI FnuDII FseI
HaeII HgaI HgiAI HhaI HindII HindIII
HinfI HinPlI HpaI HpaII I-PpoI KpnI
MaeII MfeI Mlu1131 MluI MscI MspAlI
MspI MstI MstII NaeI NarI Nco I
NdeI NheI NotI NruI NspBII PacI
PflMI pinAl PleI PmaCI PmeI PvuI
PvuII Sac I SacII SalI Saul ScaI
SciI SfaNI SfiI SgrAI SmaI SnaBI
SplI SpoI SrfI SstI SstII Stu I
SunI SwaI ThaI Tth1111 VspI XbaI
XcmI XhoI XhoII XmaI XmaIII XorII
Restriction analysis on TVOO1Gll
Enzymes with >1 sites are not shown
15 sites found
List by Site Order
20 SspI 453 NsiI 655 AlwNI 1207 AvrIl
206 SapI 478 XmnI 1054 ppuMI 1244 BanI
261 Bsp14071 621 Pst I 1206 BanII 1400 TaqI
334 HindII 649 SphI 1206 ApaI
Non Cut Enzymes
AatII Acc651 AccI AccII AccIII AclI
Acyl AflII AflIII Agel Alw44 I ApaBI
ApaLI AscI Asp7181 AsuII Ava I Ball
BamHI BbeI BbvII BclI BglI BglIl
Bpu11021 BsaHI BsaOI Bsc911 BsiI BspHI
BspMI BspMII BssHII BstD1021 BstEII BstXI
Bsu361 Cfr101 CfrI ClaI Csp451 CspI
CvnI DraIII DrdI EagI Ec1136II Eco311
Eco47II1 Eco521 Eco561 Eco721 EcoHI EcoICRI
EcoNI EcoRI EcoRV EheI Esp I FnuDII
FseI HaeII HgaI HgiAI HhaI HindIII
HinfI HinP11 HpaI HpaII I- PpoI KpnI
MaeII MfeI Mlu1131 MluI MscI MspAII
MspI MstI MstII NaeI NarI NcoI
NdeI NheI Not I NruI NspBII PacI
PflMI PinAl PleI PmaCI PmeI PvuI
PvuII Sac I SacII Sall Saul ScaI
SciI SfaNI SfiI SgrAI Sma I SnaBI
SplI SpoI SrfI SstI SstII StuI
SunI SwaI ThaI Tth1111 VspI XbaI
XcmI XhoI XhoII XmaI XmaIII XorII
Restriction analysis on TVOO2G8
Enzymes with >1 sites are not shown
29 sites found
List by Site Order
206 SapI 481 XmnI 884 AccI 1209 SduI
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226 MboI 551 RleAI 1057 ppuMI 1209 Bsp12861
226 Sau3AI 624 PstI 1062 CfrI 1209 Ban!!
228 DpnI 652 SphI 1064 Ball 1209 ApaI
261 Bsp14071 712 SpeI 1064 MscI 1210 Avr!!
338 PleI 763 Hpa!! 1109 SfaNI 1382 TaqI
428 HphI 763 MspI 1167 MfeI 1389 BstDl021
456 NsiI
Non Cut Enzymes
AatII Acc651 Acc!! Acc!!I AclI Acyl
AflII AflI!! Agel Alw441 AlwNI ApaBI
ApaLI AscI Asp7181 Asu!! Ava! BamHI
BanI BbeI BbvII BclI BglI BglII
Bpu11021 BsaHI BsaOI Bsc911 BsiI BsmI
BspHI BspMI BspMII BssHII BstEII BstXI
Bsu361 Cfr101 ClaI Csp451 CspI CvnI
DraIII DrdI EagI Ecl136II Eco311 Eco47!!I
Eco521 Eco561 Eco721 EcoHI EcoICRI EcoNI
EcoRI EcoRV EheI EspI FnuDII FseI
HaeII HgaI HgiAI HhaI HindII Hind!!I
HinPlI HpaI I-PpoI KpnI MaeII Mlul131
MluI MspAlI MstI MstII NaeI NarI
NcoI NdeI NheI NotI NruI NspBII
Pac I PflMI pinAl PmaCI PmeI PvuI
PvuII SacI Sac II SalI Saul ScaI
Sci I SfiI SgrAI Sma I SnaBI SplI
SpoI SrfI SspI SstI SstII StuI
SunI SwaI ThaI Tth1111 VspI XbaI
XcmI XhoI XhoII XmaI XmaIII XorII
Restriction analysis on TVOO3G15
Enzymes with >1 sites are not shown
34 sites found
List by Site Order
20 SspI 361 NspB!! 621 PstI 1141 XhaI
206 SapI 370 DrdI 709 SpeI 1206 BanII
226 MboI 418 ApaLI 881 AccI 1206 ApaI
226 Sau3AI 418 ApaBI 1054 ppuMI 1321 RleAI
228 DpnI 418 Alw441 1059 CfrI 1379 TaqI
261 Bsp14071 422 HgiAI 1061 Ball 1396 ThaI
361 PvuII 425 HphI 1061 MscI 1396 FnuDII
361 AlwNI 436 AvrIl 1106 SfaNI 1396 AccII
361 MspAlI 453 NsiI
Non Cut Enzymes
AatII Acc651 AccIII AclI Acyl AflII
AflIII Agel AscI Asp7181 AsuII Ava I
BamHI BanI BbeI BbvII BclI BglI
BglII Bpu11021 BsaHI BsaOI Bsc91I BsiI
BspHI BspMI BspMII BssHII BstD1021 BstE!!
BstXI Bsu361 Cfr101 ClaI Csp451 CspI
CvnI DraIII EagI Ec1l36II Eco311 Eco47III
Eco521 Eco561 Eco721 EcoHI EcoICRI EcoNI
EcoRI EcoRV EheI EspI FseI HaeII
HgaI HhaI HindII HindIII HinfI HinP11
HpaI HpaII I-PpoI KpnI MaeII MfeI
Mlul131 MluI MspI MstI MstII NaeI
NarI Nco I NdeI NheI NotI NruI
PacI PflMI PinAl PleI PmaCI PmeI
PvuI SacI Sac II SalI Saul ScaI
Sci I SfiI SgrAI SmaI SnaBI SphI
SplI SpoI SrfI SstI SstII StuI
SunI SwaI Tth11lI VspI XcmI XhoI
XhoII XmaI XmaIII XmnI XorII
Restriction analysis on TVOO4G17
Enzymes with >1 sites are not shown
26 sites found
List by Site Order
20 SspI 425 HphI 884 Cfr101 1109 SfaNI
206 SapI 453 NsiI 884 PinAl 1209 ApaI
226 MboI 453 BsmI 884 Agel 1209 BanII
226 Sau3AI 621 Pst I 885 HpaII 1210 AvrIl
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228 DpnI 655 AlwNI 885 MspI 1324 RleAI
370 DrdI 709 SpeI 1054 ppuMI 1382 TaqI
399 HinfI 881 AccI
Non CUt Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflII AflIII Alw441 ApaBI ApaLI AscI
Asp7181 AsuII Ava I Ball BamHI BanI
BbeI BbvII BclI BglI BglII Bpu11021
BsaHI BsaOI Bsc911 BsiI Bsp14071 BspHI
BspMI BspMII BssHII BstD1021 BstEII BstXI
Bsu36l Cfrl ClaI Csp451 CspI CvnI
DraIII Eagl Ec1l36II Eco31I Eco47Il1 Eco521
Eco561 Eco721 EcoHI EcolCRI EcoNI EcoRI
EcoRV EheI EspI FnuDlI FseI Haell
HgaI HgiAI HhaI HindII HindIII HinP11
Hpal I-PpoI KpnI Maell MfeI Mlu1131
MluI MscI MspAlI MstI MstII NaeI
NarI NcoI NdeI NheI NotI NruI
NspBII Pac I PflMI PleI PrnaCI PmeI
PvuI PvuII Sac I SacII SalI Saul
Seal Scil SfiI SgrAI Sma I SnaBI
SphI SplI SpoI SrfI SstI SstII
StuI SunI Swal ThaI Tth11lI VspI
XbaI XcmI XhoI XhoIl Xmal XmaIII
XmnI XorII
Restriction analysis on TVOO4G24
Enzymes with >1 sites are not shown
27 sites found
List by Site Order
20 SspI 453 BsmI 884 PinAl 1209 BanII
206 SapI 453 NsiI 884 Cfr101 1210 AvrIl
226 MboI 621 PstI 885 Hpall 1324 RleAI
226 Sau3Al 655 AlwNI 885 MspI 1352 HindI I
228 DpnI 709 SpeI 1054 ppuMI 1356 PleI
370 DrdI 881 AccI 1109 SfaNI 1382 TaqI
425 HphI 884 Agel 1209 ApaI
Non CUt Enzymes
AatII Acc651 AccII AccIlI AclI Acyl
AflII AflIII Alw441 ApaBI ApaLI AscI
Asp718l AsuII Ava I Ball BamHI BanI
BbeI BbvII Bcll BglI BglII Bpu11021
BsaHI BsaOI Bsc911 BsiI Bsp14071 BspHI
BspMI BspMII BssHII BstD1021 BstEII BstXI
Bsu361 CfrI ClaI Csp451 CspI CvnI
DraIIl EagI Ecl136II Eco311 Eco47III Eco521
Eco56l Eco721 EcoHI EcoICRI EcoNI EcoRI
EcoRV Ehel EspI FnuDlI FseI HaeII
HgaI HgiAl HhaI HindlII HinPlI HpaI
I-PpoI KpnI Maell MfeI Mlu1l31 MluI
MscI MspAlI MstI MstII NaeI NarI
Nco I NdeI NheI NotI NruI NspBlI
PacI PflMl PmaCI PrneI PvuI Pvull
Sac I SacII SalI Saul ScaI Sci I
SfiI SgrAI SmaI SnaBI SphI SplI
SpoI Srfl SstI SstII StuI Sun I
SwaI ThaI Tth11lI VspI XbaI XcmI
XhoI XhoII XmaI XmaIlI XmnI XorII
Restriction analysis on TVOOSG29
Enzymes with >1 sites are not shown
27 sites found
List by Site Order
206 SapI 425 HphI 884 Agel 1059 CfrI
223 AflII 453 BsmI 885 MspI 1061 MscI
260 Alw441 621 Pst I 885 HpaII 1061 Ball
260 ApaLI 709 SpeI 956 MboI 1106 ApaBI
264 HgiAI 881 AccI 956 Sau3AI 1209 BanlI
370 DrdI 884 Cfr101 958 DpnI 1382 TaqI
399 HinfI 884 PinAl 1054 ppuMI
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Restriction analysis on TVOOSG36
Enzymes with >1 sites
22 sites found
























































































Restriction analysis on TV006Gll
Enzymes with >1 sites
28 sites found
































































































































































































82.2 Unique cutting and non-cutting Restriction Digest Enzymes for the gag clones
Bsc911 BsiI BspHI BspMI BspMIl BssHII
BstDl021 BstEIl BstXI Bsu361 CfrI ClaI
Csp451 CspI CvnI DraIlI DrdI EagI
Ecl136I1 Eco31I Eco47IIl Eco521 Eco561 Eco72 I
EcoHI EcoICRI EcoNI EcoRI EcoRV EheI
EspI FnuDIl FseI HaeII HgaI HgiAI
HindIl HinfI HpaI I-PpoI KpnI MfeI
Mlul13 I MluI MscI MspAlI MstI MstIl
NaeI NarI NcoI NdeI NheI NotI
NruI NspBIl Pac I PflMI PleI PmaCI
PmeI PvuI PvuIl Sac I SacII SaIl
SapI Saul ScaI SciI SfiI SgrAI
Sma I SnaBI SplI SpoI SrfI Sst I
SstII StuI Sun I SwaI ThaI Tthl111
VspI XbaI XcmI XhoI XhoIl XmaI
XmaIIl XorII
Restriction analysis on TVOO6G97
Enzymes with >1 sites are not shown
29 sites found
List by Site Order
17 HindIl 478 XmnI 884 Cfrl01 1210 AvrIl
226 MboI 649 SphI 884 PinAl 1371 HindIIl
226 Sau3AI 654 StuI 885 HpaII 1382 TaqI
228 DpnI 691 MaeIII 885 MspI 1393 BbvII
261 Bsp14071 709 SpeI 1054 DraII 1393 Bsc911
405 BsmI 881 AccI 1054 ppuMI 1399 HinPlI
442 MaeII 884 Agel 1057 PssI 1401 HhaI
442 AclI
Non Cut Enzymes
AatII Acc651 AccII AccIII Acyl AflII
AflIlI Alw441 AlwNI ApaBI ApaI ApaLI
AscI Asp7181 AsuII Ava I Ball BamHI
BanI BbeI BclI BglI BglII Bpull021
BsaH1 Bsa01 BsiI BspH1 BspM1 BspM1I
BssHII BstDl021 BstEII BstXI Bsu361 CfrI
ClaI Csp451 CspI CvnI DraI1I DrdI
EagI Eamll051 Ecl136II Eco311 Eco47III Eco521
Eco561 Eco721 EcoHI EcoICR1 EcoNI EcoRI
EcoRV EheI EspI FnuDIl FseI HaeII
HgaI HgiAI HinfI HpaI HphI I-PpoI
KpnI MfeI Mlul131 Mlu1 MscI MspAl1
MstI Mst11 NaeI NarI NcoI NdeI
Nhe1 Not I NruI NspBI1 PacI PflMI
PleI PmaCI PmeI PvuI PvuIl Sac I
SacII SaIl SapI Saul ScaI Sci I
SfiI SgrAI Sma I SnaBI SplI SpoI
SrfI SspI Sst I SstIl SunI SwaI
ThaI Tthl111 VspI XbaI XcmI XhoI
XhoII XmaI XmaIlI XorIl
Restriction analysis on TVOO7G59
Enzymes with >1 sites are not shown
26 sites found
List by Site Order
20 SspI 478 XmnI 884 PinAl 1210 AvrIl
206 SapI 548 RleAI 884 Agel 1396 Bsu361
261 Bsp14071 621 PstI 1054 ppuMI 1396 CvnI
399 HinfI 630 CIa I 1102 XcmI 1396 Saul
427 StuI 771 EcoRV 1187 Bsp12861 1396 MstII
453 BsmI 881 AccI 1187 Sdu1 1420 BstDl021
453 NsiI 884 Cfrl01
Non CUt Enzymes
AatII Acc651 AccIl AccIII AclI Acyl
AflIl AflIII Alw441 AlwNI ApaBI ApaI
ApaLI AscI Asp7181 AsuII AvaI Ball
BamHI BanI BanII BbeI BbvII BclI
BglI BglII Bpull021 BsaHI Bsa01 Bsc911
Bsi1 BspHI BspM1 BspMII BssHII BstEII
BstXI CfrI Csp451 CspI DraIII DrdI
EagI Ec1l36Il Eco311 Eco47I11 Eco521 Eco561
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Eco721 EcoHI EcoICRI EcoNI EcoRI EheI
EspI FnuDII FseI HaeII HgaI HgiAI
HhaI HindII HindIII HinP11 HpaI I-PpoI
KpnI MaeII MfeI Mlul131 MluI MscI
MspAlI MstI NaeI NarI NcoI NdeI
NheI Not I NruI NspBII PacI PflMI
PleI PmaCI PmeI PvuI PvuII SacI
SacII SalI ScaI SciI SfiI SgrAI
SmaI SnaBI SpeI SphI SplI SpoI
SrfI Sst I SstII Sun I SwaI ThaI
Tth1111 VspI XbaI XhoI XhoII XmaI
XmaIII XorII
Restriction analysis on TVOO8G65
Enzymes with >1 sites are not shown
26 sites found
List by Site Order
206 SapI 682 AvrII 1059 CfrI 1396 BstD1021
261 Bsp14071 709 SpeI 1061 MscI 1408 HinfI
370 DrdI 881 AccI 1061 Ball 1416 PleI
425 HphI 884 Cfr101 1077 BstXI 1441 Sau3AI
453 NsiI 884 Agel 1206 ApaI 1441 MboI
453 BsmI 884 PinAl 1321 RleAI 1443 DpnI
621 PstI 1054 PpuMI
Non CUt Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflII AflIII Alw441 AlwNI ApaBI ApaLI
AscI Asp7181 Asu!! Ava I BamHI BanI
BbeI BbvII BclI BglI BglII Bpull021
BsaHI BsaOI Bsc91I BsiI BspHI BspMI
BspMII BssHII BstEII Bsu361 ClaI Csp451
CspI CvnI DraIII EagI Ec1l36II Eco311
Eco47III Eco521 Eco561 Eco721 EcoHI EcoICRI
EcoNI EcoRI EcoRV EheI Esp I FnuDII
FseI HaeII HgaI HgiAI HhaI HindII
HindIII HinPlI HpaI I-PpoI KpnI MaeII
MfeI Mlul131 MluI MspA11 MstI MstII
NaeI NarI NcoI NdeI NheI Not I
NruI NspBII PacI PflMI PmaCI PmeI
PvuI PvuII Sac I SacII Sail Saul
ScaI SciI SfaNI SfiI SgrAI Sma I
SnaBI SphI SplI SpoI SrfI SspI
SstI SstII StuI SunI SwaI ThaI
TthlllI VspI XbaI XcmI XhoI XhoII
XmaI XmaIII XmnI XorII
Restriction analysis on TVOO8G66
Enzymes with >1 sites are not shown
29 sites found
List by Site Order
206 SapI 656 ApaBI 885 HpaII 1206 ApaI
261 Bsp14071 682 AvrII 885 MspI 1321 RleAI
370 DrdI 709 SpeI 1054 ppuMI 1396 BstD1021
425 HphI 881 AccI 1059 CfrI 1416 PleI
453 NsiI 884 Agel 1061 Ball 1441 MboI
453 BsmI 884 Cfr101 1061 MscI 1441 Sau3AI
621 PstI 884 pinAl 1077 BstXI 1443 DpnI
655 AlwNI
Non CUt Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflII AflIII Alw441 ApaLI AscI Asp7181
AsuII Ava I BamHI BanI BbeI BbvII
BclI BglI BglII Bpu11021 BsaHI BsaOI
Bsc911 BsiI BspHI BspMI BspMII BssHII
BstEII Bsu361 ClaI Csp451 CspI CvnI
DraIII EagI Ec1l36II Eco311 Eco47III Eco521
Eco561 Eco721 EcoHI EcoICRI EcoNI EcoRI
EcoRV EheI EspI FnuDII FseI HaeII
HgaI HgiAI HhaI HindI I HindIII HinP11
HpaI I-PpoI KpnI MaeII MfeI Mlul131
MluI MspA11 MstI MstII NaeI NarI
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NdeI NheI NotI NruI NspBII
PflMI PmaCI PmeI PvuI PvuII
SacII SaIl Saul ScaI SciI
SfiI SgrAI Sma I SnaBI SphI
SpoI SrfI SspI SstI Sst II
SunI SwaI ThaI Tth111I VspI
XcmI XhoI XhoII XmaI XmaIII
XorII
Restriction analysis on TVOO9G12
Enzymes with >1 sites are not shown
26 sites found
List by Site Order
261 Bsp14071 709 SpeI 885 MspI ll09 SfaNI
425 HphI 745 BstEII 1040 NspI 1209 BanII
453 NsiI 881 AccI 1054 ppuMI 1209 ApaI
453 BsmI 884 Cfr10I 1059 CfrI 1210 AvrII
478 XmnI 884 Agel 1061 MscI 1345 Ava I
537 XhoII 884 PinAl 1061 Ball 1419 PIe I
537 BglII 885 HpaII
Non CUt Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflII AflIII Alw441 AlwNI ApaBI ApaLI
AscI Asp7181 AsuII BamHl BanI BbeI
BbvlI BclI Bgll Bpu11021 BsaHI BsaOl
Bsc91I BsiI BspHI BspMI BspMII BssHll
BstD102l BstXI Bsu361 Clal Csp451 CspI
CvnI DraIII Drdl Eagl Ec1l36II Eco311
Eco47lII Eco52l Eco561 Eco721 EcoHl EcolCRI
EcoNl EcoRl EcoRV Ehel Esp I FnuDII
Fsel Haell HgaI HgiAl HhaI HindII
HindIII HinP1l HpaI I-Ppol KpnI MaeII
MfeI Mlu113l MluI MspA1l MstI MstII
NaeI NarI Ncol Ndel NheI Not I
NruI NspBII Pacl PflMI PmaCI PmeI
PstI PvuI PvuII SacI Sac II SaIl
SapI Saul ScaI SciI SfiI SgrAI
SmaI SnaBI SphI SplI SpoI SrfI
SstI SstII StuI SunI SwaI ThaI
Tth1ll1 VspI XbaI XcmI XhoI XmaI
XmaIII XorII
Restriction analysis on TVOIOG74
Enzymes with >1 sites are not shown
22 sites found
List by Site Order
20 SspI 624 PstI ll03 Bgll 1212 ApaI
202 AflII 658 AlwNI 1112 SfaNI 1213 AvrIl
261 Bsp14071 681 XhoII 1212 SduI 1314 Ava I
298 StuI 712 SpeI 1212 Bsp12861 1385 TaqI
456 NsiI 1057 PpuMI 1212 BanII 1402 BstD1021
481 XmnI 1084 PleI
Non CUt Enzymes
AatII Acc651 AccI AccII AccIII AclI
Acyl AflIII Agel Alw441 ApaBI ApaLI
AscI Asp7181 AsuII Ball BamHI BanI
BbeI BbvII Bcll BgllI Bpu11021 BsaHI
BsaOI Bsc91I BsiI BsmI BspHI BspMI
BspMII BssHII BstEII BstXI Bsu361 Cfr10I
CfrI ClaI Csp451 CspI CvnI DraIII
DrdI EagI Ecl136II Eco311 Eco47III Eco521
Eco561 Eco721 EcoHI EcoICRI EcoNI EcoRI
EcoRV EheI EspI FnuDII FseI HaeII
HgaI HgiAI HhaI HindII HindIII HinP11
HpaI HpaIl I-PpoI KpnI MaeII MfeI
Mlul131 MluI MscI MspA11 MspI MstI
MstII NaeI NarI NcoI NdeI NheI
Not I NruI NspBII Pac I PflMI PinAT
PmaCI PmeI PvuI PvuII RleAI Sac I
SacII SaIl SapI Saul ScaI Sci I
SfiI SgrAI Sma I SnaBI SphI SplI
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SpoI SrfI Sst I SstIl Sun I SwaI
ThaI Tth1111 VspI XbaI XcmI XhoI
XmaI XmaIIl XorIl
Restriction analysis on TV012G34
Enzymes with >1 sites are not shown
28 sites found
List by Site Order
20 SspI 370 DrdI 884 Agel 1152 ScaI
138 HpaI 425 HphI 884 Cfr101 1209 ApaI
138 HindIl 453 BsmI 885 HpaIl 1209 BanIl
206 SapI 453 NsiI 885 MspI 1210 AvrIl
226 MboI 655 AlwNI 1054 ppuMI 1403 TaqI
226 Sau3AI 709 SpeI 1106 ApaBI 1404 PleI
228 DpnI 884 PinAl 1109 SfaNI 1410 HinfI
Non Cut Enzymes
AatII Acc651 AccIl AccIlI AclI Acyl
AflII AflIII Alw441 ApaLI AscI Asp7181
AsuII Ava! Ball BamHI BanI BbeI
BbvII BclI BglI BglII Bpull021 BsaHI
BsaOI Bsc91I Bsi1 BspHI BspMI BspMII
BssHII BstD1021 BstEIl BstXI Bsu361 CfrI
ClaI Csp451 CspI CvnI DraIIl EagI
Ecl136II Eco311 Eco47IIl Eco521 Eco561 Eco721
EcoHI EcoICRI EcoNI EcoRI EcoRV EheI
EspI FnuDII FseI Haell HgaI HgiAI
HhaI HindIlI HinPlI I-PpoI KpnI Mae II
MfeI Mlu1131 MluI MscI MspAlI MstI
MstII NaeI NarI NcoI NdeI NheI
Not I NruI NspBIl PacI PflMI PmaCI
PmeI PstI PvuI PvuII SacI SacIl
SalI Saul SciI SfiI SgrAI Sma I
SnaBI SphI SplI SpoI SrfI Sst I
SstII StuI Sun I SwaI ThaI Tth1l11
VspI XbaI XcmI XhoI XhoII XmaI
XmaIII XmnI XorII
Restriction analysis on TV012G40
Enzymes with >1 sites are not shown
24 sites found
List by Site Order
20 SspI 370 DrdI 884 Cfr101 1209 ApaI
138 HpaI 425 HphI 884 PinAl 1209 BanIl
138 HindIl 453 BsmI 884 Agel 1210 AvrIl
226 Sau3AI 453 Nsil 885 MspI 1403 TaqI
226 MboI 655 A1wNI 885 HpaII 1404 PleI
228 DpnI 709 SpeI 1054 ppuMI 1410 HinfI
Non Cut Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflII AflIIl Alw441 ApaBI ApaLI AscI
Asp7181 AsuII Ava I Ball BamHI BanI
BbeI BbvII BclI BglI BglII Bpu11021
BsaHI BsaOI Bsc91I BsiI BspHI BspMI
BspMII BssHII BstD1021 BstEII BstXI Bsu361
CfrI ClaI Csp451 CspI CVnI DraIII
EagI Ecl136I1 Eco311 Eco47III Eco521 Eco561
Eco721 EcoHI EcoICRI EcoNI EcoRI EcoRV
EheI EspI FnuDII FseI HaeIl HgaI
HgiAI HhaI HindIIl HinPlI I-PpoI KpnI
MaeII MfeI Mlu1131 MluI MscI MspA11
MstI MstII NaeI NarI NcoI NdeI
NheI Not I NruI NspBIl PacI PflMI
PmaCI PmeI Pst I PvuI Pvull SacI
SacII SalI Saul ScaI SciI SfaNI
SfiI SgrAI SmaI SnaBI SphI SplI
SpoI SrfI Sst I SstII Stu I SunI
SwaI ThaI Tth1111 VspI XbaI XcmI
XhoI XhoII XmaI XmaIII XmnI XorII
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Restriction analysis on TV013G2
Enzymes with >1 sites are not shown
28 sites found
List by Site Order
20 SspI 627 Pst I 890 PinAl 1215 Bsp12861
206 SapI 666 BanI 891 HpaII 1215 SduI
261 Bsp14071 676 MfeI 891 MspI 1215 ApaI
376 DrdI 715 SpeI 906 AflII 1215 BanII
405 Hinfl 887 AccI 1046 NspI 1216 AvrIl
431 HphI 890 Agel 1060 ppuMI 1430 TaqI
459 BsmI 890 Cfr101 1064 TthlllI 1473 BamHI
Non Cut Enzymes
AatII Acc651 AccII AcclII AclI Acyl
AflIII Alw441 AlwNI ApaBI ApaLI AscI
Asp7181 AsuII Ava I Ball BbeI BbvII
BclI BglI BglII Bpu11021 BsaHI BsaOI
Bsc9l1 BsiI BspHI BspMI BspMII BssHII
BstD1021 BstEII BstXI Bsu361 CfrI ClaI
Csp451 CspI CVnI DraIII EagI Ecl136II
Eco31I Eco4 ?III Eco521 Eco561 Eco721 EcoHI
EcoICRI EcoNI EcoRI EcoRV EheI EspI
FnuDII FseI HaeII HgaI HgiAI HhaI
HindII HindIII HinPlI HpaI 1-PpoI KpnI
MaeII Mlu1131 MluI MscI MspAlI MstI
MstII NaeI NarI NcoI NdeI NheI
Not I NruI NspBII PacI PflMI PleI
PmaCI PmeI PvuI PvuII SacI SacII
Sail Saul ScaI SciI SfiI SgrAI
SmaI SnaBI SphI SplI SpoI SrfI
SstI SstII StuI Sun I SwaI ThaI
VspI XbaI XcmI XhoI XmaI XmaIII
XmnI XorII
Restriction analysis on TV013G15
Enzymes with >1 sites are not shown
32 sites found
List by Site Order
20 SspI 666 BanI 891 MspI 1215 SduI
206 SapI 676 MfeI 906 AflII 1216 AvrIl
261 Bsp14071 715 SpeI 1046 NspI 1430 TaqI
376 DrdI 887 Accl 1060 ppuMI 1473 XhoII
405 HinfI 890 PinAl 1064 Tth1111 1473 BamHI
431 HphI 890 Agel 1215 ApaI 1473 Sau3AI
459 BsmI 890 Cfr101 1215 Bsp12861 1473 MboI
627 Pst I 891 HpaII 1215 BanII 1475 DpnI
Non Cut Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflIII Alw441 AlwNI ApaBI ApaLI AscI
Asp7181 AsuII Ava I Ball BbeI BbvII
BclI BglI BglII Bpu11021 BsaHI BsaOI
Bsc91I BsiI BspHI BspMl BspMII BssHII
BstD1021 BstEII BstXI Bsu361 CfrI ClaI
Csp451 CspI CvnI DraIII EagI Ecl136II
Eco31I Eco4 ?III Eco521 Eco561 Eco721 EcoHI
EcoICRI EcoNl EcoRI EcoRV EheI EspI
FnuDII FseI HaeII HgaI HgiAI HhaI
HindII HindIII HinPlI HpaI I-PpoI KpnI
MaeII Mlu1131 MluI MscI MspAlI MstI
MstII NaeI NarI NcoI NdeI NheI
Not I NruI NspBII PacI PflMI PleI
PmaCI PmeI PvuI PvuII SacI SacII
Sail Saul ScaI SciI SfiI SgrAI
SmaI SnaBl SphI SplI SpoI SrfI
Sst I SstII StuI Sun I SwaI ThaI
VspI XbaI XcmI XhoI XmaI XmaIII
XmnI XorII
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82.2 Unique cutting and non-cutting Restriction Digest Enzymes for the gag clones
Restriction analysis on TV014G73
Enzymes with >1 sites are not shown
24 sites found
List by Site Order
20 SspI 453 BsmI 1009 MspAlI 1061 MscI
202 AflI! 621 PstI 1009 NspBI! ll06 SfaNI
261 Bsp14071 655 AlwNI 1040 NspI 1138 Xholl
298 StuI 656 ApaBI 1054 ppuMI 1206 ApaI
370 DrdI 709 SpeI 1059 CfrI 1206 BanIl
453 NsiI 745 BstEIl 1061 Ball 1396 BstD1021
Non Cut Enzymes
AatII Acc651 AccI AccII AccIIl AclI
Acyl Afl!Il Agel Alw441 ApaLI AscI
Asp7181 AsuII Ava I AvrIl BamHI BanI
BbeI BbvII Bcll Bgl! Bgl!I Bpull021
BsaHI BsaOI Bsc91I BsiI BspHI BspMl
BspMII BssHIl BstXl Bsu361 Cfr101 ClaI
Csp45l CspI CvnI DraIII EagI Ec1136I!
Eco31I Eco47II1 Eco521 Eco561 Eco721 EcoHl
EcoICRl EcoNI EcoRI EcoRV EheI EspI
FnuDIl FseI Haell HgaI HgiAI HhaI
HindIl HindIlI HinPlI HpaI Hpall I-PpoI
KpnI MaeII MfeI Mlul131 MluI MspI
MstI MstII NaeI NarI Ncol Ndel
NheI Not I NruI PacI PflMI PinAl
PmaCI PmeI PvuI Pvull SacI SacIl
Sal! SapI Saul ScaI SciI SfiI
SgrAI Sma I SnaBI SphI Spl! SpoI
SrfI SstI SstIl Sun I SwaI ThaI
Tth1lll Vspl XbaI XcmI XhoI Xmal
XmaIIl XmnI XorII
Restriction analysis on TV018G60
Enzymes with >1 sites are not shown
20 sites found
List by Site Order
20 SspI 453 NsiI 882 Sau3Al 1209 ApaI
206 Sapl 453 Bsml 884 Dpnl 1209 BanIl
261 Bsp14071 478 StuI 1106 ApaBI 1210 AvrIl
370 DrdI 709 SpeI ll09 SfaNI 1411 HinfI
425 HphI 882 MboI ll99 AlwNI 1419 PleI
Non Cut Enzymes
AatII Acc651 AccI AccII AccIIl AclI
Acyl AflI! AflIIl Agel Alw44l ApaLI
AscI Asp718l Asull AvaI Ball BamHI
BanI BbeI BbvIl BclI BglI BgIIl
Bpu1102l BsaHI BsaOI Bsc911 BsiI BspHI
BspMI BspMIl BssHIl BstD1021 BstElI BstXI
Bsu361 Cfr101 CfrI ClaI Csp451 CspI
CvnI DraIII EagI Ec1l36Il Eco311 Eco47Il1
Eco521 Eco561 Eco721 EcoHI EcoICRI EcoNI
EcoRI EcoRV EheI Esp I FnuDII FseI
HaeII HgaI HgiAI HhaI HindIl HindI!l
HinPlI HpaI Hpall I-PpoI KpnI Maell
MfeI Mlul131 Mlul MscI MspA11 MspI
MstI MstII NaeI NarI NcoI NdeI
NheI NotI NruI NspBII PacI PflMl
PinAl PmaCl PmeI PvuI Pvull Sac I
SacII SaIl Saul Seal SciI SfiI
SgrAI SmaI SnaBI SphI SplI SpoI
SrfI SstI SstIl SunI SwaI ThaI
Tth1ll1 VspI XbaI XcmI XhoI Xholl
Xmal XmaIIl XmnI XorII
Restriction analysis on TV019G20
Enzymes with >1 sites are not shown
19 sites found
List by Site Order
20 SspI 453 BsmI 1059 CfrI 1209 ApaI
206 SapI 453 NsiI 1061 Ball 1209 BanIl
303 EcoNI 621 Pst I 1061 Msc! 1210 AvrIl
201
82.2 Unique cutting and non-cutting Restriction Digest Enzymes for the gag clones
399 HinfI 709 SpeI 1109 SfaNI 1382 TagI
425 HphI 1054 PpuMI 1184 BanI
Non Cut Enzymes
AatII Acc651 AccI AccII AccIII AclI
Acyl AflI! AflIII Agel Alw441 AlwNI
ApaBI ApaLI AscI Asp7181 AsuII AvaI
BamHI BbeI BbvIl BclI BglI BglII
Bpu11021 BsaHI BsaOI Bsc911 BsiI BspHI
BspMI BspMIl BssHII BstD1021 BstEII BstXI
Bsu361 Cfr101 ClaI Csp451 CspI CvnI
DraIII DrdI EagI Ecl136Il Eco311 Eco47II1
Eco521 Eco561 Eco721 EcoHI EcoICRI EcoRI
EcoRV EheI EspI FnuDII FseI HaeII
HgaI HgiAI HhaI HindI I HindIII HinP11
HpaI HpaII I-PpoI KpnI MaeII MfeI
Mlul131 MluI MspAlI MspI MstI MstII
NaeI NarI Nco I NdeI NheI Not I
NruI NspBII PacI PflMI PinAl PleI
PmaCI PmeI PvuI PvuII SacI SacII
SalI Saul ScaI SciI SfiI SgrAI
Sma I SnaBI SphI SplI SpoI SrfI
Sst I SstII StuI SunI SwaI ThaI
Tth11lI VspI XbaI XcmI XhoI XhoII
XmaI XmaIII XmnI XorII
Restriction analysis on TV019G25
Enzymes with >1 sites are not shown
26 sites found
List by Site Order
20 SspI 709 SpeI 1054 PpuMI 1209 ApaI
206 SapI 881 AccI 1059 CfrI 1209 BanII
399 HinfI 884 Cfr101 1061 Ball 1210 AvrIl
425 HphI 884 Agel 1061 MscI 1323 Bsc911
453 NsiI 884 PinAl 1109 SfaNI 1323 BbvII
453 BsmI 885 HpaII 1184 BanI 1382 TagI
621 Pst I 885 MspI
Non Cut Enzymes
AatII Acc651 AccII AccIII AclI Acyl
AflI! AflIII Alw441 AlwNI ApaBI ApaLI
AscI Asp7181 AsuII AvaI BamHI BbeI
BclI BglI BglII Bpu11021 BsaHI BsaOI
BsiI BspHI BspMI BspMII BssHII BstD1021
BstEII BstXI Bsu361 ClaI Csp451 CspI
CvnI DraIIl DrdI EagI Ecl136II Eco311
Eco47III Eco521 Eco561 Eco721 EcoHI EcoICRI
EcoNI EcoRI EcoRV EheI Esp I FnuDII
FseI HaeII HgaI HgiAI HhaI HindI I
HindIII HinP11 HpaI I-PpoI KpnI Mae II
MfeI Mlul131 MluI MspA11 MstI MstII
NaeI NarI NcoI NdeI NheI Not I
NruI NspBII PacI PflMI PleI PmaCI
PmeI PvuI PvuIl SacI SacII Sal I
Saul ScaI SciI SfiI SgrAI Sma I
SnaBI SphI SplI SpoI SrfI Sst I
SstII StuI SunI SwaI ThaI Tth111I
VspI XhaI XcmI XhoI XhoII XmaI
XmaIII XmnI XorII
Restriction analysis on TV016G95
Enzymes with >1 sites are not shown
23 sites found
List by Site Order
53 XmnI 358 AlwNI 899 PinAl 1113 MaeIII
138 HpaI 440 HphI 899 Cfr101 1185 MfeI
138 HindII 607 Eco311 899 Agel 1227 ApaI
311 SapI 636 Pst I 1052 Eam11051 1227 BanIl
358 NspBII 664 SphI 1071 EcoHI 1228 AvrIl
358 MspA11 724 SpeI 1074 CfrI
Non Cut Enzymes
AatII Acc651 AccIl AccIII AclI Acyl
202
82.2 Unique cutting and non-cutting Restriction Digest Enzymes for the gag clones
AflII AflIII Alw441 ApaLI AscI Asp71BI
AsuII AvaI Ball BamBI BanI BbeI
BbvII BclI BglI BglII Bpul1021 BsaHI
BsaOI Bsc911 BsiI Bsp14071 BspHI BspMI
BspMII BssHII BstD1021 BstEII BstXI Bsu361
ClaI Csp451 CspI CvnI DraIII DrdI
EagI Ecl136I1 Eco47II1 Eco521 Eco561 Eco721
EcoICRI EcoNI EcoRI EcoRV EheI EspI
FnuDII FseI HaeII HgaI HgiAI HhaI
HinfI HinPlI I-PpoI KpnI MaeII Mlul131
MluI MscI MstI MstII NaeI NarI
Nco I NdeI NheI NotI NruI PacI
PflMI PleI PmaCI PmeI PvuI PvuII
SacI SacII Sail Saul ScaI SciI
SfiI SgrAI Sma I SnaBI SplI SpoI
SrfI SspI SstI SstII StuI Sun I
SwaI TaqI ThaI TthlllI VspI XbaI
XcmI XhoI XhoII XmaI XmaIII XorII
203
B3. Similarity Plots of the gag clones obtained from the NCBIsubtyping tool
B3. The similarity plots of the NCB I HIV-1 subtyping database for the different
gag clones. The right hand legend indicates the different reference
subtypes, which the query sequence was compared to. The solid bar at
the top of the graph represents the sybtype most similar to the query
sequence. The X-axis represents the nucleotide position, while the Y-axis
represents the score of identity obtained when comparing the query
sequence to the individual reference sequences. The similarity between
the query and reference sequences increases with an increase in score.
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The distance matrices are generated by GeneDoc and is a function describing
the relationships between pairs of sequences. Three numbers are generated:
1. The number of residues that match exactly (identical residues) between
the two sequences.
2. The number of residues that match similar residues (conservative
substitutions) between two sequences. This number differs from the first
number when amino acids are compared, but are identical to the first
when nucleotides are compared.
3. The number of residues lined up with a gap character.
Each number is expressed as a count and as percentage on different sides of the
matrix diagonal. The diagonal shows how many locations have at least one
residue for the single sequence, i.e., the sequence length.
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84.2 Distance Matrix for the p17 matrix domain
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Distance Matrix for the three areas of the p17 matrix containing published CTL
epitopes
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85. Predicted amino acid sequencealignment of the completeGagof the subtype C
strains
B5. The predicted amino acid sequence alignment of the complete Gag of the
HIV-1 subtype C gag clones, HIV-1 subtype C strains in the Los Alamos
database as well as a subtype B strain and the subtype B gag clone of the isolate
TV016. The amino acid sequence of the clone, TV001G8 is the reference
sequence. Dots indicate similarity to the reference sequence, while dashes
indicate a deletion at that position. A mismatch is indicated by the amino acid at
that particular position of the sequence. The positions of the individual
sequences are given on the right hand side. A general position indication is given
in multiples of 20 at the top of the sequences. The different domains of Gag is
indicated by a two way arrow on top of the alignment. The protease cleavage
sites are indicated by a green line down the sequences.
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